Document And Entity Information
Document And Entity Information - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2016 | Jan. 31, 2017 | Jun. 30, 2016 | |
Document Information [Line Items] | |||
Entity Registrant Name | AMYRIS, INC. | ||
Entity Central Index Key | 1,365,916 | ||
Trading Symbol | amrs | ||
Current Fiscal Year End Date | --12-31 | ||
Entity Filer Category | Non-accelerated Filer | ||
Entity Current Reporting Status | Yes | ||
Entity Voluntary Filers | No | ||
Entity Well-known Seasoned Issuer | No | ||
Entity Common Stock, Shares Outstanding (in shares) | 278,320,194 | ||
Entity Public Float | $ 37 | ||
Document Type | 10-K | ||
Document Period End Date | Dec. 31, 2016 | ||
Document Fiscal Year Focus | 2,016 | ||
Document Fiscal Period Focus | FY | ||
Amendment Flag | false |
Consolidated Balance Sheets
Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2016 | Dec. 31, 2015 | |
Assets | |||
Cash and cash equivalents | $ 27,150 | $ 11,992 | |
Restricted cash | 4,326 | 216 | |
Short-term investments | 1,374 | 1,520 | |
Accounts receivable, net of allowance of $478 and $479, respectively | 13,105 | 4,004 | |
Related party accounts receivable, net of allowance of $23 and $490, respectively | 872 | 1,176 | |
Inventories, net | 6,213 | 10,886 | |
Prepaid expenses and other current assets | 6,083 | 4,583 | |
Total current assets | 59,123 | 34,377 | |
Property, plant and equipment, net | 53,735 | 59,797 | |
Restricted Cash and Cash Equivalents, Noncurrent | 957 | 957 | |
Equity and loans in affiliates | 34 | 68 | |
Other assets | 15,464 | 10,357 | |
Goodwill and intangible assets | 560 | 560 | |
Total assets | 129,873 | 106,116 | |
Liabilities, Mezzanine Equity and Stockholders' Deficit | |||
Accounts payable | 15,315 | 7,943 | |
Deferred revenue | 5,288 | 6,509 | |
Accrued and other current liabilities | 29,188 | 24,268 | |
Capital lease obligation, current portion | 922 | 523 | |
Debt, current portion (Note 16) | 25,853 | 36,281 | |
Related party debt | 33,302 | ||
Total current liabilities | 109,868 | 75,524 | |
Long-term portion | 334 | 176 | |
Long-term debt, net of current portion | 128,744 | 72,854 | |
Related party debt | 39,144 | 42,839 | |
Deferred rent, net of current portion | 8,906 | 9,682 | |
Deferred revenue, net of current portion | 6,650 | 4,469 | |
Derivative liabilities | 6,894 | 51,439 | |
Other liabilities | 7,841 | 7,589 | |
Total liabilities | 308,381 | 264,572 | |
Commitments and contingencies (Note 6) | |||
Contingently redeemable common stock (Note 8) | [1] | 5,000 | |
Stockholders’ deficit: | |||
Preferred stock - $0.0001 par value, 5,000,000 shares authorized, none issued and outstanding | |||
Common stock - $0.0001 par value, 500,000,000 and 400,000,000 shares authorized as of December 31, 2016 and 2015; 274,108,808 and 206,130,282 shares issued and outstanding as of December 31, 2016 and 2015, respectively | 27 | 21 | |
Additional paid-in capital | 990,870 | 926,216 | |
Accumulated other comprehensive loss | (40,904) | (47,198) | |
Accumulated deficit | (1,134,438) | (1,037,104) | |
Total Amyris, Inc. stockholders’ deficit | (184,445) | (158,065) | |
Noncontrolling interest | 937 | (391) | |
Total stockholders' deficit | (183,508) | (158,456) | |
Total liabilities, mezzanine equity and stockholders' deficit | $ 129,873 | $ 106,116 | |
[1] | See Note 8, "Significant Agreements" for details regarding the Bill & Melinda Gates Foundation Investment, classified as mezzanine equity. |
Consolidated Balance Sheets (Pa
Consolidated Balance Sheets (Parentheticals) - USD ($) $ in Thousands | Dec. 31, 2016 | Dec. 31, 2015 |
Allowance for doubtful accounts | $ 478 | $ 479 |
Related party accounts receivable allowace | $ 23 | $ 490 |
Preferred stock, par value (in dollars per share) | $ 0.0001 | $ 0.0001 |
Preferred stock, shares authorized (in shares) | 5,000,000 | 5,000,000 |
Preferred stock, shares issued (in shares) | 0 | 0 |
Preferred stock, shares outstanding (in shares) | 0 | 0 |
Common stock, par value (in dollars per share) | $ 0.0001 | $ 0.0001 |
Common stock, shares authorized (in shares) | 500,000,000 | 400,000,000 |
Common stock, shares issued (in shares) | 274,108,808 | 206,130,282 |
Common stock, shares outstanding (in shares) | 274,108,808 | 206,130,282 |
Consolidated Statements of Oper
Consolidated Statements of Operations - USD ($) | 12 Months Ended | ||
Dec. 31, 2016 | Dec. 31, 2015 | Dec. 31, 2014 | |
Revenues | |||
Renewable product sales | $ 24,788,000 | $ 14,032,000 | $ 22,793,000 |
Related party renewable product sales | 1,561,000 | 864,000 | 646,000 |
Total product sales | 26,349,000 | 14,896,000 | 23,439,000 |
Grants, collaborations and license fee revenue | 40,843,000 | 19,257,000 | 19,835,000 |
Total revenues | 67,192,000 | 34,153,000 | 43,274,000 |
Cost and operating expenses | |||
Cost of products sold | 56,678,000 | 37,374,000 | 33,202,000 |
Loss on purchase commitments, impairment of property, plant and equipment and other asset allowances | 7,305,000 | 34,166,000 | 1,769,000 |
Withholding tax related to conversion of related party notes | 4,723,000 | ||
Impairment of intangible assets | 5,525,000 | 3,035,000 | |
Research and development | 51,412,000 | 44,636,000 | 49,661,000 |
Sales, general and administrative | 47,721,000 | 56,262,000 | 55,435,000 |
Total cost and operating expenses | 163,116,000 | 182,686,000 | 143,102,000 |
Loss from operations | (95,924,000) | (148,533,000) | (99,828,000) |
Other income (expense): | |||
Interest income | 258,000 | 264,000 | 387,000 |
Interest expense | (37,629,000) | (78,854,000) | (28,949,000) |
Gain from change in fair value of derivative instruments | 41,355,000 | 16,287,000 | 144,138,000 |
Loss upon extinguishment of debt | (4,146,000) | (1,141,000) | (10,512,000) |
Other income (expense), net | (695,000) | (1,423,000) | 336,000 |
Total other income (expense) | (857,000) | (64,867,000) | 105,400,000 |
Income (loss) before income taxes and loss from investments in affiliates | (96,781,000) | (213,400,000) | 5,572,000 |
Provision for income taxes | (553,000) | (468,000) | (495,000) |
Net income (loss) before loss from investments in affiliates | (97,334,000) | (213,868,000) | 5,077,000 |
Loss from investments in affiliates | (4,184,000) | (2,910,000) | |
Net income (loss) | (97,334,000) | (218,052,000) | 2,167,000 |
Income attributable to noncontrolling interest | 100,000 | 119,000 | |
Net income (loss) attributable to Amyris, Inc. common stockholders | $ (97,334,000) | $ (217,952,000) | $ 2,286,000 |
Net income (loss) per share attributable to common stockholders: | |||
Basic (in dollars per share) | $ (0.41) | $ (1.75) | $ 0.03 |
Diluted (in dollars per share) | $ (0.44) | $ (1.75) | $ (0.90) |
Weighted-average shares of common stock outstanding used in computing net income (loss) per share of common stock: | |||
Basic (in shares) | 238,440,197 | 126,961,576 | 78,400,098 |
Diluted (in shares) | 264,644,449 | 126,961,576 | 121,859,441 |
Consolidated Statements of Comp
Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2016 | Dec. 31, 2015 | Dec. 31, 2014 | |
Comprehensive loss: | |||
Net income (loss) | $ (97,334) | $ (218,052) | $ 2,167 |
Foreign currency translation adjustment, net of tax | 6,294 | (16,901) | (9,798) |
Total comprehensive loss | (91,040) | (234,953) | (7,631) |
Income attributable to noncontrolling interest | 100 | 119 | |
Foreign currency translation adjustment attributable to noncontrolling interest | (320) | (92) | |
Comprehensive loss attributable to Amyris, Inc. | $ (91,040) | $ (235,173) | $ (7,604) |
Consolidated Statements of Stoc
Consolidated Statements of Stockholders' Deficit - USD ($) $ in Thousands | Common Stock [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] | AOCI Attributable to Parent [Member] | Noncontrolling Interest [Member] | Mezzanine Equity [Member] | Total |
Balance (in shares) at Dec. 31, 2013 | 76,662,812 | ||||||
Balance at Dec. 31, 2013 | $ 8 | $ 706,253 | $ (821,438) | $ (20,087) | $ (584) | $ (135,848) | |
Issuance of common stock upon exercise of stock options, net of restricted stock (in shares) | 779,490 | ||||||
Issuance of common stock upon exercise of stock options, net of restricted stock | 2,133 | 2,133 | |||||
Issuance of common stock in a private placement (in shares) | 943,396 | ||||||
Issuance of common stock in a private placement | 4,000 | 4,000 | |||||
Shares issued from restricted stock unit settlement (in shares) | 836,185 | ||||||
Shares issued from restricted stock unit settlement | (1,822) | (1,822) | |||||
Stock-based compensation | 14,105 | 14,105 | |||||
Foreign currency translation adjustment, net of tax | (9,890) | 92 | (9,798) | ||||
Net income (loss) | 2,286 | (119) | 2,167 | ||||
Balance (in shares) at Dec. 31, 2014 | 79,221,883 | ||||||
Balance at Dec. 31, 2014 | $ 8 | 724,669 | (819,152) | (29,977) | (611) | (125,063) | |
Issuance of common stock upon exercise of stock options, net of restricted stock (in shares) | 13,250 | ||||||
Issuance of common stock upon exercise of stock options, net of restricted stock | 18 | 18 | |||||
Issuance of common stock in a private placement (in shares) | 16,025,642 | ||||||
Issuance of common stock in a private placement | $ 2 | 24,624 | 24,626 | ||||
Shares issued from restricted stock unit settlement (in shares) | 908,877 | ||||||
Shares issued from restricted stock unit settlement | (333) | (333) | |||||
Stock-based compensation | 9,134 | 9,134 | |||||
Foreign currency translation adjustment, net of tax | (17,221) | 320 | (16,901) | ||||
Net income (loss) | (217,952) | (100) | (218,052) | ||||
Balance (in shares) at Dec. 31, 2015 | 206,130,282 | ||||||
Balance at Dec. 31, 2015 | $ 21 | 926,216 | (1,037,104) | (47,198) | (391) | (158,456) | |
Issuance of common stock upon conversion of debt (in shares) | 62,192,238 | ||||||
Issuance of common stock upon conversion of debt | $ 6 | 96,616 | 96,622 | ||||
Issuance of warrants on conversion of debt | 51,704 | 51,704 | |||||
Shares issued upon ESPP purchase (in shares) | 385,892 | ||||||
Shares issued upon ESPP purchase | 595 | 595 | |||||
Issuance of common stock upon exercise of warrants (in shares) | 47,382,500 | ||||||
Issuance of common stock upon exercise of warrants | $ 5 | 19,189 | $ 19,194 | ||||
Issuance of common stock upon exercise of stock options, net of restricted stock (in shares) | 134 | 134 | |||||
Shares issued from restricted stock unit settlement (in shares) | 1,803,496 | ||||||
Shares issued from restricted stock unit settlement | (254) | $ (254) | |||||
Stock-based compensation | 7,325 | 7,325 | |||||
Foreign currency translation adjustment, net of tax | 6,294 | 6,294 | |||||
Net income (loss) | (97,334) | (97,334) | |||||
Balance (in shares) at Dec. 31, 2016 | 274,108,808 | ||||||
Balance at Dec. 31, 2016 | $ 27 | 990,870 | $ (1,134,438) | $ (40,904) | 937 | $ 5,000 | (183,508) |
Issuance of common stock upon conversion of debt (in shares) | 15,729,015 | ||||||
Issuance of common stock upon conversion of debt | $ 2 | 14,364 | 14,364 | ||||
Issuance of warrants on conversion of debt | 4,387 | 4,387 | |||||
Shares issued upon ESPP purchase (in shares) | 336,075 | ||||||
Shares issued upon ESPP purchase | 180 | 180 | |||||
Issuance of common stock upon exercise of warrants (in shares) | 10,000,000 | ||||||
Issuance of common stock upon exercise of warrants | 10,435 | 10,435 | |||||
Issuance of common stock for settlement of debt principal payments (in shares) | 35,723,842 | ||||||
Issuance of common stock for settlement of debt principal payments | $ 4 | 17,410 | 17,414 | ||||
Disposal of noncontrolling interest in Neossance LLC | 9,063 | 937 | 10,000 | ||||
Contribution upon restructuring of Fuels JV | 4,252 | 4,252 | |||||
Issuance of contingently redeemable common stock (in shares) | 4,385,964 | ||||||
Issuance of contingently redeemable common stock | $ 5,000 | ||||||
Acquisitions of noncontrolling interests | $ (2,508) | $ 391 | $ (2,117) |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows - USD ($) | 12 Months Ended | ||
Dec. 31, 2016 | Dec. 31, 2015 | Dec. 31, 2014 | |
Operating activities | |||
Net income (loss) | $ (97,334,000) | $ (218,052,000) | $ 2,167,000 |
Adjustments to reconcile net income (loss) to net cash used in operating activities: | |||
Depreciation and amortization | 11,374,000 | 12,920,000 | 14,969,000 |
Loss (gain) on disposal of property, plant and equipment | (161,000) | 154,000 | 263,000 |
Impairment of Intangible Assets (Excluding Goodwill) | 0 | 5,525,000 | 3,035,000 |
Stock-based compensation | 7,325,000 | 9,134,000 | 14,105,000 |
Amortization of debt discount and issuance costs | 14,445,000 | 58,559,000 | 9,981,000 |
Loss upon extinguishment of debt | 4,146,000 | 1,141,000 | 10,512,000 |
Loss on purchase commitments, impairment of property, plant and equipment and other asset allowances | 7,305,000 | 34,166,000 | 1,769,000 |
Withholding tax related to conversion of related party notes | 4,723,000 | ||
Change in fair value of derivative instruments | (41,355,000) | (16,287,000) | (144,138,000) |
Loss from investments in affiliates | 4,184,000 | 2,910,000 | |
Other non-cash expenses | 999,000 | (413,000) | (113,000) |
Changes in assets and liabilities: | |||
Accounts receivable | (9,331,000) | 4,920,000 | (1,217,000) |
Related party accounts receivable | 372,000 | (649,000) | (4,000) |
Inventories, net | 5,686,000 | 4,470,000 | (4,481,000) |
Prepaid expenses and other assets | (4,913,000) | (4,297,000) | (2,907,000) |
Accounts payable | 6,442,000 | 4,373,000 | (3,209,000) |
Accrued and other liabilities | 12,696,000 | 10,954,000 | 6,830,000 |
Deferred revenue | 714,000 | (89,000) | 4,760,000 |
Deferred rent | (777,000) | (568,000) | 60,000 |
Net cash used in operating activities | (82,367,000) | (85,132,000) | (84,708,000) |
Investing activities | |||
Purchase of short-term investments | (5,559,000) | (2,759,000) | (1,371,000) |
Maturities of short-term investments | 6,187,000 | 2,321,000 | 1,409,000 |
Change in restricted cash | (4,040,000) | 240,000 | |
Proceeds on disposal of noncontrolling interest | 10,000,000 | (2,075,000) | |
Loan to affiliate | (1,579,000) | (2,790,000) | |
Purchase of property, plant and equipment, net of disposals | (922,000) | (3,367,000) | (5,004,000) |
Change in restricted stock | (24,000) | ||
Net cash provided (used) in investing activities | 5,642,000 | (5,144,000) | (9,831,000) |
Financing activities | |||
Proceeds from exercise of common stock, net of repurchases | 180,000 | 614,000 | 2,488,000 |
Employees' taxes paid upon vesting of restricted stock units | (253,000) | (333,000) | (1,822,000) |
Proceeds from issuance of common stock in private placements, net of issuance costs | 24,625,000 | 4,000,000 | |
Proceeds from exercise of warrants | 5,000,000 | 285,000 | |
Proceeds from issuance of contingently redeemable equity | 5,000,000 | ||
Principal payments on capital leases | (1,579,000) | (729,000) | (1,045,000) |
Proceeds from debt issued, net of discounts and issuance costs | 63,911,000 | 66,931,000 | 83,171,000 |
Proceeds from debt issued to related parties | 29,699,000 | 10,850,000 | 49,862,000 |
Principal payments on debt | (9,759,000) | (40,819,000) | (5,733,000) |
Net cash provided by financing activities | 92,199,000 | 61,424,000 | 130,921,000 |
Effect of exchange rate changes on cash and cash equivalents | (316,000) | (1,203,000) | (1,203,000) |
Net increase/(decrease) in cash and cash equivalents | 15,158,000 | (30,055,000) | 35,179,000 |
Cash and cash equivalents at beginning of period | 11,992,000 | 42,047,000 | 6,868,000 |
Cash and cash equivalents at end of period | 27,150,000 | 11,992,000 | 42,047,000 |
Cash paid for interest | 9,983,000 | 9,425,000 | 6,910,000 |
Cash paid for income taxes, net of refunds | |||
Supplemental disclosures of non-cash investing and financing activities: | |||
Acquisitions of property, plant and equipment under accounts payable, accrued liabilities and notes payable | (1,276,000) | (73,000) | 114,000 |
Financing of equipment | 2,136,000 | 613,000 | 617,000 |
Financing of insurance premium under notes payable | (123,000) | 53,000 | 166,000 |
Acquisition of noncontrolling interest in Glycotech via debt | 3,906,000 | ||
Purchase of property, plant and equipment via deposit | 24,000 | (392,000) | |
Interest capitalized to debt | 3,147,000 | 6,354,000 | 5,590,000 |
Issuance of common stock upon conversion of debt | 14,364,000 | $ 96,622,000 | |
Issuance of common stock for settlement of debt principal payments | 17,414,000 | ||
Cancellation of debt and accrued interest on disposal of interest in affiliate | 4,252,000 | ||
Non-cash investment in joint venture | $ 1,281,000 |
Note 1 - The Company
Note 1 - The Company | 12 Months Ended |
Dec. 31, 2016 | |
Notes to Financial Statements | |
Nature of Operations [Text Block] | 1. Amyris, Inc. (or the Company) was incorporated in California on July 17, 2003 April 15, 2010 first 2014, 2015 2016 one The Company's renewable products business strategy is to generally focus on direct commercialization of specialty products while moving established commodity products into joint venture arrangements with leading industry partners. To commercialize its products, the Company must be successful in using its technology to manufacture its products at commercial scale and on an economically viable basis (i.e., low per unit production costs) and developing sufficient sales volume for those products to support its operations. The Company's prospects are subject to risks, expenses and uncertainties frequently encountered by companies in this stage of development. Liquidity The Company expects to fund its operations for the foreseeable future with cash and investments currently on hand, with cash inflows from collaborations and grants, with cash contributions from product sales, with new debt and equity financings and with proceeds from strategic asset divestments. The Company's planned 2017 2018 The Company has incurred significant operating losses since its inception and believes that it will continue to incur losses and negative cash flow from operations into at least 2018. December 31, 2016, $50.7 $1,134.4 $28.5 second 2017 one may may As of December 31, 2016, $42.5 $227.0 $59.2 twelve $18.3 5, 6, 16, In addition to the need for financing described above, the Company may second 2017 2017 2018: • Effect significant headcount reductions, particularly with respect to employees not connected to critical or contracted activities across all functions of the Company, including employees involved in general and administrative, research and development, and production activities. • Shift focus to existing products and customers with significantly reduced investment in new product and commercial development efforts. • Reduce production activity at the Company’s Brotas manufacturing facility to levels only sufficient to satisfy volumes required for product revenues forecast from existing products and customers. • Reduce expenditures for third • Reduce or delay uncommitted capital expenditures, including those relating to proposed additional manufacturing capacity, non-essential facility and lab equipment, and information technology projects. • Closely monitor the Company’s working capital position with customers and suppliers, as well as suspend operations at pilot plants and demonstration facilities. Implementing this plan could have a negative impact on the Company's ability to continue its business as currently contemplated, including, without limitation, delays or failures in its ability to: • Achieve planned production levels; • Develop and commercialize products within planned timelines or at planned scales; and • Continue other core activities. Furthermore, any inability to scale-back operations as necessary, and any unexpected liquidity needs, could create pressure to implement more severe measures. Such measures could have an adverse effect on the Company's ability to meet contractual requirements, including obligations to maintain manufacturing operations, and increase the severity of the consequences described above. |
Note 2 - Summary of Significant
Note 2 - Summary of Significant Accounting Policies | 12 Months Ended |
Dec. 31, 2016 | |
Notes to Financial Statements | |
Significant Accounting Policies [Text Block] | 2. Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with the accounting principles generally accepted in the United States of America (or GAAP) and with the instructions for Form 10 The Company uses the equity method to account for investments in companies, if its investments provide it with the ability to exercise significant influence over operating and financial policies of the investee. Consolidated net income or loss includes the Company’s proportionate share of the net income or loss of these companies. Judgments made by the Company regarding the level of influence over each equity method investment include considering key factors such as the Company’s ownership interest, representation on the board of directors, participation in policy-making decisions and material intercompany transactions. Principles of Consolidation The consolidated financial statements of the Company include the accounts of Amyris, Inc., its subsidiaries and two 7, Variable Interest Entities The Company has interests in joint venture entities that are VIEs. Determining whether to consolidate a VIE requires judgment in assessing (i) whether an entity is a VIE and (ii) if the Company is the entity’s primary beneficiary and thus required to consolidate the entity. To determine if the Company is the primary beneficiary of a VIE, the Company evaluates whether it has (i) the power to direct the activities that most significantly impact the VIE’s economic performance and (ii) the obligation to absorb losses or the right to receive benefits of the VIE that could potentially be significant to the VIE. The Company’s evaluation includes identification of significant activities and an assessment of its ability to direct those activities based on governance provisions and arrangements to provide or receive product and process technology, product supply, operations services, equity funding and financing and other applicable agreements and circumstances. The Company’s assessment of whether it is the primary beneficiary of its VIEs requires significant assumptions and judgment. Use of Estimates In preparing the consolidated financial statements, management must make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Concentration of Credit Risk Financial instruments that potentially subject the Company to a concentration of credit risk consist primarily of cash and cash equivalents, short term investments and accounts receivable. The Company places its cash equivalents and investments (primarily certificates of deposits) with high credit quality financial institutions and, by policy, limits the amount of credit exposure with any one may The Company performs ongoing credit evaluation of its customers, does not require collateral, and maintains allowances for potential credit losses on customer accounts when deemed necessary. Customers representing 10% December 31, Customers 2016 2015 Customer L 33 % ** Customer K 22 % * Customer H ** 23 % Customer C ** 26 % Customer G ** 10 % ______________ * No outstanding balance ** Less than 10% Customers representing 10% Years Ended December 31, Customers 2016 2015 2014 Customer N 14 % * * Customer M 22 % * * Customer E 27 % 37 % 47 % Customer J ** 10 % ** Customer C ** ** 10 % ______________ * Not a customer ** Less than 10% Fair Value of Financial Instruments The Company measures certain financial assets and liabilities at fair value based on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants. Where available, fair value is based on or derived from observable market prices or other observable inputs. Where observable prices or inputs are not available, valuation techniques are applied. These valuation techniques involve some level of management estimation and judgment, the degree of which is dependent on the price transparency for the instruments or market and the instruments’ complexity. The carrying amounts of certain financial instruments, such as cash equivalents, short term investments, accounts receivable, accounts payable and accrued liabilities, approximate fair value due to their relatively short maturities. The fair values of the loans payable, convertible notes and credit facilities are based on the present value of expected future cash flows and assumptions about current interest rates and the creditworthiness of the Company. The loans payable, convertible notes and credit facilities are carried on the consolidated balance sheet on a historical cost basis, because the Company has not elected to recognize the fair value of these liabilities. However, the Remaining Notes subject to the Maturity Treatment Agreement were revalued to fair value on July 29, 2015 5, The Company estimates the fair value of the compound embedded derivatives for the convertible promissory notes issued to Total Energies Nouvelles Activités USA (formerly known as Total Gas & Power USA, SAS, or Total) under the Total Fuel Agreements (refer to Note 5, may The Company estimates the fair value of the compound embedded derivatives for the notes issued in the first second August 2013 2014 144A 2015 144A 5, two one (1) (2) Changes in the inputs into these valuation models have a significant impact on the estimated fair value of the embedded derivatives. For example, a decrease (increase) in the estimated credit spread for the Company results in an increase (decrease) in the estimated fair value of the embedded derivatives. Conversely, a decrease (increase) in the stock price results in a decrease (increase) in the estimated fair value of the embedded derivatives. The changes during 2016, 2015 2014 Cash and Cash Equivalents All highly liquid investments purchased with an original maturity date of 90 Short Term Investments Investments with original maturities greater than 90 1 90 one December 31, 2016, 2015 2014. December 31, 2016 2015, Accounts Receivable The Company maintains an allowance for doubtful accounts receivable for estimated losses resulting from the inability of its customers to make required payments. The Company determines this allowance based on specific doubtful account identification and management judgment on estimated exposure. The Company writes off accounts receivable against the allowance when it determines a balance is uncollectible and no longer actively pursues collection of the receivable. Inventories Inventories, which consist of farnesene-derived products and flavor and fragrances ingredients are stated at the lower of cost or market and categorized as finished goods, work-in-process or raw material inventories. The Company evaluates the recoverability of its inventories based on assumptions about expected demand and net realizable value. If the Company determines that the cost of inventories exceeds its estimated net realizable value, the Company records a write-down equal to the difference between the cost of inventories and the estimated net realizable value. If actual net realizable values are less favorable than those projected by management, additional inventory write-downs may may first first Investments in Affiliates We use the equity method to account for our investments in affiliates. We include our proportionate share of earnings and/or losses of our equity method investees in the loss from investments in affiliates in the consolidated statements of operations. The carrying value of our investments in affiliates includes loans to affiliates. Investments in affiliates are carried at cost less impairment, as adjusted for market rates of interest imputed to non-market interest rate loans advanced to affiliates. Restricted Cash Cash accounts that are restricted as to withdrawal or usage are presented as restricted cash. As of December 31, 2016 2015, $5.3 $1.2 Derivative Instruments The Company makes limited use of derivative instruments, which includes currency interest rate swap agreements, to manage the Company's exposure to foreign currency exchange rate fluctuations and interest rate fluctuations related to the Company's Banco Pine S.A. loan (discussed below under Note 5, Embedded derivatives that are required to be bifurcated from the underlying debt instrument (i.e., host) are accounted for and valued as separate financial instruments. The Company evaluated the terms and features of its convertible notes payable and identified compound embedded derivatives requiring bifurcation and accounting at fair value because the economic and contractual characteristics of the embedded derivatives met the criteria for bifurcation and separate accounting due to the conversion options containing “make-whole interest” provisions, down round conversion price adjustment provisions and conversion rate adjustments. Property, Plant and Equipment, net Property, plant and equipment, net are stated at cost less accumulated depreciation and amortization. Depreciation and amortization is computed using the straight-line method over the estimated useful lives of the related assets. Maintenance and repairs are charged to expense as incurred, and improvements and betterments are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in operations in the period realized. Depreciation and amortization periods for the Company’s property, plant and equipment are as follows: Machinery and equipment (years) 7 - 15 Buildings (years) 15 Computers and software (years) 3 - 5 Furniture and office equipment (years) 5 Vehicles (years) 5 Buildings and leasehold improvements are amortized on a straight-line basis over the term of the lease, or the useful life of the assets, whichever is shorter. Computers and software includes internal-use software that is acquired to meet the Company’s needs. Amortization commences when the software is ready for its intended use and the amortization period is the estimated useful life of the software, generally 3 5 Impairment of Long-Lived Assets Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may $7.3 $28.5 $1.8 December 31, 2016, 2015 2014, Goodwill and Intangible Assets Goodwill represents the excess of the cost over the fair value of net assets acquired from business combinations. Intangible assets are comprised primarily of in-process research and development (or IPR&D). Goodwill and IPR&D were recognized on an acquisition completed in 2011. There are several methods that can be used to determine the estimated fair value of the IPR&D acquired in a business combination. We used the "income method," which applies a probability weighting that considers the risk of development and commercialization, to the estimated future net cash flows that are derived from projected sales revenues and estimated costs. These projections are based on factors such as relevant market size, pricing of similar products, and expected industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. These assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets will be amortized over the remaining useful life or written off, as appropriate. Amounts recorded as IPR&D will begin being amortized upon the completion of development activities over the estimated useful life of the technology. The development activities have not been completed, and therefore the amortization of the acquired IPR&D has not begun. Factors that could trigger an impairment review include significant under-performance relative to expected historical or projected future operating results, significant changes in the manner of use of the acquired assets or the strategy for the Company's overall business or significant negative industry or economic trends. If this evaluation indicates that the value of the intangible asset may zero, $5.5 $3.0 December 31, 2016, 2015 2014, December 31, 2016, zero. Noncontrolling Interest Changes in noncontrolling interest ownership that do not result in a change of control and where there is a difference between the fair value of the consideration paid/received and the amount by which the noncontrolling interest is adjusted are accounted for as equity transactions. Revenue Recognition The Company recognizes revenue from the sale of renewable products, delivery of research and development services, licensing of intellectual property, and from governmental grants. Revenue is recognized when all of the following criteria are met: persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the fee is fixed or determinable, and collectability is reasonably assured. If sales arrangements contain multiple elements, the Company evaluates whether the components of each arrangement represent separate units of accounting. Product Sales The Company's renewable product sales do not include rights of return. Returns are only accepted if the product does not meet product specifications and such nonconformity is communicated to the Company within a set number of days of delivery. The Company offers a two March 31, 2012, Grants, Collaborative Research Services and License Fees Revenues from collaborative research services are recognized as the services are performed consistent with the performance requirements of the contract. In cases where the planned levels of research services fluctuate over the research term, we recognize revenues using the proportionate performance method based upon actual efforts to date relative to the amount of expected effort to be incurred by us. When up-front payments are received and the planned levels of research services do not fluctuate over the research term, revenues are recorded on a ratable basis over the arrangement term, up to the amount of cash received. When up-front payments are received and the planned levels of research services fluctuate over the research term, revenues are recorded using the proportionate performance method, up to the amount of cash received. Where arrangements include milestones that are determined to be substantive and at risk at the inception of the arrangement, revenues are recognized upon achievement of the milestone and is limited to those amounts whereby collectability is reasonably assured. License fees for intellectual property transferred to other parties, representing non-refundable payments received at the time of signature of license agreements, are recognized as revenue upon signature of the license agreements when the Company has no significant future performance obligations and collectability of the fees is assured. Upfront payments received at the beginning of licensing agreements are deferred and recognized as revenue on a systematic basis over the period during which the related services are rendered and all obligations are performed. Government grants are agreements that generally provide cost reimbursement for certain types of expenditures in return for research and development activities over a contractually defined period. Revenues from government grants are recognized in the period during which the related costs are incurred, provided that the conditions under which the government grants were provided have been met and only perfunctory obligations are outstanding. Cost of Products Sold Cost of products sold includes production costs of renewable products, which include cost of raw materials, amounts paid to contract manufacturers and period costs including inventory write-downs resulting from applying lower-of-cost-or-market inventory valuation. Cost of products sold also includes certain costs related to the scale-up in production of such products. Shipping and handling costs charged to customers are recorded as revenues. Shipping costs are included in cost of products sold. Such charges were not material in any of the periods presented. Research and Development Research and development costs are expensed as incurred and include costs associated with research performed pursuant to collaborative agreements and government grants, including internal research. Research and development costs consist of direct and indirect internal costs related to specific projects as well as fees paid to others that conduct certain research activities on the Company’s behalf. Debt Extinguishment The Company accounts for the income or loss from extinguishment of debt in accordance with ASC 470, Income Taxes The Company accounts for income taxes under the asset and liability method, which requires, among other things, that deferred income taxes be provided for temporary differences between the tax basis of the Company’s assets and liabilities and their financial statement reported amounts. In addition, deferred tax assets are recorded for the future benefit of utilizing net operating losses and research and development credit carryforwards. A valuation allowance is provided against deferred tax assets unless it is more likely than not that they will be realized. The Company recognizes and measures uncertain tax positions in accordance with Income Taxes subtopic 05 6 740, 50% Currency Translation The Company considers the local currency to be the functional currency of the Company’s wholly-owned subsidiary in Brazil and of the Company's consolidated joint venture in Brazil. Accordingly, asset and liability accounts of those operations are translated into United States dollars using the current exchange rate in effect at the balance sheet date and equity accounts are translated into United States dollars using historical rates. The revenues and expenses are translated using the exchange rates in effect when the transactions occur. Gains and losses from foreign currency translation adjustments are included as a component of accumulated other comprehensive income (loss) on the consolidated balance sheets. Foreign currency differences arising from the translation of intercompany loans from a foreign currency into the functional currency of an entity, which are of a long-term investment nature (that is, settlement is not planned or anticipated in the foreseeable future) are recorded in “Accumulated other comprehensive income (loss)” on our Consolidated Balance Sheets. Foreign currency differences arising from the translation of other intercompany loans are recorded in “Other income (expense)” on our Consolidated Statements of Operations. Stock-Based Compensation The Company accounts for stock-based compensation arrangements with employees using a fair value method which requires the recognition of compensation expense for costs related to all stock-based payments including stock options. The fair value method requires the Company to estimate the fair value of stock-based payment awards on the date of grant. The Company uses the Black-Scholes option pricing model to estimate the fair value of options granted, which is expensed on a straight-line basis over the vesting period. The Company accounts for restricted stock unit awards issued to employees based on the fair market value of the Company’s common stock. Comprehensive Income (Loss) Comprehensive income (loss) represents all changes in stockholders’ deficit except those resulting from investments or contributions by stockholders. The Company’s foreign currency translation adjustments represent the components of comprehensive income (loss) excluded from the Company’s net income (loss) and have been disclosed in the consolidated statements of comprehensive loss for all periods presented. The components of accumulated other comprehensive loss are as follows (in thousands): December 31, 2016 2015 Foreign currency translation adjustment, net of tax $ (40,904 ) $ (47,198 ) Total accumulated other comprehensive loss $ (40,904 ) $ (47,198 ) Net Loss Attributable to Common Stockholders and Net Loss per Share The Company computes net loss per share in accordance with ASC 260, 2015 December 31, 2015, The following table presents the calculation of basic and diluted net loss per share of common stock attributable to Amyris, Inc. common stockholders (in thousands, except share and per share amounts): Years Ended December 31, 2016 2015 2014 Numerator: Net income (loss) attributable to Amyris, Inc. common stockholders $ (97,334 ) $ (217,952 ) $ 2,286 Adjustment to exclude fair value gain on liability classified warrants (1) — (3,825 ) — Net income (loss) attributable to Amyris, Inc. common stockholders (for basic income (loss) per share) (97,334 ) (221,777 ) 2,286 Interest on convertible debt 4,428 — 9,365 Accretion of debt discount 2,889 — 5,597 Gain from change in fair value of derivative instruments (25,630 ) — (127,109 ) Net loss attributable to Amyris, Inc. common stockholders after assumed conversion $ (115,647 ) $ (221,777 ) $ (109,861 ) Denominator: Weighted-average shares of common stock outstanding used in computing net loss per share of common stock, basic 238,440,197 126,961,576 78,400,098 Basic income (loss) per share $ (0.41 ) $ (1.75 ) $ 0.03 Weighted average shares of common stock outstanding 238,440,197 126,961,576 78,400,098 Effect of dilutive securities: Convertible promissory notes 26,204,252 — 43,459,343 Weighted common stock equivalents 26,204,252 — 43,459,343 Diluted weighted-average common shares 264,644,449 126,961,576 121,859,441 Diluted loss per share $ (0.44 ) $ (1.75 ) $ (0.9 ) ______________ (1) The amount represents a net gain related to a change in the fair value of a liability classified common stock warrant included in the Company’s consolidated statement of operations for the year ended December 31, 2015. 2015. The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share of common stock for the periods presented because including them would have been anti-dilutive: Years Ended December 31, 2016 2015 2014 Period-end stock options to purchase common stock 13,487,685 12,930,112 10,539,978 Convertible promissory notes (1) 35,933,931 72,537,306 26,887,005 Period-end common stock warrants 5,021,087 2,901,926 1,021,087 Period-end restricted stock units 6,991,133 5,554,844 1,975,503 Total 61,433,836 93,924,188 40,423,573 ______________ (1) The potentially dilutive effect of convertible promissory notes was computed based on conversion ratios in effect as of December 31, 2016. Recent Accounting Pronouncements In May 2014, March, April, May December 2016, The FASB has issued several updates to the standard which i) clarify the application of the principal versus agent guidance (ASU 2016 08); 2016 10) 2016 12). July 9, 2015, one December 15, 2017 December 15, 2016. March 31, 2018. may In August 2014, December 15, 2016 2016 In January 2015, 225 20, December 15, 2015. 2016 In February 2015, 810 December 15, 2015. 2016 In April 2015, 2015 3, Simplifying the Presentation of Debt Issuance Costs December 15, 2015, 2016. December 31, 2015, $2.8 $1.4 $2.8 $1.4 In July 2015, 2015 11, Simplifying the Measurement of Inventory December 15, 2016, In January 2016, 2016 01 Financial Instruments-Overall December 15, 2017, In February 2016, 2016 02 Leases December 15, 2018. may In March 2016, 2016 06, Contingent Put and Call Options in Debt Instruments four December 15, 2016, In March 2016, 2016 09, Compensation - Stock Compensation (Topic 718): December 15, 2016, In June 2016, 2016 13, Allowance for Loan and Lease Losses (Financial Instruments - Credit Losses Topic 326.) December 15, 2019, December 15, 2018, In August 2016, 2016 15 Classification of Certain Cash Receipts and Cash Payments December 15, 2017 In October 2016, 2016 16, Intra-Entity Transfers of Assets Other Than Inventory December 15, 2017. first 2017. In November 2016, 2016 18 Statement of Cash Flows - Restricted Cash. December 15, 2017, |
Note 3 - Fair Value of Financia
Note 3 - Fair Value of Financial Instruments | 12 Months Ended |
Dec. 31, 2016 | |
Notes to Financial Statements | |
Financial Instruments Disclosure [Text Block] | 3. The inputs to the valuation techniques used to measure fair value are classified into the following categories: Level 1: Level 2: Level 3: There were no transfers between the levels during 2016, December 31, 2016, Level 1 Level 2 Level 3 Balance as of December 31, 2016 Financial Assets Money market funds $ 1,549 $ — $ — $ 1,549 Certificates of deposit 1,373 — — 1,373 Total financial assets $ 2,922 $ — $ — $ 2,922 Financial Liabilities Loans payable (1) $ — $ 53,579 $ — $ 53,579 Credit facilities (1) — 51,261 — 51,261 Convertible notes (1) — — 117,767 117,767 Compound embedded derivative liabilities — — 4,135 4,135 Currency interest rate swap derivative liability — 3,343 — 3,343 Total financial liabilities $ — $ 108,183 $ 121,902 $ 230,085 _________ (1) The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. The fair values of money market funds and certificates of deposit are based on fair values of identical assets. The fair values of the loans payable, convertible notes, credit facilities and currency interest rate swaps are based on the present value of expected future cash flows and assumptions about current interest rates and the creditworthiness of the Company. The method of determining the fair value of the compound embedded derivative liabilities is described subsequently in this note. Market risk associated with the fixed and variable rate long-term loans payable, credit facilities and convertible notes relates to the potential reduction in fair value and negative impact to future earnings, from an increase in interest rates. Market risk associated with the compound embedded derivative liabilities relates to the potential reduction in fair value and negative impact to future earnings from a decrease in interest rates. The carrying amounts of certain financial instruments, such as cash equivalents, accounts receivable, accounts payable and accrued liabilities, approximate fair value due to their relatively short maturities and low market interest rates, if applicable. As of December 31, 2015, Level 1 Level 2 Level 3 Balance as of December 31, 2015 Financial Assets Money market funds $ 2,078 $ — $ — $ 2,078 Certificates of deposit 1,520 — — 1,520 Total financial assets $ 3,598 $ — $ — $ 3,598 Financial Liabilities Loans payable (1) $ — $ 9,541 $ — $ 9,541 Credit facilities (1) — 34,893 — 34,893 Convertible notes (1) — — 96,291 96,291 Compound embedded derivative liabilities — — 46,430 46,430 Currency interest rate swap derivative liability — 5,009 — 5,009 Total financial liabilities $ — $ 49,443 $ 142,721 $ 192,164 _________ (1) July 29, 2015, 5 The following table provides a reconciliation of the beginning and ending balances for the convertible notes disclosed at fair value using significant unobservable inputs (Level 3) 2016 2015 Balance at January 1 $ 96,291 $ 222,031 Additions to convertible notes 25,000 31,984 Conversion/extinguishment of convertible notes (28,310 ) (127,583 ) Change in fair value of convertible notes 24,786 (30,141 ) Balance at December 31 $ 117,767 $ 96,291 Derivative Instruments The following table provides a reconciliation of the beginning and ending balances for the compound embedded derivative liabilities measured at fair value using significant unobservable inputs (Level 3) 2016 2015 Balance at January 1 $ 46,430 $ 56,026 Additions to Level 3 2,050 40,359 Derecognition on conversion/extinguishment (2,886 ) (30,806 ) Gain from change in fair value of derivative liabilities (41,459 ) (19,149 ) Balance at December 31 $ 4,135 $ 46,430 The compound embedded derivative liabilities represent the fair value of the equity conversion options and "make-whole" provisions, as well as the down round conversion price adjustment or conversion rate adjustment provisions of the R&D Notes, the Tranche I Notes, the Tranche II Notes, the 2014 144A 2015 144A 5, 2014 144A 2015 144A may two one (1) (2) December 31, 2016 2015, $4.1 $46.4 The market-based assumptions and estimates used in valuing the compound embedded derivative liabilities include amounts in the following ranges/amounts: December 31, 2016 December 31, 2015 Risk-free interest rate 0.55% - 1.31% 1.26% - 1.40% Risk-adjusted yields 12.80% - 22.93% 35.80% - 45.93% Stock-price volatility 45% 45% Probability of change in control 5% 5% Stock price $0.73 $1.62 Credit spread 11.59% - 21.64% 34.48% - 44.55% Estimated conversion dates 2017 - 2019 2016 - 2019 Changes in valuation assumptions can have a significant impact on the valuation of the embedded derivative liabilities. For example, all other things being equal, a decrease/increase in the Company’s stock price, probability of change of control, credit spread, term to maturity/conversion or stock price volatility decreases/increases the valuation of the liabilities, whereas a decrease/increase in risk adjusted yields or risk-free interest rates increases/decreases the valuation of the liabilities. Certain of the Convertible Notes also include conversion price adjustment features and, for example, issuances of common stock by the Company at prices lower than the current conversion price result in a reduction of the conversion price of such notes, which increases the value of the embedded derivative liabilities. See Note 5, In June 2012, 5, R$22.0 US$6.8 December 31, 2016) 3.94%. Income Years Ended December 31, Type of Derivative Contract Statement Classification 2016 2015 2014 Gain (Loss) Recognized Currency interest rate swap Gain (loss) from change in fair value of derivative instruments $ 1,946 $ (3,367 ) $ (480 ) The Company granted a warrant to Temasek to purchase the Company’s common stock (or the Temasek Funding Warrant), as part of the Exchange transaction completed on July 29, 2015. may 815 40 15 Initial recognition (July 29, 2015) Expected dividend yield — % Risk-free interest rate 2 % Expected term (in years) 10.0 Expected volatility 74 % The Company recognized a derivative liability for the Temasek Funding Warrant of $19.4 July 29, 2015. December 15, 2015, $0.1 $18.9 12.7 February May 2016, 5, 127,194 2,335,342 Derivative instruments measured at fair value as of December 31, 2016 2015, December 31, 2016 2015 Non-current fair market value of swap obligation 3,343 5,009 Fair value of compound embedded derivative liabilities 4,135 46,430 Total derivative liabilities (of which $584 is a current liability) $ 7,478 $ 51,439 |
Note 4 - Balance Sheet Componen
Note 4 - Balance Sheet Components | 12 Months Ended |
Dec. 31, 2016 | |
Notes to Financial Statements | |
Supplemental Balance Sheet Disclosures [Text Block] | 4. Inventories, net Inventories are stated at the lower of cost or market and consist of the following (in thousands): December 31, 2016 2015 Raw materials $ 3,159 $ 2,204 Work-in-process 1,848 3,583 Finished goods 1,206 5,099 Inventories, net $ 6,213 $ 10,886 Property, Plant and Equipment, net Property, plant and equipment, net is comprised of the following (in thousands): December 31, 2016 2015 Leasehold improvements $ 38,785 $ 38,519 Machinery and equipment 82,688 72,876 Computers and software 9,585 9,117 Furniture and office equipment 2,333 2,234 Buildings 4,699 3,922 Vehicles 164 215 Land 460 — Construction in progress 2,216 5,736 140,930 132,619 Less: accumulated depreciation and amortization (87,195 ) (72,822 ) Property, plant and equipment, net $ 53,735 $ 59,797 The Company's first, December 2012. In July 2015, December 2015, December 2016, As a result of the above developments, the Company recorded an impairment charge of $7.3 $4.2 $3.1 December 31, 2016. $1.9 may Property, plant and equipment, net includes $3.1 $2.7 December 31, 2016 2015, $0.6 $0.5 December 31, 2016 2015, Depreciation and amortization expense, including amortization of assets under capital leases, was $11.4 $12.9 $15.0 December 31, 2016, 2015 2014, Other Assets Other assets are comprised of the following (in thousands): December 31, 2016 2015 Deposits on property and equipment, including taxes $ 291 $ 243 Recoverable taxes from Brazilian government entities, net 13,723 8,887 Other 1,450 1,227 Total other assets $ 15,464 $ 10,357 Recoverable taxes from Brazilian government entities represents value added taxes paid on purchases in Brazil, which are reclaimable from the Brazilian tax authorities, net of reserves for amounts estimated not to be recoverable. Accrued and Other Current Liabilities Accrued and other current liabilities are comprised of the following (in thousands): December 31, 2016 2015 Professional services $ 6,876 $ 4,017 Accrued vacation 2,034 2,023 Payroll and related expenses 4,310 3,122 Tax-related liabilities 2,610 2,505 Withholding tax related to conversion of related party notes 1,370 4,723 Deferred rent, current portion 1,111 1,111 Accrued interest 4,847 1,984 SMA relocation accrual 3,641 3,641 Other 2,389 1,142 Total accrued and other current liabilities $ 29,188 $ 24,268 |
Note 5 - Debt and Mezzanine Equ
Note 5 - Debt and Mezzanine Equity | 12 Months Ended |
Dec. 31, 2016 | |
Notes to Financial Statements | |
Debt Disclosure [Text Block] | 5. Debt is comprised of the following (in thousands): December 31, 2016 2015 FINEP credit facility $ 696 $ 840 BNDES credit facility 1,172 1,956 Guanfu credit facility 19,564 — Senior secured loan facility 27,658 31,590 Total credit facilities 49,090 34,386 Convertible notes 78,981 61,233 Related party convertible notes 42,754 42,749 Related party loan payable 29,691 — Loans payable 26,527 13,606 Total debt 227,043 151,974 Less: current portion (59,155 ) (36,281 ) Long-term debt $ 167,888 $ 115,693 Mezzanine equity(1) $ 5,000 $ — ____________ (1) 8, Senior Secured Loan Facility In March 2014, $25.0 $25.0 6.25% 9.50%. may (October 15, 2018) 1% 1% 10% $25.0 In June 2014, first first May 31, 2015 February 1, 2017 $10.0 October 1, 2014, July 1, 2014, 3 June 30, 2014 $50.0 September 30, 2014. 50% $5.0 $5.0 June 2014, 5.25% 8.5%. In March 2015, second second $15.0 March 31, 2016 $20.0 second 3.0% April 1, 2015. June 30, 2015 $20.0 June 30, 2015, 5.0% June 30, 2015. June 30, 2015, 5.0% June 30, 2015. July 2015. In November 2015, third third $10,960,000 November 30, 2015. December 1, 2015, $9.1 third $31.7 9.5% 6.25%, October 15, 2018. $767,200. third $1.0 $750,000 $15.0 second $250,000 third December 1, 2015, February 29, 2016. March 1, 2016, third 2016, December 1, 2016. $20.0 February 2016 $20.0 May 31, 2016. June 1, 2016, June 2016, June 29, 2016, October 31, 2016. 8, October 6, 2016, fourth $1 January 2017, October 15, 2018. 16, December 2016, 7, $425,000 December 31, 2017 $450,000 January 2017 fifth $3 16, As of December 31, 2016, $27.7million $0.9 December 31, 2016 December 31, 2017, January 2017. may BNDES Credit Facility In December 2011, R$22.4 US$6.9 December 31, 2016). R$19.1 R$3.3 2013. The principal of the loans under the BNDES Credit Facility is required to be repaid in 60 first January 2013 December 2017. first March 2012. January 2013, 7% 0.1% The BNDES Credit Facility is collateralized by a first R$24.9 US$7.7 December 31, 2016). 10% (R$22.4 second R$19.1 90% 130% may December 31, 2016 2015, R$3.8 US$1.2 December 31, 2016) R$7.6 US$1.9 December 31, 2015), FINEP Credit Facility In November 2010, R$6.4 US$2.0 December 31, 2016), Interest on loans drawn under the FINEP Credit Facility is fixed at 5% 6%, 5% 11% 10% 1% 81 July 2012 March 2019. March 2011. December 31, 2016 December 31, 2015, R$2.3 US$0.7 December 31, 2016) R$3.4 US$0.9 December 31, 2015), Guanfu Credit Facility On October 26, 2016, $25.0 three November 16, 2016, December 1, 2016, December 31, 2016. December 31, 2016, $25.0 five 10% March 31, 2017. may, 100% Upon the occurrence of certain specified events of default under the Guanfu Credit Facility, the Company will grant to Guanfu an exclusive, royalty-free, global license to certain intellectual property useful in connection with Guanfu’s existing commercial relationship with the Company. In addition, in the event the Company fails to pay interest or principal under the Guanfu Note within ten 90% 90 two Convertible Notes Fidelity In February 2012, $25.0 3% March 1, 2017 $7.0682 October 2015, $57.6 $8.8 $9.7 December 31, 2016, 2,165,898 101% $200.0 50% $125.0 30% $35.0 October 2013 August 2013 $7.6 first August 2013 5, December 28, 2016, $19.1 2015 144A 1:1.25 i.e. $1.00 $1.25 2015 144A 1933, January 2017, 16, December 31, 2016 December 31, 2016 December 31, 2017, January 2017. 2014 144A In May 2014, $75.0 6.50% 2019 2014 144A 2014 144A $15.0 2014 144A 2014 144A May 29, 2014 2014 2014 144A $72.0 2014 144A $9.7 2014 144A $24.7 2014 144A October 2015, $57.6 $18.3 $22.9 2014 144A 2014 144A 6.50% May 15 November 15 November 15, 2014. 2014 144A May 15, 2019, 2014 144A 2014 144A 267.037 $1,000 2014 144A $3.74 May 15, 2015, 20 30 five 2014 144A three (May 15, 2019), 0.75%. 2014 2014 144A may 2014 144A 100% 2014 144A 2014 144A 2014 144A 5, 2014 144A 2015 144A In October 2015, $57.6 9.50% 2019 2015 144A 2015 144A 2015 144A October 20, 2015 2015 2015 144A $54.4 $18.3 $22.9 2014 144A $8.8 $9.7 2015 144A 2015 144A 9.50% April 15 October 15 April 15, 2016. 2015 144A April 15, 2016 October 15, 2016 2015 144A April 15, 2019 The 2015 144A April 15, 2019. 2015 144A 443.6557 $1,000 2015 144A $2.25 February 2016 May September 2016, 2015 144A 446.6719 $1,000 2015 144A December 31, 2016. October 2016, 2015 144A 446.8707 $1,000 2015 144A $2.24 November 27, 2015, 2015 144A three (April 15, 2019), 0.75%. may may 92.5% 10 December 31, 2016, 2015 2015 144A may 2015 144A 100% 2015 144A 2015 144A 2015 144A 2015 144A 2015 144A 38,415,626 May 17, 2016. 2015 144A 2015 144A $25.0 $200.0 $65.0 30% January 2017, $19.1 2015 144A $15.3 16, May 2016 In May 2016, May 2016 $15.0 May 2016 $1.90 May 2016 May 2016 first third May 2016 May 2016 Pursuant to the May 2016 May 2016 two May 10, 2016. May 2016 $10.0 $9.9 second first first three May 2016 second May 2016 $5.0 $5.0 September 2, 2016, second May 2016 May 2016 $3.0 $3.0 May 2016 $2.0 May 2016 May 2016 May 2016 December 31, 2016. October 13, 2016, May 2016 $2.0 The May 2016 May 2016 18 The May 2016 118% May 2016 May 2016 50% $200,000. May, June, July, August, September October 2016 May 2016 October 31, 2016, May 2016 The May 2016 may May 2016 118% In the event of a Fundamental Transaction (as defined in the May 2016 May 2016 may May 2016 118% The Company has the right to redeem the May 2016 118% May 2016 $1.00 30 $0.50 five four 2016 May 2016 112% May 2016 Notwithstanding the foregoing, the holders will not have the right to convert any portion of a May 2016 may May 2016 4.99% 9.99%, 61 May 2016 19.99% May 10, 2016. May 2016 For as long as they hold the May 2016 May 2016 may $1.05 May 2016 $1.00, may December 2016 On December 1, 2016, December 2016 $10.0 December 2016 $1.90 December 2016 first third December 2016 December 2016 The December 2016 December 2, 2016, $9.9 The December 2016 December 2016 May 1, 2018, The December 2016 January 1, 2017, 118% December 1, 2016 December 31, 2016, December 2016 December 2016 50% $200,000. The December 2016 , including failure to pay amounts due, breaches of warranties, material adverse effect events, certain cross defaults and judgments, and insolvency, after which the holders may December 2016 118% In the event of a Fundamental Transaction (as defined in the December 2016 December 2016 may December 2016 118% The Company has the right to redeem the December 2016 118% December 2016 Notwithstanding the foregoing, the holder will not have the right to convert any portion of the December 2016 4.99% 9.99%, 61 December 2016 19.99% December 1, 2016. December 2016 For as long as it holds the December 2016 December 2016 may $1.05 December 2016 $1.00, may December 31, 2016. Related Party Convertible Notes Total R&D Convertible Notes In July 2012 December 2013, The purchase agreement for the notes related to the funding from Total (or the Total Purchase Agreement) provided for the sale of an aggregate of $105.0 1.5% March 2017 • As part of an initial closing under the purchase agreement (which was completed in two July 30, 2012, $38.3 $15.0 $23.3 September 14, 2012, $15.0 $7.0682 • At a second two $30.0 ($10.0 June 2013 $20.0 July 2013). $3.08 • At a third two $21.7 ($10.85 July 2014 $10.85 January 2015). $4.11 In March 2013, March 2013 July 2013 July 2013 $30.0 • Reduce the conversion price for the $30.0 second $7.0682 March 2013 $0.01, $3.08 • Grant Total a senior security interest in the Company's intellectual property, subject to certain exclusions and subject to release by Total when the Company and Total enter into final documentation regarding the establishment of the Fuels JV. In addition to the waiver by Total described above, Total also agreed that, at the Company's request and contingent upon the Company meeting its obligations described above, it would pay advance installments of the amounts otherwise payable at the second In June 2013, $10.0 second March 2013 $3.08 In July 2013, $20.0 second $30.0 second July 2013. March 2013 $3.08 In December 2013, December 2, 2013 December 2, 2013 7, $69.0 1.5% March 2017 third October 16, 2013, December 2, 2013 In April 2014, March 29, 2014 March 2014 December 2, 2013 March 2014 third $7.0682 $4.11 2014 May 2014), may June 30, 2014 December 31, 2014 $75.0 third March 31, 2014, third In July 2014, $10.85 March 1, 2017 $21.7 third March 2014 $4.11 In January 2015, $10.85 March 1, 2017 $21.7 third March 2014 $4.11 In July 2015, $5.0 $70 30.4 5, In March 2016, 7, one 75% 25% $1.3 ($2.8 July 29, 2015) 50,000, $5.0 $3.7 25% $4.2 As of December 31, 2016 December 31, 2015, $3.7 $5.0 December 31, 2016, March 1, 2017 $3.08 February 2017, March 1, 2017 May 15, 2017. 16, 1.5% 2.5%), The R&D Notes become convertible into the Company's common stock (i) within 10 101% may $200.0 50% may $125.0 30% August 2013 In August 2013, August 2013 $73.0 August 2013 24 August 2013 August 2013 two first $42.6 second $30.4 $25.0 ($25.0 second $35.0 $13.0 ($7.6 first $5.4 second August 2013 second 1,000,000 $0.01 second September 2013, August 2013 $110.0 1,000,000 August 2013 In October 2013, $35.0 February 2, 2014 5.5% October 4, 2013 October 16, 2013 first August 2013 In October 2013, August 2013 first August 2013 $7.6 first $9.2 first October 2013, first August 2013 $51.8 $7.6 $44.2 $35.0 $9.2 $35.0 $9.2 $19.9 sixty $2.44 15% 60 August 7, 2013, 18 August 2013 5% six 6.5% first 180 8% 6.5% first 30 six may six may December 31, 2016, may 30 six In December 2013, August 2013 $3.0 second August 2013 $25.0 January 2014, $34.0 second August 2013 $25.0 $3.0 $6.0 $6.0 $9.4 sixty $2.87 60 August 7, 2013, 12 10%, 13% first 180 16% 12% first 36 may may The conversion prices of the Tranche I Notes and Tranche II Notes are subject to adjustment (i) according to proportional adjustments to outstanding common stock of the Company in case of certain dividends and distributions, (ii) according to anti-dilution provisions, and (iii) with respect to notes held by any purchaser other than Total, in the event that Total exchanges existing convertible notes for new securities of the Company in connection with future financing transactions in excess of its pro rata amount. The holders have a right to require repayment of 101% August 2013 August 2013 may In July 2015, $71.0 30.86 5, The conversion price of the Tranche I Notes and Tranche II Notes was reduced to $1.42 July 2015, February 2016, $1.40 May 2016, $1.14 As of December 31, 2016 December 31, 2015, $21.8 $23.3 $0.0 $0.0 5, 2014 144A As of December 31, 2016 December 31, 2015, 2014 144A $17.3 $14.6 $7.4 $10.1 As of December 31, 2016 December 31, 2015, $42.8 $42.8 $5.4 $4.9 Loans Payable In July 2012, July 2012 July 2012 R$52.0 R$68.0 US$20.9 December 31, 2016). July 2012 R$52.0 US$16.0 December 31, 2016) R$22.0 R$30.0 July 15, 2022 5.5% 30 first two August 15, 2014, December 31, 2016 December 31, 2015, R$36.3 US$11.1 December 31, 2016) R$43.0 US$11.0 December 30, 2015), In March 2014, $2.2 March 2015. April 2015, $1.6 March 2016. December 31, 2016, zero ($1.6 December 31, 2015). Exchange (Debt Conversion - Related Party Transaction) On July 29, 2015, July 26, 2015 Under the Exchange Agreement, at the closing of the Exchange, Temasek exchanged $71.0 July 29, 2015) $70.0 $2.30 30,860,633 30,434,782 $39.2 December 31, 2015. Under the Exchange Agreement, Total also received the following warrants, each with a five • 18,924,191 • 2,000,000 March 1, 2017, Additionally, under the Exchange Agreement, Temasek received the following warrants at the closing of the Exchange: • 14,677,861 • (1) may 2,000,000, 30.6% 69.4% (2) may 13.3% 86.7% • 880,339 2,000,000 880,339 The Temasek Exchange Warrant, the Temasek Funding Warrant and the Temasek R&D Warrant each have ten $0.01 In addition to the grant of the Exchange Warrants, a warrant issued by the Company to Temasek in October 2013 2013 1,000,000 2013 $0.01 The exercisability of all of the Exchange Warrants was subject to stockholder approval, which was obtained on September 17, 2015. As of December 31, 2016, 2013 12,700,244 December 31, 2016. 16, 2,462,536 December 31, 2016. Maturity Treatment Agreement - Related Party Transaction At the closing of the Exchange, the Company, Total and Temasek also entered into a Maturity Treatment Agreement, dated as of July 29, 2015, 2014 144A $10.0 2014 144A $27.0 $9.7 2014 144A $15.3 February 2016 On February 12, 2016, February 2016 $18.0 February 2016 2,571,428 $0.01 $18 February 15, 2016, February 2016 $2.0 February 2016 285,714 $0.01 $2 February 2016 February 2016 $16.0 February 2016 2,285,714 $2.0 February 2016 285,714 $2.0 February 2016 285,714 February 12, 2016, February 15, 2016. The February 2016 February 12, 2016, February 2016 February 12, 2016, February 15, 2016, 13.50% May 15, 2017, February 2016 February 2016 February 2016 February 2016 February 2016 may February 2016 The exercisability of the warrants issued in the February 2016 five May 17, 2016. December 31, 2016, February 2016 $18.7 June 2016 On June 24, 2016, June 2016 $5.0 June 2016 $5.0 June 2016 June 2016 June 2016 June 24, 2016. The June 2016 second June 24, 2016, June 2016 June 24, 2016 13.50% May 15, 2017, June 2016 June 2016 June 2016 June 2016 June 2016 may June 2016 October 2016 On October 21 October 27, 2016, October 2016 $6.0 $8.5 October 2016 $6.0 $8.5 October 2016 October 2016 October 2016 October 21 October 27, 2016, The October 2016 second October 2016 October 2016 October 21 27, 2016, 13.50% May 15, 2017, October 2016 October 2016 October 2016 October 2016 October 2016 may October 2016 Salisbury Note In December 2016, 7, $3.5 5% 13 January 1, 2017 5% 5 may may January 2017, Nikko Note In December 2016, 7, $3.9 5% 13 January 1, 2017 5% 5 first 10% $400,000 $100,000 January 1, 2017, February 1, 2017, March 1, 2017 April 1, 2017 fourth may may Letters of Credit In June 2012, $1.0 $1.0 December 31, 2016 2015. Future minimum payments under the debt agreements as of December 31, 2016 Years ending December 31: Related Party Convertible Debt Convertible Debt Loans Payable Related Party Loans Payable Credit Facility Total 2017 $ 4,837 $ 18,883 $ 16,628 $ 32,551 $ 7,014 $ 79,913 2018 16,550 18,142 2,808 — 33,648 71,148 2019 34,260 88,902 2,699 — 2,578 128,439 2020 — — 2,592 — 2,500 5,092 2021 — — 2,483 — 27,395 29,878 Thereafter — — 4,075 — — 4,075 Total future minimum payments (1) 55,647 125,927 31,285 32,551 73,135 318,545 Less: amount representing interest (2) (12,893 ) (46,946 ) (4,758 ) (2,860 ) (24,045 ) (91,502 ) Present value of minimum debt payments 42,754 78,981 26,527 29,691 49,090 227,043 Less: current portion (3,610 ) (8,957 ) (15,448 ) (29,691 ) (1,449 ) (59,155 ) Noncurrent portion of debt $ 39,144 $ 70,024 $ 11,079 $ — $ 47,641 $ 167,888 ______________ (1) Including $11.8 2017 may $46.8 2018 2019 (2) Including debt discount and issuance cost of $42.5 During the year ended December 31, 2016, 2015 03, Interest - Imputation of Interest: Simplifying the Presentation of Debt Issuance Costs December 31, 2015, $2.8 $1.4 $2.8 $1.4 |
Note 6 - Commitments and Contin
Note 6 - Commitments and Contingencies | 12 Months Ended |
Dec. 31, 2016 | |
Notes to Financial Statements | |
Commitments Contingencies and Guarantees [Text Block] | 6. Lease Obligations The Company leases certain facilities and finances certain equipment under operating and capital leases, respectively. Operating leases include leased facilities and capital leases include leased equipment (see Note 4, tenant February 2031. $5.3 $5.5 $5.4 December 31, 2016, 2015 2014, Future minimum payments under the Company's lease obligations as of December 31, 2016, Years ending December 31: Capital Operating Total Lease Obligations 2017 $ 1,233 $ 6,854 $ 8,087 2018 47 6,883 6,930 2019 6 6,774 6,780 2020 — 7,004 7,004 2021 — 7,240 7,240 Thereafter — 10,948 10,948 Total future minimum lease payments 1,286 $ 45,703 $ 46,989 Less: amount representing interest (30 ) Present value of minimum lease payments 1,256 Less: current portion (922 ) Long-term portion $ 334 Guarantor Arrangements The Company has agreements whereby it indemnifies its officers and directors for certain events or occurrences while the officer or director is serving in his or her official capacity. The indemnification period remains enforceable for the officer's or director’s lifetime. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is unlimited; however, the Company has a director and officer insurance policy that limits its exposure and enables the Company to recover a portion of any future payments. As a result of its insurance policy coverage, the Company believes the estimated fair value of these indemnification agreements is minimal. Accordingly, the Company had no December 31, 2016 2015. The Company entered into the FINEP Credit Facility to finance a research and development project on sugarcane-based biodiesel (see Note 5, R$6.0 US$1.8 December 31, 2016). The Company entered into the BNDES Credit Facility to finance a production site in Brazil (see Note 5, first R$24.9 US$7.7 December 31, 2016). zero December 31, 2016 2015 The Company entered into loan agreements and a security agreement whereby the Company pledged certain farnesene production assets as collateral (the fiduciary conveyance of movable goods) with each of Nossa Caixa and Banco Pine (see Note 5, R$68.0 US$20.9 December 31, 2016). The Company had an export financing agreement with ABC Brasil for approximately $2.2 one March 2015. December 31, 2015, April 8, 2015, $1.6 one March 2016. In December 2013, 5, 7, $69.0 1.5% March 2017, $10.85 third July 2014 $10.85 second third January 2015 5,"Debt" March 2016, 5, 7, $3.7 February 2017, March 1, 2017 May 15, 2017, 16, The Senior Secured Loan Facility and the June 2016 October 2016 5, first second first 10% Purchase Obligations As of December 31, 2016, $0.8 $0.6 Production Cost Commitment As of December 31, 2016, Other Matters Certain conditions may may one may If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company's financial statements. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be reasonably estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material would be disclosed. Loss contingencies considered to be remote by management are generally not disclosed unless they involve guarantees, in which case the guarantee would be disclosed. The Company has levied indirect taxes on sugarcane-based biodiesel sales by Amyris Brasil to customers in Brazil based on advice from external legal counsel. In the absence of definitive rulings from the Brazilian tax authorities on the appropriate indirect tax rate to be applied to such product sales, the actual indirect rate to be applied to such sales could differ from the rate we levied. The Company is subject to disputes and claims that arise or have arisen in the ordinary course of business and that have not resulted in legal proceedings or have not been fully adjudicated. Such matters that may one |
Note 7 - Joint Ventures and Non
Note 7 - Joint Ventures and Noncontrolling Interest | 12 Months Ended |
Dec. 31, 2016 | |
Notes to Financial Statements | |
Equity Method Investments and Joint Ventures Disclosure [Text Block] | 7. Novvi LLC In September 2011, March 2013, first may December 31, 2015 50% six 20 50% $10.0 50% $10.0 March 2013, zero. In April 2014, $0.2 April 2014, $2.1 50% In September 2014, $3.7 September 1, 2017 0.36% September 1, 2017. 50% $1.8 two first $1.2 September 2014 second $0.6 October 2014. November 2014, second $1.9 September 2014, November 10, 2017. 50% $1.0 November 2014. May 2015, third $1.1 September 2014, May 14, 2018. 50% In the fourth 2015, four $1.6 September 2014, August 19, 2018, October 15, 2018, November 12, 2018 December 17, 2018. 50% four July 2016, seven In February 2016, $0.6 $0.6 50% On July 19, 2016, $10.0 one third seven three one third two July 19, 2016. July 19, 2016. December 31, 2016, $9.0 16, In November 2016, $1.0 20,000 3% 25% may, Additional funding requirements to finance the ongoing operations of Novvi are expected to happen through revolving credit or other loan facilities provided by unrelated parties (i.e., such as financial institutions); cash advances or other credit or loan facilities provided by Novvi’s members or their affiliates; or additional capital contributions by the existing Novvi members or new investors. The Company has identified Novvi as a VIE and determined that the power to direct activities which most significantly impact the economic success of the joint venture (i.e., continuing research and development, marketing, sales, distribution and manufacturing of Novvi products) are shared among the Company, Cosan U.S. and ARG. Accordingly, the Company is not the primary beneficiary and therefore accounts for its investment in Novvi under the equity method of accounting. The Company will continue to reassess its primary beneficiary analysis of Novvi if there are changes in events and circumstances impacting the power to direct activities that most significantly affect Novvi's economic success. Under the equity method, the Company's share of profits and losses and impairment charges on investments in affiliates are included in “Loss from investments in affiliates” in the consolidated statements of operations. The carrying amount of the Company's equity investment in Novvi was zero December 31, 2016 2015. Total Amyris BioSolutions B.V. In November 2013, March 2016 December 2, 2013 5, 8, In July 2015, February 2016, On February 12, 2016, $1.3 July 29, 2015), 50,000, 25% 75% 25% $3.7 On March 21, 2016, 5, 16, Under the Jet Fuel Agreement, (a) the Company granted exclusive (co-exclusive in Brazil), world-wide, royalty-free rights to TAB for the production and commercialization of farnesene- or farnesane-based jet fuel, (b) the Company granted TAB the option, until March 1, 2018, Upon all farnesene-or farnesane-based diesel fuel rights reverting back to the Company, the Company granted to Total, pursuant to the EU Diesel Fuel Agreement, (a) an exclusive, royalty-free license to offer for sale and sell farnesene- or farnesane-based diesel fuel in the EU, (b) the non-exclusive right to make farnesene or farnesane anywhere in the world, but Total must (i) use such farnesene or farnesane to produce only diesel fuel to offer for sale or sell in the EU and (ii) pay the Company a to-be-negotiated, commercially reasonable, “most-favored” basis royalty and (c) the right to purchase farnesene or farnesane for its EU diesel fuel business from the Company on a “most-favored” pricing basis. As a result of the EU Diesel Fuel Agreement, the Company generally no longer has an independent right to make or sell, without the approval of Total, farnesene- or farnesane-based diesel fuels in the EU. As a result of, and in order to reflect, the changes to the ownership structure of TAB described above, on March 21, 2016, December 2, 2013 April 1, 2015, As of December 31, 2016, 25% 75% December 31, 2016 €0.1 US$0.1 December 31, 2016). SMA Indústria Química S.A. In April 2010, 20 SMA was initially managed by a three two one four two The joint venture agreements required the Company to fund the construction costs of the new facility and SMSA would reimburse the Company up to R$61.8 US$19.0 December 31, 2016) first four four Under the terms of the joint venture agreements, if the Company became controlled, directly or indirectly, by a competitor of SMSA, then SMSA would have the right to acquire the Company’s interest in SMA. If SMSA became controlled, directly or indirectly, by a competitor of the Company, then the Company would have the right to sell its interest in SMA to SMSA. In either case, the purchase price would be determined in accordance with the joint venture agreements, and the Company would continue to have the obligation to acquire products produced by SMA for the remainder of the term of the supply agreement then in effect even though the Company would no longer be involved in SMA’s management. The Company initially had a 50% December 31, 2016, 100% The Company completed a significant portion of the construction of the new facility in 2012. 2013 February 2014, 18 March 31, 2017, second December 31, 2018 second April 1, 2019. July 1, 2015 July 2015, December 2015, R$50,000 US$15,342 December 31, 2016), 50,000 January 11, 2016. 12 12 R$9,853 US$3,023 December 31, 2016). September 1, 2016, December 31, 2017. Salisbury transaction In January 2011, two February 1, 2011 one first On November 10, 2016, December 5, 2016, $4.35 $3.5 5, first Neossance JV On December 12, 2016, third At the closing of the formation of the Neossance JV, which occurred on December 19, 2016, 50% $10 three $10 Pursuant to the Joint Venture Agreement, the Company and Nikko agreed to make working capital loans to the Neossance JV in the amounts of $500,000 $1,500,000, Under the Neossance JV Agreement, in the event of a merger, acquisition, sale or other similar reorganization, or a bankruptcy, dissolution, insolvency or other similar event, of the Company, on the one first In connection with the formation of the Neossance JV, the members entered into a First Amended and Restated LLC Operating Agreement of the Neossance JV (Operating Agreement). Pursuant to the Operating Agreement, the Neossance JV will be managed by a Board of Directors, which shall initially consist of four two two one one Under the Operating Agreement, profits from the operations of the Neossance JV, if any, will be distributed as follows: (i) first, zero second, (50%/50%) one In connection with the contribution of the Glycotech Assets by the Company to the Neossance JV, at the closing of the formation of the Neossance JV, Nikko made a loan to the Company in the principal amount of $3.9 5, The table table below reflects the carrying amount of the assets and liabilities of the consolidated VIE for which the Company is the primary beneficiary at December 31, 2016 (two December 31, 2015). December 31, (In thousands) 2016 2015 Assets $ 2,277 $ 6,993 Liabilities $ 135 $ 1,221 The change in noncontrolling interest for the years ended December 31, 2016 2015 2016 2015 Balance at January 1 $ 391 $ 611 Foreign currency translation adjustment — (320 ) Income attributable to noncontrolling interest (1,328 ) 100 Balance at December 31 $ (937 ) $ 391 |
Note 8 - Significant Agreements
Note 8 - Significant Agreements | 12 Months Ended |
Dec. 31, 2016 | |
Notes to Financial Statements | |
Collaborative Arrangement Disclosure [Text Block] | 8. Research and Development Activities Firmenich Collaboration Agreement In March 2013, November 2010 10 3 twelve The Firmenich Collaboration Agreement provided for annual, up-front funding to the Company by Firmenich of $10.0 first three $10.0 March 2013, 2014 2015. $5.0 four December 2016, third $7.5 $11.0 December 31, 2016 2015, six, six, Under the Firmenich Collaboration Agreement, the parties agreed to jointly select target compounds, subject to final approval of compound specifications by Firmenich. During the development phase, the Company would be required to provide labor, intellectual property and technology infrastructure and Firmenich would be required to contribute downstream polishing expertise and market access. The Firmenich Collaboration Agreement provides that the Company will own research and development and strain engineering intellectual property, and Firmenich will own blending and, if applicable, chemical conversion intellectual property. Under certain circumstances, such as the Company’s insolvency, Firmenich would gain expanded access to the Company’s intellectual property. The Firmenich Collaboration Agreement contemplates that, following development of flavors and fragrances compounds, the Company will manufacture the initial target molecules for the compounds and Firmenich will perform any required downstream polishing and distribution, sales and marketing. The Firmenich Collaboration Agreement provides that the parties will mutually agree on a supply price for each compound developed under the agreement and, subject to certain exceptions, will share product margins from sales of each such compound on a 70/30 (70% $15.0 50/50. one $2.5 In September 2014, $9.7 $1.4 December 31, 2016 2015, In December 2016, third ten third DARPA Technology Investment Agreement In September 2015, 2015 five 2015 2015 2015 2015 $35.0 four $15.5 four may, 2015 The Company recognized collaboration revenues of $9.7 zero December 31, 2016 2015, Ginkgo Initial Strategic Partnership Agreement and Collaboration Agreement In June 2016, $20.0 two ten first $15.0 July 25, 2016. second $5.0 may March 31, 2017. March 31, 2017, second In addition, pursuant to the Initial Ginkgo Agreement, (i) the Company and Ginkgo agreed to pursue the negotiation and execution of a detailed definitive partnership and license agreement setting forth the terms of a commercial partnership and collaboration arrangement between the parties (Ginkgo Collaboration), (ii) the Company agreed to issue to Ginkgo an option to purchase five $0.50, one October 31, 2016 5, 16, On August 6, 2016, five $0.50 one On September 30, 2016, third March 30, 2017, $5 March 31, 2017. March 31, 2017, second Under the Ginkgo Collaboration Agreement, subject to certain exceptions, including excluded or refused products and cost savings initiatives, the profit on the sale of products subject to the Ginkgo Collaboration Agreement as well as cost-sharing, milestone and “value-creation” payments associated with the development and production of such products will be shared equally between the parties. The parties also agreed to provide each other with a license and other rights to certain intellectual property necessary to support the development and manufacture of the products under the Ginkgo Collaboration, and also to provide each other with access to certain other intellectual property useful in connection with the activities to be undertaken under the Ginkgo Collaboration Agreement, subject to certain carve-outs. The initial term of the Ginkgo Collaboration Agreement is three one 90 18 30 The Company recognized $15.0 zero December 31, 2016. December 31, 2016, $1.6 Intellectual Property License and Strain Access Agreement In December 2016, $10 may Financing Agreements 2016 See Note 5, February, June October 2016 At Market Issuance Sales Agreement On March 8, 2016, may $50.0 3 333 203216), April 15, 2015. 415 one may 3.0% During the year ended December 31, 2016, $50.0 March 2016 See Note 7, March 2016 Bill & Melinda Gates Foundation Investment On April 8, 2016, 4,385,964 $1.14, twenty April 7, 2016, $5 May 10, 2016. In connection with the entry into the Securities Purchase Agreement, on April 8, 2016, 2017. third $1.14 10%. December 31, 2016, $5.0 2016 See Note 5, May December 2016 Fourth Amendment to LSA See Note 5, fourth Guanfu Credit Facility See Note 5, Glycotech Acquisition and Salisbury Note See Note 5, 7, Neossance JV and Nikko Note See Note 5, 7, Fidelity Exchange See Note 5, 16, |
Note 9 - Goodwill and Intangibl
Note 9 - Goodwill and Intangible Assets | 12 Months Ended |
Dec. 31, 2016 | |
Notes to Financial Statements | |
Goodwill and Intangible Assets Disclosure [Text Block] | 9. The following table presents the components of the Company's goodwill and intangible assets (in thousands): December 31, 2016 December 31, 2015 Useful Life in Years Gross Carrying Amount Accumulated Amortization/ Net Carrying Value Gross Carrying Amount Accumulated Amortization/ Net Carrying Value In-process research and development Indefinite $ 8,560 $ (8,560 ) $ — $ 8,560 $ (8,560 ) $ — Acquired licenses and permits 2 772 (772 ) — 772 (772 ) — Goodwill Indefinite 560 — 560 560 — 560 $ 9,892 $ (9,332 ) $ 560 $ 9,892 $ (9,332 ) $ 560 The in-process research and development (IPR&D) of $8.6 October 2011 2015. The Company has a single reportable segment (see Note 15, |
Note 10 - Stockholders' Deficit
Note 10 - Stockholders' Deficit | 12 Months Ended |
Dec. 31, 2016 | |
Notes to Financial Statements | |
Stockholders' Equity Note Disclosure [Text Block] | 10. Private Placement December 2012 In December 2012, 14,177,849 $2.98 $37.2 $5.0 1,677,852 December 31, 2012 $22.2 $15.0 January 2013. $10.0 December 2012 $15.0 March 31, 2013 In January 2013, $15.0 December 2012. 5,033,557 14,177,849 March 2013 In March 2013, 1,533,742 $3.26 $5.0 $15.0 April 2014 In April 2014, 943,396 $4.24 $4.0 July 2015 In July 2015, 16,025,642 $1.56 1,602,562 $0.01 $25 May 2016 In May 2016, 4,385,964 $1.14 $5.0 8, Evergreen Shares for 2010 2010 In January 2016, 2010 2010 10,301,709 1,030,170, 5% 0.5%, 206,034,184 December 31, 2015. January 1, 2016. 8 October 1, 2010 333 169715). 8 April 1, 2016 333 210569) January 1, 2016. Common Stock As of December 31, 2016 2015, 500,000,000 400,000,000 May 2016, 400,000,000 500,000,000 May 2016). one Preferred Stock Pursuant to the Company’s amended and restated certificate of incorporation, the Company is authorized to issue 5,000,000 one December 31, 2016 December 31, 2015, zero Common Stock Warrants In December 2011, 21,087 $10.67 $0.2 10 2%, 86% zero December 31, 2016. In October 2013, 5, 1,000,000 $0.01 $1.3 3.4 0.77%, 45% zero December 31, 2016. Each of these warrants includes a cashless exercise provision which permits the holder of the warrant to elect to exercise the warrant without paying the cash exercise price, and receive a number of shares determined by multiplying (i) the number of shares for which the warrant is being exercised by (ii) the difference between the fair market value of the stock on the date of exercise and the warrant exercise price, and dividing such by (iii) the fair market value of the stock on the date of exercise. During the years ended December 31, 2016 2015, no The Temasek Exchange Warrant and Total Funding Warrant issued under the Exchange Agreement were recognized in equity at fair value on July 29, 2015. 2%, 74% zero 5, In July 2015, 1,602,562 $0.01 December 31, 2016, 1,442,307 In February 2016, $0.01 2,857,142 5, December 31, 2016, In August 2016, 5,000,000 $0.50 8, December 31, 2016, In November 2016, 10,000,000 $0.50 October 26, 2016, December 31, 2016, As of December 31, 2016 2015, 14,663,411 4,343,733 |
Note 11 - Stock-based Compensat
Note 11 - Stock-based Compensation Plans | 12 Months Ended |
Dec. 31, 2016 | |
Notes to Financial Statements | |
Disclosure of Compensation Related Costs, Share-based Payments [Text Block] | 11. 2010 The Company's 2010 2010 September 28, 2010 2020. 2010 2005 (2005 2005 2010 2010 2,193,704 2005 2010 The number of shares reserved for issuance under the 2010 January 1 st January 1, 2011, 5% December 31 st 2010 2010 may may may 30,000,000 2010 2010 may ten ten may 100% 10% may 110% four five As of December 31, 2016 2015, 11,924,020 11,321,194 2010 December 31, 2016 2015, 8,285,891 1,833,004 may 2010 December 31, 2016 2015 $3.01 $4.27 2005 In 2005, 2005 2005 2005 2005 All options issued under the 2005 ten 2005 100% 10% 110% 5 As of December 31, 2016 2015, 1,503,665 1,548,918 2005 2010 zero 2005 2005 December 31, 2016 2015 $8.51 $8.46 2010 The 2010 (2010 September 28, 2010. 2010 one two six twelve May 16 th November 16 th two six 2010 85% first 168,627 2010 2010 January 1 st January 1, 2011, 1% December 31 st 10,000,000 may 2010 may During the years ended December 31, 2016 2015, 336,075 385,892 2010 December 31, 2016 2015, 885,821 1,221,896 2010 Stock Option Activity The Company’s stock option activity and related information for the year ended December 31, 2016 Number Weighted- Weighted-Average Aggregate (in thousands) Outstanding - December 31, 2015 12,930,112 $ 4.77 7.39 $ 22 Options granted 3,585,175 $ 0.59 — — Options exercised (134 ) $ 0.28 — — Options cancelled (3,087,468 ) $ 4.92 — — Outstanding - December 31, 2016 13,427,685 $ 3.63 6.70 $ 443 Vested and expected to vest after December 31, 2016 12,387,314 $ 3.84 6.54 $ 361 Exercisable at December 31, 2016 7,357,308 $ 5.48 5.32 $ 1 The aggregate intrinsic value of options exercised under all option plans was $0.0 $0.0 $0.6 December 31, 2016, 2015 2014, The Company’s restricted stock units (or RSUs) and restricted stock activity and related information for the year ended December 31, 2016 RSUs Weighted-Average Grant-Date Fair Value Weighted Average Remaining Contractual Life (Years) Outstanding - December 31, 2015 5,554,844 $ 2.03 1.61 Awarded 4,897,840 $ 0.61 — Vested (2,064,881 ) $ 1.98 — Forfeited (1,390,719 ) $ 1.39 — Outstanding - December 31, 2016 6,997,084 $ 1.18 1.44 Expected to vest after December 31, 2016 5,642,538 $ 1.20 1.28 The following table summarizes information about stock options outstanding as of December 31, 2016: Options Outstanding Options Exercisable Exercise Price Number of Options Weighted- Weighted-Average Exercise Price Number of Options Weighted-Average Exercise Price $0.28—$0.57 346,234 9.47 $ 0.43 2,734 $ 0.28 $0.59—$0.59 2,424,375 8.62 $ 0.59 — $ — $0.78—$1.67 1,461,082 8.53 $ 1.46 396,916 $ 1.61 $1.69—$1.96 2,218,041 7.30 $ 1.84 863,045 $ 1.85 $1.98—$2.85 1,371,168 5.82 $ 2.61 1,129,021 $ 2.67 $2.87—$3.44 1,255,796 6.52 $ 3.02 1,095,271 $ 3.01 $3.51—$3.51 1,503,891 7.06 $ 3.51 1,020,549 $ 3.51 $3.55—$4.08 1,354,152 3.90 $ 3.88 1,296,826 $ 3.88 $4.31—$24.20 1,350,946 3.40 $ 13.05 1,350,946 $ 12.05 24.50—$30.17 202,000 4.31 $ 27.52 202,000 $ 27.52 $0.28—$30.17 13,487,685 6.70 $ 3.63 7,357,308 $ 5.48 Stock-Based Compensation Expense Stock-based compensation expense related to options and restricted stock units granted to employees was allocated to research and development expense and sales, general and administrative expense as follows (in thousands): Years Ended December 31, 2016 2015 2014 Research and development $ 1,948 $ 2,306 $ 3,508 Sales, general and administrative 5,377 6,828 10,597 Total stock-based compensation expense $ 7,325 $ 9,134 $ 14,105 During the years ended December 31, 2016, 2015 2014, 3,585,175 4,720,278 3,683,791 $0.59, $1.21, $2.31 $3.5 $6.0 $10.1 December 31, 2016, 2015 2014, December 31, 2016, 2015 2014, $4.4 $8.0 $11.4 2.7 3.0 December 31, 2016 2015, During the years ended December 31, 2016, 2015 2014, 4,897,840, 4,988,539 1,083,300 $0.61, $1.82 $3.51 $3.6 $2.8 $3.3 December 31, 2016, 2015 2014 December 31, 2016, 2015 2014, $5.4 $7.7 $3.6 During the years ended December 31, 2016, 2015 2014, 2010 $0.1 $0.3 $0.5 Employee stock-based compensation expense recognized for the years ended December 31, 2016, 2015 2014 zero, zero $0.1 zero, zero zero December 31, 2016, 2015 2014, Stock-based compensation cost for RSUs is measured based on the closing fair market value of the Company's common stock on the date of grant. Stock-based compensation expense for stock options and employee stock purchase plan rights is estimated at the grant date and offering date, respectively, based on the fair-value using the Black-Scholes option pricing model. The fair value of employee stock options is being amortized on a straight-line basis over the requisite service period of the awards. The fair value of employee stock options was estimated using the following weighted-average assumptions: Years Ended December 31, 2016 2015 2014 Expected dividend yield — % — % — % Risk-free interest rate 1.4 % 1.8 % 1.9 % Expected term (in years) 6.16 6.08 6.10 Expected volatility 73 % 74 % 75 % Expected Dividend Yield Risk-Free Interest Rate - Expected Term Expected Volatility Forfeiture Rate may Each of the inputs discussed above is subjective and generally requires significant management and director judgment. |
Note 12 - Employee Benefit Plan
Note 12 - Employee Benefit Plan | 12 Months Ended |
Dec. 31, 2016 | |
Notes to Financial Statements | |
Pension and Other Postretirement Benefits Disclosure [Text Block] | 12. The Company established a 401(k) may 401(k) 90% January 2014, December 31, 2014 90% one December 31, 2016 2015 $0.5 |
Note 13 - Related Party Transac
Note 13 - Related Party Transactions | 12 Months Ended |
Dec. 31, 2016 | |
Notes to Financial Statements | |
Related Party Transactions Disclosure [Text Block] | 13. Related Party Financings See Note 5, February 2016 March 2016 June 2016 October 2016 16, March 2016 As of December 31, 2016 December 31, 2015, $72.4 $42.7 $6.7 $4.9 The fair value of the derivative liabilities related to the related party convertible notes as of December 31, 2016 December 31, 2015 $0.8 $7.9 $7.6 $10.5 $141.2 December 31, 2016, 2015 2014, 3, Related Party Revenues The Company recognized related party revenues from product sales to Total of $0.2 $0.9 $0.6 December 31, 2016, 2015 2014, December 31, 2016 2015, $0.8 $1.2 $1.4 zero $0.1 December 31, 2016, 2015 2014, zero December 31, 2016 2015. October 2016 2016. Loans to Related Parties See Note 7, Joint Venture with Total In November 2013, 7, Pilot Plant and Secondee Agreements In May 2014, April 4, 2014 five $0.9 July 2015, #1 $2.0 $0.1 As of December 31, 2016, $1.7 $0.4 $0.9 December 31, 2016 2015, secondees 2016 2015 $0.8 $0.9 $2.2 $1.4 December 31, 2016 2015, Office Sublease As of December 31, 2016, $0.4 $0.4 2016 $0.7 2015. December 31, 2016, 2015, $0.2 zero, |
Note 14 - Income Taxes
Note 14 - Income Taxes | 12 Months Ended |
Dec. 31, 2016 | |
Notes to Financial Statements | |
Income Tax Disclosure [Text Block] | 14. For each of the years ended December 31, 2016, 2015 2014, $0.5 December 31, 2016, 2015 2014, no The components of income (loss) before income taxes, loss from investments in affiliates and noncontrolling interest are as follows for the years ended December 31, 2016, 2015 2014 Years Ended December 31, 2016 2015 2014 United States $ (101,210 ) $ (188,943 ) $ 10,847 Foreign 4,429 (24,457 ) (5,275 ) Income (loss) before income taxes and loss from investments in affiliates $ (96,781 ) $ (213,400 ) $ 5,572 The components of the provision for income taxes are as follows for the years ended December 31, 2016, 2015 2014 Years Ended December 31, 2016 2015 2014 Current: Federal $ — $ — $ — State — — — Foreign 553 468 495 Total current provision 553 468 495 Deferred: Federal — — — State — — — Foreign — — — Total deferred provision — — — Total provision for income taxes $ 553 $ 468 $ 495 A reconciliation between the statutory federal income tax and the Company’s effective tax rates as a percentage of income (loss) before income taxes is as follows: Years Ended December 31, 2016 2015 2014 Statutory tax rate (34.0 )% (34.0 )% (34.0 )% State tax rate, net of federal benefit 0.0 % (0.3 )% 23.3 % Stock-based compensation — % 0.1 % (2.8 )% Federal R&D credit (0.8 )% (0.6 )% 31.0 % Derivative liabilities 1.4 % 3.6 % 541.5 % Non-Deductible Interest 5.0 % 5.5 % 0.0 % Other (3.2 )% 0.1 % (7.8 )% Foreign losses 0.5 % (1.2 )% 32.3 % Change in valuation allowance 31.7 % 27.1 % (592.4 )% Effective income tax rate 0.6 % 0.3 % (8.9 )% Temporary differences and carryforwards that gave rise to significant portions of deferred taxes are as follows (in thousands): December 31, 2016 2015 2014 Net operating loss carryforwards $ 236,741 $ 207,241 $ 195,536 Fixed assets 12,917 10,519 1,299 Research and development credits 17,348 16,612 14,701 Foreign Tax Credit 2,452 1,899 1,431 Accruals and reserves 30,303 26,366 16,425 Stock-based compensation 17,184 19,048 18,773 Capitalized start-up costs 9,182 9,568 13,095 Capitalized research and development costs 65,962 63,339 56,880 Other 6,714 9,999 6,700 Total deferred tax assets 398,803 364,591 324,840 Fixed assets — — — Debt discount and derivative (11,936 ) (4,402 ) (12,517 ) Total deferred tax liabilities (11,936 ) (4,402 ) (12,517 ) Net deferred tax asset prior to valuation allowance 386,867 360,189 312,323 Less: Valuation allowance (386,867 ) (360,189 ) (312,323 ) Net deferred tax assets (liabilities) $ — $ — $ — Recognition of deferred tax assets is appropriate when realization of such assets is more likely than not. Based upon the weight of available evidence, especially the uncertainties surrounding the realization of deferred tax assets through future taxable income, the Company believes it is more likely than not that the net deferred tax assets will not December 31, 2016, 2015 2014. $26.7 $47.9 $28.3 December 31, 2016, 2015 2014, As of December 31, 2016, $645.3 $208.7 December 31, 2016 $27.2 $12.9 2016 09, Recent Accounting Pronouncements 2, 2016 09 During the year ended December 31, 2015, $8.5 As of December 31, 2016, $9.8 $11.4 The Tax Reform Act of 1986 382. 2025, 2016. 2024 A reconciliation of the beginning and ending amounts of unrecognized tax benefits is as follows: Balance at December 31, 2013 $ 6,080 Increases in tax positions for prior period 4,736 Increases in tax positions during current period 6,265 Balance at December 31, 2014 $ 17,081 Decreases in tax positions for prior period (9,404 ) Increases in tax positions during current period 957 Balance at December 31, 2015 $ 8,634 Decreases in tax positions for prior period (314 ) Increases in tax positions during current period 781 Balance at December 31, 2016 9,101 The Company’s policy is to include interest and penalties related to unrecognized tax benefits within the provision for taxes. The Company determined that no December 31, 2016, December 31, 2015 December 31, 2014. None not 12 The Company’s primary tax jurisdiction is the United States. For United States federal and state tax purposes, returns for tax years 2004 2009 As of December 31, 2016, 2008 no 2008, may |
Note 15 - Reporting Segments
Note 15 - Reporting Segments | 12 Months Ended |
Dec. 31, 2016 | |
Notes to Financial Statements | |
Segment Reporting Disclosure [Text Block] | 15. The chief operating decision maker for the Company is the chief executive officer. The chief executive officer reviews financial information presented on a consolidated basis, accompanied by information about revenues by geographic region, for purposes of allocating resources and evaluating financial performance. The Company has one Revenues by geography are based on the location of the customer. The following tables set forth revenues and long-lived assets by geographic area (in thousands): Revenues Years Ended December 31, 2016 2015 2014 United States $ 3 0,944 $ 20,897 $ 21,331 Brazil 489 5,070 5,961 Europe 23,612 3,557 9,738 Asia 12,068 4,629 6,244 Other 79 — — Total $ 6 7,192 $ 34,153 $ 43,274 Long-Lived Assets December 31, 2016 2015 United States $ 9,342 $ 18,401 Brazil 44,153 41,093 Europe 240 303 Total $ 53,735 $ 59,797 |
Note 16 - Subsequent Events
Note 16 - Subsequent Events | 12 Months Ended |
Dec. 31, 2016 | |
Notes to Financial Statements | |
Subsequent Events [Text Block] | 16. LSA Amendment On January 10, 2017, fifth fifth $3 As described in more detail below under “Fidelity Notes Exchange,” on January 11, 2017, February 1, 2017 October 15, 2018 Fidelity Notes Exchange As described in more detail in Note 5, December 28, 2016, $19.1 2015 144A 1:1.25, The closing of the Fidelity Exchange occurred on January 11, 2017. $19.1 2015 144A 2015 144A 2015 144A $0.1 first 2015 144A The Additional 2015 144A 2015 January 11, 2017, 2015 2015 144A 5, 2015 144A 2015 2015 144A 2015 144A 2015 144A 2015 144A 19.99% December 28, 2016 Pursuant to the Exchange Agreement, upon the closing of the Fidelity Exchange, the Fidelity Securities Purchase Agreement terminated. In addition, upon the closing of the Fidelity Exchange, in accordance with the terms of the fourth October 15, 2018. 5, fourth Novvi Investment As discussed above in Note 7, July 2016, $10.0 one third $9.0 December 31, 2016. February 15, 2017, $1.0 Amendment to March 2016 On February 27, 2017, March 21, 2016 $3.7 March 1, 2017 May 15, 2017. 5, Total and Temasek R&D Warrants As discussed above under Note 5, July 2015, 2,000,000 March 1, 2017, 880,339 2,000,000 March 1, 2017, March 1, 2017 880,339 2,000,000. Ginkgo Collaboration Note On April 13, 2017, $3 Ginkgo Collaboration Note 8, second October 27, 2016 April 13, 2017, April 13, 2017 13.50% May 15, 2017, may |
Supplementary Financial Data -
Supplementary Financial Data - Selected Quarterly Financial Data | 12 Months Ended |
Dec. 31, 2016 | |
Notes to Financial Statements | |
Quarterly Financial Information [Text Block] | SUPPLEMENTARY FINANCIAL DATA Selected Quarterly Financial Data (unaudited) The following table presents selected unaudited consolidated financial data for each of the eight two December 31, 2016. four may Quarter First Second Third Fourth (In thousands, except share and per share amounts) Year Ended December 31, 2016 Total revenues $ 8,811 $ 9,599 $ 26,544 $ 22,238 Product sales $ 3,140 $ 4,922 $ 6,820 $ 11,467 Gross loss from product sales $ (8,038 ) $ (2,969 ) $ (8,056 ) $ (11,290 ) Net loss attributable to common stockholders (for basic loss per share) (1) $ (15,308 ) $ (13,566 ) $ (19,704 ) $ (48,756 ) Net loss attributable to common stockholders (for diluted loss per share) $ (30,273 ) $ (29,245 ) $ (19,704 ) $ (48,756 ) Net loss per share: Basic (1) $ (0.07 ) $ (0.06 ) $ (0.08 ) $ (0.18 ) Diluted $ (0.12 ) $ (0.11 ) $ (0.08 ) $ (0.18 ) Shares used in calculation: Basic 207,199,563 223,112,019 249,190,339 273,406,492 Diluted 260,932,085 262,896,140 249,190,339 273,406,492 Year Ended December 31, 2015 Total revenues $ 7,872 $ 7,843 $ 8,591 $ 9,847 Product sales $ 2,095 $ 3,340 $ 4,228 $ 5,233 Gross loss from product sales $ (4,548 ) $ (7,619 ) $ (4,227 ) $ (6,084 ) Net loss attributable to common stockholders (for basic loss per share) (1) $ (52,240 ) $ (47,130 ) $ (76,664 ) $ (48,352 ) Net loss attributable to common stockholders (for diluted loss per share) $ (52,240 ) $ (54,527 ) $ (76,664 ) $ (68,316 ) Net loss per share: Basic (1) $ (0.66 ) $ (0.59 ) $ (0.55 ) $ (0.23 ) Diluted $ (0.66 ) $ (0.62 ) $ (0.55 ) $ (0.30 ) Shares used in calculation: Basic 79,222,051 80,041,152 140,374,297 206,661,506 Diluted 79,222,051 87,421,439 140,374,297 231,014,248 _________ (1) fourth 2015 $6,424 |
Schedule II - Valuation and Qua
Schedule II - Valuation and Qualifying Accounts | 12 Months Ended |
Dec. 31, 2016 | |
Notes to Financial Statements | |
Schedule of Valuation and Qualifying Accounts Disclosure [Text Block] | SCHEDULE II VALUATION AND QUALIFYING ACCOUNTS FOR THE YEARS ENDED DECEMBER 31, 2016, 2015 2014 (in thousands) Balance at Beginning of Period Additions Write-off Adjustments Balance at End of Period Deferred Tax Assets Valuation Allowance: Year ended December 31, 2016 $ 360,189 $ 26,678 $ — $ 386,867 Year ended December 31, 2015 $ 312,323 $ 47,866 $ — $ 360,189 Year ended December 31, 2014 $ 284,021 $ 28,302 $ — $ 312,323 Balance at Beginning of Period Additions Write-off Adjustments Balance at End of Period Allowance for Doubtful Accounts: Year ended December 31, 2016 $ 969 $ — $ (468 ) $ 501 Year ended December 31, 2015 $ 479 $ 490 $ — $ 969 Year ended December 31, 2014 $ 479 $ — $ — $ 479 |
Significant Accounting Policies
Significant Accounting Policies (Policies) | 12 Months Ended |
Dec. 31, 2016 | |
Accounting Policies [Abstract] | |
Basis of Accounting, Policy [Policy Text Block] | Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with the accounting principles generally accepted in the United States of America (or GAAP) and with the instructions for Form 10 The Company uses the equity method to account for investments in companies, if its investments provide it with the ability to exercise significant influence over operating and financial policies of the investee. Consolidated net income or loss includes the Company’s proportionate share of the net income or loss of these companies. Judgments made by the Company regarding the level of influence over each equity method investment include considering key factors such as the Company’s ownership interest, representation on the board of directors, participation in policy-making decisions and material intercompany transactions. |
Consolidation, Policy [Policy Text Block] | Principles of Consolidation The consolidated financial statements of the Company include the accounts of Amyris, Inc., its subsidiaries and two 7, |
Consolidation, Variable Interest Entity, Policy [Policy Text Block] | Variable Interest Entities The Company has interests in joint venture entities that are VIEs. Determining whether to consolidate a VIE requires judgment in assessing (i) whether an entity is a VIE and (ii) if the Company is the entity’s primary beneficiary and thus required to consolidate the entity. To determine if the Company is the primary beneficiary of a VIE, the Company evaluates whether it has (i) the power to direct the activities that most significantly impact the VIE’s economic performance and (ii) the obligation to absorb losses or the right to receive benefits of the VIE that could potentially be significant to the VIE. The Company’s evaluation includes identification of significant activities and an assessment of its ability to direct those activities based on governance provisions and arrangements to provide or receive product and process technology, product supply, operations services, equity funding and financing and other applicable agreements and circumstances. The Company’s assessment of whether it is the primary beneficiary of its VIEs requires significant assumptions and judgment. |
Use of Estimates, Policy [Policy Text Block] | Use of Estimates In preparing the consolidated financial statements, management must make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. |
Concentration Risk, Credit Risk, Policy [Policy Text Block] | Concentration of Credit Risk Financial instruments that potentially subject the Company to a concentration of credit risk consist primarily of cash and cash equivalents, short term investments and accounts receivable. The Company places its cash equivalents and investments (primarily certificates of deposits) with high credit quality financial institutions and, by policy, limits the amount of credit exposure with any one may The Company performs ongoing credit evaluation of its customers, does not require collateral, and maintains allowances for potential credit losses on customer accounts when deemed necessary. Customers representing 10% December 31, Customers 2016 2015 Customer L 19 % ** Customer K 13 % * Customer H ** 23 % Customer C ** 26 % Customer G ** 10 % ______________ * No outstanding balance ** Less than 10% Customers representing 10% Years Ended December 31, Customers 2016 2015 2014 Customer N 13 % * * Customer M 19 % * * Customer E 23 % 37 % 47 % Customer J ** 10 % ** Customer C ** ** 10 % ______________ * Not a customer ** Less than 10% |
Fair Value Measurement, Policy [Policy Text Block] | Fair Value of Financial Instruments The Company measures certain financial assets and liabilities at fair value based on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants. Where available, fair value is based on or derived from observable market prices or other observable inputs. Where observable prices or inputs are not available, valuation techniques are applied. These valuation techniques involve some level of management estimation and judgment, the degree of which is dependent on the price transparency for the instruments or market and the instruments’ complexity. The carrying amounts of certain financial instruments, such as cash equivalents, short term investments, accounts receivable, accounts payable and accrued liabilities, approximate fair value due to their relatively short maturities. The fair values of the loans payable, convertible notes and credit facilities are based on the present value of expected future cash flows and assumptions about current interest rates and the creditworthiness of the Company. The loans payable, convertible notes and credit facilities are carried on the consolidated balance sheet on a historical cost basis, because the Company has not elected to recognize the fair value of these liabilities. However, the Remaining Notes subject to the Maturity Treatment Agreement were revalued to fair value on July 29, 2015 5, The Company estimates the fair value of the compound embedded derivatives for the convertible promissory notes issued to Total Energies Nouvelles Activités USA (formerly known as Total Gas & Power USA, SAS, or Total) under the Total Fuel Agreements (refer to Note 5, may The Company estimates the fair value of the compound embedded derivatives for the notes issued in the first second August 2013 2014 144A 2015 144A 5, two one (1) (2) Changes in the inputs into these valuation models have a significant impact on the estimated fair value of the embedded derivatives. For example, a decrease (increase) in the estimated credit spread for the Company results in an increase (decrease) in the estimated fair value of the embedded derivatives. Conversely, a decrease (increase) in the stock price results in a decrease (increase) in the estimated fair value of the embedded derivatives. The changes during 2016, 2015 2014 |
Cash and Cash Equivalents, Policy [Policy Text Block] | Cash and Cash Equivalents All highly liquid investments purchased with an original maturity date of 90 |
Investment, Policy [Policy Text Block] | Short Term Investments Investments with original maturities greater than 90 1 90 one December 31, 2016, 2015 2014. December 31, 2016 2015, |
Receivables, Policy [Policy Text Block] | Accounts Receivable The Company maintains an allowance for doubtful accounts receivable for estimated losses resulting from the inability of its customers to make required payments. The Company determines this allowance based on specific doubtful account identification and management judgment on estimated exposure. The Company writes off accounts receivable against the allowance when it determines a balance is uncollectible and no longer actively pursues collection of the receivable. |
Inventory, Policy [Policy Text Block] | Inventories Inventories, which consist of farnesene-derived products and flavor and fragrances ingredients are stated at the lower of cost or market and categorized as finished goods, work-in-process or raw material inventories. The Company evaluates the recoverability of its inventories based on assumptions about expected demand and net realizable value. If the Company determines that the cost of inventories exceeds its estimated net realizable value, the Company records a write-down equal to the difference between the cost of inventories and the estimated net realizable value. If actual net realizable values are less favorable than those projected by management, additional inventory write-downs may may first first |
Equity Method Investments, Policy [Policy Text Block] | Investments in Affiliates We use the equity method to account for our investments in affiliates. We include our proportionate share of earnings and/or losses of our equity method investees in the loss from investments in affiliates in the consolidated statements of operations. The carrying value of our investments in affiliates includes loans to affiliates. Investments in affiliates are carried at cost less impairment, as adjusted for market rates of interest imputed to non-market interest rate loans advanced to affiliates. |
Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] | Restricted Cash Cash accounts that are restricted as to withdrawal or usage are presented as restricted cash. As of December 31, 2016 2015, $5.3 $1.2 |
Derivatives, Policy [Policy Text Block] | Derivative Instruments The Company makes limited use of derivative instruments, which includes currency interest rate swap agreements, to manage the Company's exposure to foreign currency exchange rate fluctuations and interest rate fluctuations related to the Company's Banco Pine S.A. loan (discussed below under Note 5, Embedded derivatives that are required to be bifurcated from the underlying debt instrument (i.e., host) are accounted for and valued as separate financial instruments. The Company evaluated the terms and features of its convertible notes payable and identified compound embedded derivatives requiring bifurcation and accounting at fair value because the economic and contractual characteristics of the embedded derivatives met the criteria for bifurcation and separate accounting due to the conversion options containing “make-whole interest” provisions, down round conversion price adjustment provisions and conversion rate adjustments. |
Property, Plant and Equipment, Policy [Policy Text Block] | Property, Plant and Equipment, net Property, plant and equipment, net are stated at cost less accumulated depreciation and amortization. Depreciation and amortization is computed using the straight-line method over the estimated useful lives of the related assets. Maintenance and repairs are charged to expense as incurred, and improvements and betterments are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in operations in the period realized. Depreciation and amortization periods for the Company’s property, plant and equipment are as follows: Machinery and equipment (years) 7 - 15 Buildings (years) 15 Computers and software (years) 3 - 5 Furniture and office equipment (years) 5 Vehicles (years) 5 Buildings and leasehold improvements are amortized on a straight-line basis over the term of the lease, or the useful life of the assets, whichever is shorter. Computers and software includes internal-use software that is acquired to meet the Company’s needs. Amortization commences when the software is ready for its intended use and the amortization period is the estimated useful life of the software, generally 3 5 |
Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block] | Impairment of Long-Lived Assets Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may $7.3 $28.5 $1.8 December 31, 2016, 2015 2014, |
Goodwill and Intangible Assets, Policy [Policy Text Block] | Goodwill and Intangible Assets Goodwill represents the excess of the cost over the fair value of net assets acquired from business combinations. Intangible assets are comprised primarily of in-process research and development (or IPR&D). Goodwill and IPR&D were recognized on an acquisition completed in 2011. There are several methods that can be used to determine the estimated fair value of the IPR&D acquired in a business combination. We used the "income method," which applies a probability weighting that considers the risk of development and commercialization, to the estimated future net cash flows that are derived from projected sales revenues and estimated costs. These projections are based on factors such as relevant market size, pricing of similar products, and expected industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. These assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets will be amortized over the remaining useful life or written off, as appropriate. Amounts recorded as IPR&D will begin being amortized upon the completion of development activities over the estimated useful life of the technology. The development activities have not been completed, and therefore the amortization of the acquired IPR&D has not begun. Factors that could trigger an impairment review include significant under-performance relative to expected historical or projected future operating results, significant changes in the manner of use of the acquired assets or the strategy for the Company's overall business or significant negative industry or economic trends. If this evaluation indicates that the value of the intangible asset may zero, $5.5 $3.0 December 31, 2016, 2015 2014, December 31, 2016, zero. |
Combination of Entities under Common Control, Policy [Policy Text Block] | Noncontrolling Interest Changes in noncontrolling interest ownership that do not result in a change of control and where there is a difference between the fair value of the consideration paid/received and the amount by which the noncontrolling interest is adjusted are accounted for as equity transactions. |
Revenue Recognition, Policy [Policy Text Block] | Revenue Recognition The Company recognizes revenue from the sale of renewable products, delivery of research and development services, licensing of intellectual property, and from governmental grants. Revenue is recognized when all of the following criteria are met: persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the fee is fixed or determinable, and collectability is reasonably assured. If sales arrangements contain multiple elements, the Company evaluates whether the components of each arrangement represent separate units of accounting. Product Sales The Company's renewable product sales do not include rights of return. Returns are only accepted if the product does not meet product specifications and such nonconformity is communicated to the Company within a set number of days of delivery. The Company offers a two March 31, 2012, Grants, Collaborative Research Services and License Fees Revenues from collaborative research services are recognized as the services are performed consistent with the performance requirements of the contract. In cases where the planned levels of research services fluctuate over the research term, we recognize revenues using the proportionate performance method based upon actual efforts to date relative to the amount of expected effort to be incurred by us. When up-front payments are received and the planned levels of research services do not fluctuate over the research term, revenues are recorded on a ratable basis over the arrangement term, up to the amount of cash received. When up-front payments are received and the planned levels of research services fluctuate over the research term, revenues are recorded using the proportionate performance method, up to the amount of cash received. Where arrangements include milestones that are determined to be substantive and at risk at the inception of the arrangement, revenues are recognized upon achievement of the milestone and is limited to those amounts whereby collectability is reasonably assured. License fees for intellectual property transferred to other parties, representing non-refundable payments received at the time of signature of license agreements, are recognized as revenue upon signature of the license agreements when the Company has no significant future performance obligations and collectability of the fees is assured. Upfront payments received at the beginning of licensing agreements are deferred and recognized as revenue on a systematic basis over the period during which the related services are rendered and all obligations are performed. Government grants are agreements that generally provide cost reimbursement for certain types of expenditures in return for research and development activities over a contractually defined period. Revenues from government grants are recognized in the period during which the related costs are incurred, provided that the conditions under which the government grants were provided have been met and only perfunctory obligations are outstanding. |
Cost of Sales, Policy [Policy Text Block] | Cost of Products Sold Cost of products sold includes production costs of renewable products, which include cost of raw materials, amounts paid to contract manufacturers and period costs including inventory write-downs resulting from applying lower-of-cost-or-market inventory valuation. Cost of products sold also includes certain costs related to the scale-up in production of such products. Shipping and handling costs charged to customers are recorded as revenues. Shipping costs are included in cost of products sold. Such charges were not material in any of the periods presented. |
Research and Development Expense, Policy [Policy Text Block] | Research and Development Research and development costs are expensed as incurred and include costs associated with research performed pursuant to collaborative agreements and government grants, including internal research. Research and development costs consist of direct and indirect internal costs related to specific projects as well as fees paid to others that conduct certain research activities on the Company’s behalf. |
Debt, Policy [Policy Text Block] | Debt Extinguishment The Company accounts for the income or loss from extinguishment of debt in accordance with ASC 470, |
Income Tax, Policy [Policy Text Block] | Income Taxes The Company accounts for income taxes under the asset and liability method, which requires, among other things, that deferred income taxes be provided for temporary differences between the tax basis of the Company’s assets and liabilities and their financial statement reported amounts. In addition, deferred tax assets are recorded for the future benefit of utilizing net operating losses and research and development credit carryforwards. A valuation allowance is provided against deferred tax assets unless it is more likely than not that they will be realized. The Company recognizes and measures uncertain tax positions in accordance with Income Taxes subtopic 05 6 740, 50% |
Foreign Currency Transactions and Translations Policy [Policy Text Block] | Currency Translation The Company considers the local currency to be the functional currency of the Company’s wholly-owned subsidiary in Brazil and of the Company's consolidated joint venture in Brazil. Accordingly, asset and liability accounts of those operations are translated into United States dollars using the current exchange rate in effect at the balance sheet date and equity accounts are translated into United States dollars using historical rates. The revenues and expenses are translated using the exchange rates in effect when the transactions occur. Gains and losses from foreign currency translation adjustments are included as a component of accumulated other comprehensive income (loss) on the consolidated balance sheets. Foreign currency differences arising from the translation of intercompany loans from a foreign currency into the functional currency of an entity, which are of a long-term investment nature (that is, settlement is not planned or anticipated in the foreseeable future) are recorded in “Accumulated other comprehensive income (loss)” on our Consolidated Balance Sheets. Foreign currency differences arising from the translation of other intercompany loans are recorded in “Other income (expense)” on our Consolidated Statements of Operations. |
Compensation Related Costs, Policy [Policy Text Block] | Stock-Based Compensation The Company accounts for stock-based compensation arrangements with employees using a fair value method which requires the recognition of compensation expense for costs related to all stock-based payments including stock options. The fair value method requires the Company to estimate the fair value of stock-based payment awards on the date of grant. The Company uses the Black-Scholes option pricing model to estimate the fair value of options granted, which is expensed on a straight-line basis over the vesting period. The Company accounts for restricted stock unit awards issued to employees based on the fair market value of the Company’s common stock. |
Comprehensive Income, Policy [Policy Text Block] | Comprehensive Income (Loss) Comprehensive income (loss) represents all changes in stockholders’ deficit except those resulting from investments or contributions by stockholders. The Company’s foreign currency translation adjustments represent the components of comprehensive income (loss) excluded from the Company’s net income (loss) and have been disclosed in the consolidated statements of comprehensive loss for all periods presented. The components of accumulated other comprehensive loss are as follows (in thousands): December 31, 2016 2015 Foreign currency translation adjustment, net of tax $ (40,904 ) $ (47,198 ) Total accumulated other comprehensive loss $ (40,904 ) $ (47,198 ) |
Earnings Per Share, Policy [Policy Text Block] | Net Loss Attributable to Common Stockholders and Net Loss per Share The Company computes net loss per share in accordance with ASC 260, 2015 December 31, 2015, The following table presents the calculation of basic and diluted net loss per share of common stock attributable to Amyris, Inc. common stockholders (in thousands, except share and per share amounts): Years Ended December 31, 2016 2015 2014 Numerator: Net income (loss) attributable to Amyris, Inc. common stockholders $ (97,334 ) $ (217,952 ) $ 2,286 Adjustment to exclude fair value gain on liability classified warrants (1) — (3,825 ) — Net income (loss) attributable to Amyris, Inc. common stockholders (for basic income (loss) per share) (97,334 ) (221,777 ) 2,286 Interest on convertible debt 4,428 — 9,365 Accretion of debt discount 2,889 — 5,597 Gain from change in fair value of derivative instruments (25,630 ) — (127,109 ) Net loss attributable to Amyris, Inc. common stockholders after assumed conversion $ (115,647 ) $ (221,777 ) $ (109,861 ) Denominator: Weighted-average shares of common stock outstanding used in computing net loss per share of common stock, basic 238,440,197 126,961,576 78,400,098 Basic income (loss) per share $ (0.41 ) $ (1.75 ) $ 0.03 Weighted average shares of common stock outstanding 238,440,197 126,961,576 78,400,098 Effect of dilutive securities: Convertible promissory notes 26,204,252 — 43,459,343 Weighted common stock equivalents 26,204,252 — 43,459,343 Diluted weighted-average common shares 264,644,449 126,961,576 121,859,441 Diluted loss per share $ (0.44 ) $ (1.75 ) $ (0.9 ) ______________ (1) The amount represents a net gain related to a change in the fair value of a liability classified common stock warrant included in the Company’s consolidated statement of operations for the year ended December 31, 2015. 2015. The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share of common stock for the periods presented because including them would have been anti-dilutive: Years Ended December 31, 2016 2015 2014 Period-end stock options to purchase common stock 13,487,685 12,930,112 10,539,978 Convertible promissory notes (1) 35,933,931 72,537,306 26,887,005 Period-end common stock warrants 5,021,087 2,901,926 1,021,087 Period-end restricted stock units 6,991,133 5,554,844 1,975,503 Total 61,433,836 93,924,188 40,423,573 ______________ (1) The potentially dilutive effect of convertible promissory notes was computed based on conversion ratios in effect as of December 31, 2016. |
New Accounting Pronouncements, Policy [Policy Text Block] | Recent Accounting Pronouncements In May 2014, March, April, May December 2016, The FASB has issued several updates to the standard which i) clarify the application of the principal versus agent guidance (ASU 2016 08); 2016 10) 2016 12). July 9, 2015, one December 15, 2017 December 15, 2016. March 31, 2018. may In August 2014, December 15, 2016 2016 In January 2015, 225 20, December 15, 2015. 2016 In February 2015, 810 December 15, 2015. 2016 In April 2015, 2015 3, Simplifying the Presentation of Debt Issuance Costs December 15, 2015, 2016. December 31, 2015, $2.8 $1.4 $2.8 $1.4 In July 2015, 2015 11, Simplifying the Measurement of Inventory December 15, 2016, In January 2016, 2016 01 Financial Instruments-Overall December 15, 2017, In February 2016, 2016 02 Leases December 15, 2018. may In March 2016, 2016 06, Contingent Put and Call Options in Debt Instruments four December 15, 2016, In March 2016, 2016 09, Compensation - Stock Compensation (Topic 718): December 15, 2016, In June 2016, 2016 13, Allowance for Loan and Lease Losses (Financial Instruments - Credit Losses Topic 326.) December 15, 2019, December 15, 2018, In August 2016, 2016 15 Classification of Certain Cash Receipts and Cash Payments December 15, 2017 In October 2016, 2016 16, Intra-Entity Transfers of Assets Other Than Inventory December 15, 2017. first 2017. In November 2016, 2016 18 Statement of Cash Flows - Restricted Cash. December 15, 2017, |
Note 2 - Summary of Significa27
Note 2 - Summary of Significant Accounting Policies (Tables) | 12 Months Ended |
Dec. 31, 2016 | |
Notes Tables | |
Schedules of Concentration of Risk, by Risk Factor [Table Text Block] | December 31, Customers 2016 2015 Customer L 33 % ** Customer K 22 % * Customer H ** 23 % Customer C ** 26 % Customer G ** 10 % Years Ended December 31, Customers 2016 2015 2014 Customer N 14 % * * Customer M 22 % * * Customer E 27 % 37 % 47 % Customer J ** 10 % ** Customer C ** ** 10 % |
Property, Plant, and Equipment, Useful Life [Table Text Block] | Machinery and equipment (years) 7 - 15 Buildings (years) 15 Computers and software (years) 3 - 5 Furniture and office equipment (years) 5 Vehicles (years) 5 |
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] | December 31, 2016 2015 Foreign currency translation adjustment, net of tax $ (40,904 ) $ (47,198 ) Total accumulated other comprehensive loss $ (40,904 ) $ (47,198 ) |
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] | Years Ended December 31, 2016 2015 2014 Numerator: Net income (loss) attributable to Amyris, Inc. common stockholders $ (97,334 ) $ (217,952 ) $ 2,286 Adjustment to exclude fair value gain on liability classified warrants (1) — (3,825 ) — Net income (loss) attributable to Amyris, Inc. common stockholders (for basic income (loss) per share) (97,334 ) (221,777 ) 2,286 Interest on convertible debt 4,428 — 9,365 Accretion of debt discount 2,889 — 5,597 Gain from change in fair value of derivative instruments (25,630 ) — (127,109 ) Net loss attributable to Amyris, Inc. common stockholders after assumed conversion $ (115,647 ) $ (221,777 ) $ (109,861 ) Denominator: Weighted-average shares of common stock outstanding used in computing net loss per share of common stock, basic 238,440,197 126,961,576 78,400,098 Basic income (loss) per share $ (0.41 ) $ (1.75 ) $ 0.03 Weighted average shares of common stock outstanding 238,440,197 126,961,576 78,400,098 Effect of dilutive securities: Convertible promissory notes 26,204,252 — 43,459,343 Weighted common stock equivalents 26,204,252 — 43,459,343 Diluted weighted-average common shares 264,644,449 126,961,576 121,859,441 Diluted loss per share $ (0.44 ) $ (1.75 ) $ (0.9 ) |
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] | Years Ended December 31, 2016 2015 2014 Period-end stock options to purchase common stock 13,487,685 12,930,112 10,539,978 Convertible promissory notes (1) 35,933,931 72,537,306 26,887,005 Period-end common stock warrants 5,021,087 2,901,926 1,021,087 Period-end restricted stock units 6,991,133 5,554,844 1,975,503 Total 61,433,836 93,924,188 40,423,573 |
Note 3 - Fair Value of Financ28
Note 3 - Fair Value of Financial Instruments (Tables) | 12 Months Ended |
Dec. 31, 2016 | |
Notes Tables | |
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] | Level 1 Level 2 Level 3 Balance as of December 31, 2016 Financial Assets Money market funds $ 1,549 $ — $ — $ 1,549 Certificates of deposit 1,373 — — 1,373 Total financial assets $ 2,922 $ — $ — $ 2,922 Financial Liabilities Loans payable (1) $ — $ 53,579 $ — $ 53,579 Credit facilities (1) — 51,261 — 51,261 Convertible notes (1) — — 117,767 117,767 Compound embedded derivative liabilities — — 4,135 4,135 Currency interest rate swap derivative liability — 3,343 — 3,343 Total financial liabilities $ — $ 108,183 $ 121,902 $ 230,085 Level 1 Level 2 Level 3 Balance as of December 31, 2015 Financial Assets Money market funds $ 2,078 $ — $ — $ 2,078 Certificates of deposit 1,520 — — 1,520 Total financial assets $ 3,598 $ — $ — $ 3,598 Financial Liabilities Loans payable (1) $ — $ 9,541 $ — $ 9,541 Credit facilities (1) — 34,893 — 34,893 Convertible notes (1) — — 96,291 96,291 Compound embedded derivative liabilities — — 46,430 46,430 Currency interest rate swap derivative liability — 5,009 — 5,009 Total financial liabilities $ — $ 49,443 $ 142,721 $ 192,164 |
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] | 2016 2015 Balance at January 1 $ 96,291 $ 222,031 Additions to convertible notes 25,000 31,984 Conversion/extinguishment of convertible notes (28,310 ) (127,583 ) Change in fair value of convertible notes 24,786 (30,141 ) Balance at December 31 $ 117,767 $ 96,291 |
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] | 2016 2015 Balance at January 1 $ 46,430 $ 56,026 Additions to Level 3 2,050 40,359 Derecognition on conversion/extinguishment (2,886 ) (30,806 ) Gain from change in fair value of derivative liabilities (41,459 ) (19,149 ) Balance at December 31 $ 4,135 $ 46,430 |
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block] | December 31, 2016 December 31, 2015 Risk-free interest rate 0.55% - 1.31% 1.26% - 1.40% Risk-adjusted yields 12.80% - 22.93% 35.80% - 45.93% Stock-price volatility 45% 45% Probability of change in control 5% 5% Stock price $0.73 $1.62 Credit spread 11.59% - 21.64% 34.48% - 44.55% Estimated conversion dates 2017 - 2019 2016 - 2019 Initial recognition (July 29, 2015) Expected dividend yield — % Risk-free interest rate 2 % Expected term (in years) 10.0 Expected volatility 74 % |
Derivative Instruments, Gain (Loss) [Table Text Block] | Income Years Ended December 31, Type of Derivative Contract Statement Classification 2016 2015 2014 Gain (Loss) Recognized Currency interest rate swap Gain (loss) from change in fair value of derivative instruments $ 1,946 $ (3,367 ) $ (480 ) |
Schedule of Derivative Liabilities at Fair Value [Table Text Block] | December 31, 2016 2015 Non-current fair market value of swap obligation 3,343 5,009 Fair value of compound embedded derivative liabilities 4,135 46,430 Total derivative liabilities (of which $584 is a current liability) $ 7,478 $ 51,439 |
Note 4 - Balance Sheet Compon29
Note 4 - Balance Sheet Components (Tables) | 12 Months Ended |
Dec. 31, 2016 | |
Notes Tables | |
Schedule of Inventory, Current [Table Text Block] | December 31, 2016 2015 Raw materials $ 3,159 $ 2,204 Work-in-process 1,848 3,583 Finished goods 1,206 5,099 Inventories, net $ 6,213 $ 10,886 |
Property, Plant and Equipment [Table Text Block] | December 31, 2016 2015 Leasehold improvements $ 38,785 $ 38,519 Machinery and equipment 82,688 72,876 Computers and software 9,585 9,117 Furniture and office equipment 2,333 2,234 Buildings 4,699 3,922 Vehicles 164 215 Land 460 — Construction in progress 2,216 5,736 140,930 132,619 Less: accumulated depreciation and amortization (87,195 ) (72,822 ) Property, plant and equipment, net $ 53,735 $ 59,797 |
Schedule of Other Assets, Noncurrent [Table Text Block] | December 31, 2016 2015 Deposits on property and equipment, including taxes $ 291 $ 243 Recoverable taxes from Brazilian government entities, net 13,723 8,887 Other 1,450 1,227 Total other assets $ 15,464 $ 10,357 |
Schedule of Accrued and Other Current Liabilities [Table Text Block] | December 31, 2016 2015 Professional services $ 6,876 $ 4,017 Accrued vacation 2,034 2,023 Payroll and related expenses 4,310 3,122 Tax-related liabilities 2,610 2,505 Withholding tax related to conversion of related party notes 1,370 4,723 Deferred rent, current portion 1,111 1,111 Accrued interest 4,847 1,984 SMA relocation accrual 3,641 3,641 Other 2,389 1,142 Total accrued and other current liabilities $ 29,188 $ 24,268 |
Note 5 - Debt and Mezzanine E30
Note 5 - Debt and Mezzanine Equity (Tables) | 12 Months Ended |
Dec. 31, 2016 | |
Notes Tables | |
Schedule of Debt [Table Text Block] | December 31, 2016 2015 FINEP credit facility $ 696 $ 840 BNDES credit facility 1,172 1,956 Guanfu credit facility 19,564 — Senior secured loan facility 27,658 31,590 Total credit facilities 49,090 34,386 Convertible notes 78,981 61,233 Related party convertible notes 42,754 42,749 Related party loan payable 29,691 — Loans payable 26,527 13,606 Total debt 227,043 151,974 Less: current portion (59,155 ) (36,281 ) Long-term debt $ 167,888 $ 115,693 Mezzanine equity(1) $ 5,000 $ — |
Schedule of Long-term Debt Instruments [Table Text Block] | Years ending December 31: Related Party Convertible Debt Convertible Debt Loans Payable Related Party Loans Payable Credit Facility Total 2017 $ 4,837 $ 18,883 $ 16,628 $ 32,551 $ 7,014 $ 79,913 2018 16,550 18,142 2,808 — 33,648 71,148 2019 34,260 88,902 2,699 — 2,578 128,439 2020 — — 2,592 — 2,500 5,092 2021 — — 2,483 — 27,395 29,878 Thereafter — — 4,075 — — 4,075 Total future minimum payments (1) 55,647 125,927 31,285 32,551 73,135 318,545 Less: amount representing interest (2) (12,893 ) (46,946 ) (4,758 ) (2,860 ) (24,045 ) (91,502 ) Present value of minimum debt payments 42,754 78,981 26,527 29,691 49,090 227,043 Less: current portion (3,610 ) (8,957 ) (15,448 ) (29,691 ) (1,449 ) (59,155 ) Noncurrent portion of debt $ 39,144 $ 70,024 $ 11,079 $ — $ 47,641 $ 167,888 |
Note 6 - Commitments and Cont31
Note 6 - Commitments and Contingencies (Tables) | 12 Months Ended |
Dec. 31, 2016 | |
Notes Tables | |
Schedule Of Future Minimum Payments For Lease Obligations [Table Text Block] | Years ending December 31: Capital Operating Total Lease Obligations 2017 $ 1,233 $ 6,854 $ 8,087 2018 47 6,883 6,930 2019 6 6,774 6,780 2020 — 7,004 7,004 2021 — 7,240 7,240 Thereafter — 10,948 10,948 Total future minimum lease payments 1,286 $ 45,703 $ 46,989 Less: amount representing interest (30 ) Present value of minimum lease payments 1,256 Less: current portion (922 ) Long-term portion $ 334 |
Note 7 - Joint Ventures and N32
Note 7 - Joint Ventures and Noncontrolling Interest (Tables) | 12 Months Ended |
Dec. 31, 2016 | |
Notes Tables | |
Schedule of Variable Interest Entities [Table Text Block] | December 31, (In thousands) 2016 2015 Assets $ 2,277 $ 6,993 Liabilities $ 135 $ 1,221 |
Noncontrolling Interest [Table Text Block] | 2016 2015 Balance at January 1 $ 391 $ 611 Foreign currency translation adjustment — (320 ) Income attributable to noncontrolling interest (1,328 ) 100 Balance at December 31 $ (937 ) $ 391 |
Note 9 - Goodwill and Intangi33
Note 9 - Goodwill and Intangible Assets (Tables) | 12 Months Ended |
Dec. 31, 2016 | |
Notes Tables | |
Schedule of Intangible Assets and Goodwill [Table Text Block] | December 31, 2016 December 31, 2015 Useful Life in Years Gross Carrying Amount Accumulated Amortization/ Net Carrying Value Gross Carrying Amount Accumulated Amortization/ Net Carrying Value In-process research and development Indefinite $ 8,560 $ (8,560 ) $ — $ 8,560 $ (8,560 ) $ — Acquired licenses and permits 2 772 (772 ) — 772 (772 ) — Goodwill Indefinite 560 — 560 560 — 560 $ 9,892 $ (9,332 ) $ 560 $ 9,892 $ (9,332 ) $ 560 |
Note 11 - Stock-based Compens34
Note 11 - Stock-based Compensation Plans (Tables) | 12 Months Ended |
Dec. 31, 2016 | |
Notes Tables | |
Schedule of Share-based Compensation, Stock Options and Stock Appreciation Rights Award Activity [Table Text Block] | Number Weighted- Weighted-Average Aggregate (in thousands) Outstanding - December 31, 2015 12,930,112 $ 4.77 7.39 $ 22 Options granted 3,585,175 $ 0.59 — — Options exercised (134 ) $ 0.28 — — Options cancelled (3,087,468 ) $ 4.92 — — Outstanding - December 31, 2016 13,427,685 $ 3.63 6.70 $ 443 Vested and expected to vest after December 31, 2016 12,387,314 $ 3.84 6.54 $ 361 Exercisable at December 31, 2016 7,357,308 $ 5.48 5.32 $ 1 |
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block] | RSUs Weighted-Average Grant-Date Fair Value Weighted Average Remaining Contractual Life (Years) Outstanding - December 31, 2015 5,554,844 $ 2.03 1.61 Awarded 4,897,840 $ 0.61 — Vested (2,064,881 ) $ 1.98 — Forfeited (1,390,719 ) $ 1.39 — Outstanding - December 31, 2016 6,997,084 $ 1.18 1.44 Expected to vest after December 31, 2016 5,642,538 $ 1.20 1.28 |
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block] | Options Outstanding Options Exercisable Exercise Price Number of Options Weighted- Weighted-Average Exercise Price Number of Options Weighted-Average Exercise Price $0.28—$0.57 346,234 9.47 $ 0.43 2,734 $ 0.28 $0.59—$0.59 2,424,375 8.62 $ 0.59 — $ — $0.78—$1.67 1,461,082 8.53 $ 1.46 396,916 $ 1.61 $1.69—$1.96 2,218,041 7.30 $ 1.84 863,045 $ 1.85 $1.98—$2.85 1,371,168 5.82 $ 2.61 1,129,021 $ 2.67 $2.87—$3.44 1,255,796 6.52 $ 3.02 1,095,271 $ 3.01 $3.51—$3.51 1,503,891 7.06 $ 3.51 1,020,549 $ 3.51 $3.55—$4.08 1,354,152 3.90 $ 3.88 1,296,826 $ 3.88 $4.31—$24.20 1,350,946 3.40 $ 13.05 1,350,946 $ 12.05 24.50—$30.17 202,000 4.31 $ 27.52 202,000 $ 27.52 $0.28—$30.17 13,487,685 6.70 $ 3.63 7,357,308 $ 5.48 |
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] | Years Ended December 31, 2016 2015 2014 Research and development $ 1,948 $ 2,306 $ 3,508 Sales, general and administrative 5,377 6,828 10,597 Total stock-based compensation expense $ 7,325 $ 9,134 $ 14,105 |
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] | Years Ended December 31, 2016 2015 2014 Expected dividend yield — % — % — % Risk-free interest rate 1.4 % 1.8 % 1.9 % Expected term (in years) 6.16 6.08 6.10 Expected volatility 73 % 74 % 75 % |
Note 14 - Income Taxes (Tables)
Note 14 - Income Taxes (Tables) | 12 Months Ended |
Dec. 31, 2016 | |
Notes Tables | |
Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] | Years Ended December 31, 2016 2015 2014 United States $ (101,210 ) $ (188,943 ) $ 10,847 Foreign 4,429 (24,457 ) (5,275 ) Income (loss) before income taxes and loss from investments in affiliates $ (96,781 ) $ (213,400 ) $ 5,572 |
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] | Years Ended December 31, 2016 2015 2014 Current: Federal $ — $ — $ — State — — — Foreign 553 468 495 Total current provision 553 468 495 Deferred: Federal — — — State — — — Foreign — — — Total deferred provision — — — Total provision for income taxes $ 553 $ 468 $ 495 |
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] | Years Ended December 31, 2016 2015 2014 Statutory tax rate (34.0 )% (34.0 )% (34.0 )% State tax rate, net of federal benefit 0.0 % (0.3 )% 23.3 % Stock-based compensation — % 0.1 % (2.8 )% Federal R&D credit (0.8 )% (0.6 )% 31.0 % Derivative liabilities 1.4 % 3.6 % 541.5 % Non-Deductible Interest 5.0 % 5.5 % 0.0 % Other (3.2 )% 0.1 % (7.8 )% Foreign losses 0.5 % (1.2 )% 32.3 % Change in valuation allowance 31.7 % 27.1 % (592.4 )% Effective income tax rate 0.6 % 0.3 % (8.9 )% |
Schedule of Deferred Tax Assets and Liabilities [Table Text Block] | December 31, 2016 2015 2014 Net operating loss carryforwards $ 236,741 $ 207,241 $ 195,536 Fixed assets 12,917 10,519 1,299 Research and development credits 17,348 16,612 14,701 Foreign Tax Credit 2,452 1,899 1,431 Accruals and reserves 30,303 26,366 16,425 Stock-based compensation 17,184 19,048 18,773 Capitalized start-up costs 9,182 9,568 13,095 Capitalized research and development costs 65,962 63,339 56,880 Other 6,714 9,999 6,700 Total deferred tax assets 398,803 364,591 324,840 Fixed assets — — — Debt discount and derivative (11,936 ) (4,402 ) (12,517 ) Total deferred tax liabilities (11,936 ) (4,402 ) (12,517 ) Net deferred tax asset prior to valuation allowance 386,867 360,189 312,323 Less: Valuation allowance (386,867 ) (360,189 ) (312,323 ) Net deferred tax assets (liabilities) $ — $ — $ — |
Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block] | Balance at December 31, 2013 $ 6,080 Increases in tax positions for prior period 4,736 Increases in tax positions during current period 6,265 Balance at December 31, 2014 $ 17,081 Decreases in tax positions for prior period (9,404 ) Increases in tax positions during current period 957 Balance at December 31, 2015 $ 8,634 Decreases in tax positions for prior period (314 ) Increases in tax positions during current period 781 Balance at December 31, 2016 9,101 |
Note 15 - Reporting Segments (T
Note 15 - Reporting Segments (Tables) | 12 Months Ended |
Dec. 31, 2016 | |
Notes Tables | |
Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block] | Years Ended December 31, 2016 2015 2014 United States $ 3 0,944 $ 20,897 $ 21,331 Brazil 489 5,070 5,961 Europe 23,612 3,557 9,738 Asia 12,068 4,629 6,244 Other 79 — — Total $ 6 7,192 $ 34,153 $ 43,274 |
Schedule of Disclosure on Geographic Areas, Long-Lived Assets in Individual Foreign Countries by Country [Table Text Block] | December 31, 2016 2015 United States $ 9,342 $ 18,401 Brazil 44,153 41,093 Europe 240 303 Total $ 53,735 $ 59,797 |
Supplementary Financial Data 37
Supplementary Financial Data - Selected Quarterly Financial Data (Tables) | 12 Months Ended |
Dec. 31, 2016 | |
Notes Tables | |
Quarterly Financial Information [Table Text Block] | Quarter First Second Third Fourth (In thousands, except share and per share amounts) Year Ended December 31, 2016 Total revenues $ 8,811 $ 9,599 $ 26,544 $ 22,238 Product sales $ 3,140 $ 4,922 $ 6,820 $ 11,467 Gross loss from product sales $ (8,038 ) $ (2,969 ) $ (8,056 ) $ (11,290 ) Net loss attributable to common stockholders (for basic loss per share) (1) $ (15,308 ) $ (13,566 ) $ (19,704 ) $ (48,756 ) Net loss attributable to common stockholders (for diluted loss per share) $ (30,273 ) $ (29,245 ) $ (19,704 ) $ (48,756 ) Net loss per share: Basic (1) $ (0.07 ) $ (0.06 ) $ (0.08 ) $ (0.18 ) Diluted $ (0.12 ) $ (0.11 ) $ (0.08 ) $ (0.18 ) Shares used in calculation: Basic 207,199,563 223,112,019 249,190,339 273,406,492 Diluted 260,932,085 262,896,140 249,190,339 273,406,492 Year Ended December 31, 2015 Total revenues $ 7,872 $ 7,843 $ 8,591 $ 9,847 Product sales $ 2,095 $ 3,340 $ 4,228 $ 5,233 Gross loss from product sales $ (4,548 ) $ (7,619 ) $ (4,227 ) $ (6,084 ) Net loss attributable to common stockholders (for basic loss per share) (1) $ (52,240 ) $ (47,130 ) $ (76,664 ) $ (48,352 ) Net loss attributable to common stockholders (for diluted loss per share) $ (52,240 ) $ (54,527 ) $ (76,664 ) $ (68,316 ) Net loss per share: Basic (1) $ (0.66 ) $ (0.59 ) $ (0.55 ) $ (0.23 ) Diluted $ (0.66 ) $ (0.62 ) $ (0.55 ) $ (0.30 ) Shares used in calculation: Basic 79,222,051 80,041,152 140,374,297 206,661,506 Diluted 79,222,051 87,421,439 140,374,297 231,014,248 |
Schedule II - Valuation and Q38
Schedule II - Valuation and Qualifying Accounts (Tables) | 12 Months Ended |
Dec. 31, 2016 | |
Notes Tables | |
Summary of Valuation Allowance [Table Text Block] | Balance at Beginning of Period Additions Write-off Adjustments Balance at End of Period Deferred Tax Assets Valuation Allowance: Year ended December 31, 2016 $ 360,189 $ 26,678 $ — $ 386,867 Year ended December 31, 2015 $ 312,323 $ 47,866 $ — $ 360,189 Year ended December 31, 2014 $ 284,021 $ 28,302 $ — $ 312,323 Balance at Beginning of Period Additions Write-off Adjustments Balance at End of Period Allowance for Doubtful Accounts: Year ended December 31, 2016 $ 969 $ — $ (468 ) $ 501 Year ended December 31, 2015 $ 479 $ 490 $ — $ 969 Year ended December 31, 2014 $ 479 $ — $ — $ 479 |
Note 1 - The Company (Details T
Note 1 - The Company (Details Textual) $ in Thousands | 12 Months Ended | |
Dec. 31, 2016USD ($) | Dec. 31, 2015USD ($) | |
Number of Operating Segments | 1 | |
Working Capital | $ (50,700) | |
Retained Earnings (Accumulated Deficit) | (1,134,438) | $ (1,037,104) |
Cash, Cash Equivalents, and Short-term Investments | 28,500 | |
Debt Instrument, Unamortized Discount | 42,500 | |
Long-term Debt | 227,043 | 151,974 |
Long-term Debt, Current Maturities, Including Due to Related Parties | 59,155 | $ 36,281 |
Interest Payable | $ 18,300 |
Note 2 - Summary of Significa40
Note 2 - Summary of Significant Accounting Policies (Details Textual) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2016USD ($) | Dec. 31, 2015USD ($) | Dec. 31, 2014USD ($) | |
Variable Interest Entity, Number of Entities | 2 | ||
Restricted Cash and Cash Equivalents | $ 5,300 | $ 1,200 | |
Other Asset Impairment Charges | 7,300 | 28,500 | $ 1,800 |
Impairment of Intangible Assets (Excluding Goodwill) | 0 | $ 5,525 | $ 3,035 |
Intangible Assets, Net (Excluding Goodwill) | 0 | ||
December 31, 2015 [Member] | Reduction in Noncurrent Debt [Member] | |||
Prior Period Reclassification Adjustment | 2,800 | ||
December 31, 2015 [Member] | Reduction in Current Debt [Member] | |||
Prior Period Reclassification Adjustment | 1,400 | ||
December 31, 2015 [Member] | Reduction in Noncurrent Assets [Member] | |||
Prior Period Reclassification Adjustment | 2,800 | ||
December 31, 2015 [Member] | Reduction in Prepaid Expenses and Other Current Assets [Member] | |||
Prior Period Reclassification Adjustment | $ 1,400 | ||
Squalane Products [Member] | |||
Product Warranty Term | 2 years | ||
Computer Equipment and Software [Member] | |||
Property, Plant and Equipment, Useful Life | |||
Computer Equipment and Software [Member] | Minimum [Member] | |||
Property, Plant and Equipment, Useful Life | 3 years | ||
Computer Equipment and Software [Member] | Maximum [Member] | |||
Property, Plant and Equipment, Useful Life | 5 years |
Note 2 - Summary of Significa41
Note 2 - Summary of Significant Accounting Policies - Concentration of Credit Risk (Details) | 11 Months Ended | 12 Months Ended | |||||||
Dec. 13, 2015 | Dec. 31, 2016 | Dec. 31, 2015 | Dec. 31, 2014 | ||||||
Revenues [Member] | Customer C [Member] | |||||||||
Concentration risk, percentage | [1] | 10.00% | |||||||
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Customer L [Member] | |||||||||
Concentration risk, percentage | 33.00% | [1] | |||||||
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Customer K [Member] | |||||||||
Concentration risk, percentage | 22.00% | [2] | |||||||
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Customer H [Member] | |||||||||
Concentration risk, percentage | [1] | 23.00% | |||||||
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Customer C [Member] | |||||||||
Concentration risk, percentage | [1] | 26.00% | |||||||
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Customer G [Member] | |||||||||
Concentration risk, percentage | [1] | 10.00% | |||||||
Customer Concentration Risk [Member] | Revenues [Member] | Customer N [Member] | |||||||||
Concentration risk, percentage | [3] | 14.00% | [3] | ||||||
Customer Concentration Risk [Member] | Revenues [Member] | Customer M [Member] | |||||||||
Concentration risk, percentage | [3] | 22.00% | [3] | ||||||
Customer Concentration Risk [Member] | Revenues [Member] | Customer C [Member] | |||||||||
Concentration risk, percentage | [1] | ||||||||
Customer Concentration Risk [Member] | Revenues [Member] | Customer E [Member] | |||||||||
Concentration risk, percentage | 37.00% | 27.00% | 47.00% | ||||||
Customer Concentration Risk [Member] | Revenues [Member] | Customer J [Member] | |||||||||
Concentration risk, percentage | 10.00% | [1] | [1] | ||||||
[1] | Less than 10% | ||||||||
[2] | No outstanding balance | ||||||||
[3] | Not a customer |
Note 2 - Summary of Significa42
Note 2 - Summary of Significant Accounting Policies - Depreciation and Amortization periods for Property, Plant, and Equipment (Details) | 12 Months Ended |
Dec. 31, 2016 | |
Machinery and Equipment [Member] | |
Property, plant, and equipment, useful life (Year) | |
Building [Member] | |
Property, plant, and equipment, useful life (Year) | 15 years |
Computer Equipment and Software [Member] | |
Property, plant, and equipment, useful life (Year) | |
Furniture and Office Equipment [Member] | |
Property, plant, and equipment, useful life (Year) | 5 years |
Vehicles [Member] | |
Property, plant, and equipment, useful life (Year) | 5 years |
Minimum [Member] | Machinery and Equipment [Member] | |
Property, plant, and equipment, useful life (Year) | 7 years |
Minimum [Member] | Building [Member] | |
Property, plant, and equipment, useful life (Year) | |
Minimum [Member] | Computer Equipment and Software [Member] | |
Property, plant, and equipment, useful life (Year) | 3 years |
Minimum [Member] | Furniture and Office Equipment [Member] | |
Property, plant, and equipment, useful life (Year) | |
Minimum [Member] | Vehicles [Member] | |
Property, plant, and equipment, useful life (Year) | |
Maximum [Member] | Machinery and Equipment [Member] | |
Property, plant, and equipment, useful life (Year) | 15 years |
Maximum [Member] | Building [Member] | |
Property, plant, and equipment, useful life (Year) | |
Maximum [Member] | Computer Equipment and Software [Member] | |
Property, plant, and equipment, useful life (Year) | 5 years |
Maximum [Member] | Furniture and Office Equipment [Member] | |
Property, plant, and equipment, useful life (Year) | |
Maximum [Member] | Vehicles [Member] | |
Property, plant, and equipment, useful life (Year) |
Note 2 - Summary of Significa43
Note 2 - Summary of Significant Accounting Policies - Components of Accumulated Other Comprehensive Loss (Details) - USD ($) $ in Thousands | Dec. 31, 2016 | Dec. 31, 2015 |
Foreign currency translation adjustment, net of tax | $ (40,904) | $ (47,198) |
Total accumulated other comprehensive loss | $ (40,904) | $ (47,198) |
Note 2 - Summary of Significa44
Note 2 - Summary of Significant Accounting Policies - Basic and Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | 12 Months Ended | ||||||||||||||||||
Dec. 31, 2016 | Sep. 30, 2016 | Jun. 30, 2016 | Mar. 31, 2016 | Dec. 31, 2015 | Sep. 30, 2015 | Jun. 30, 2015 | Mar. 31, 2015 | Dec. 31, 2016 | Dec. 31, 2015 | Dec. 31, 2014 | ||||||||||
Net income (loss) attributable to Amyris, Inc. common stockholders | $ (97,334) | $ (217,952) | $ 2,286 | |||||||||||||||||
Gain from change in fair value of derivative liabilities | [1] | (3,825) | ||||||||||||||||||
Net income (loss) attributable to Amyris, Inc. common stockholders (for basic income (loss) per share) | $ (48,756) | [2] | $ (19,704) | [2] | $ (13,566) | [2] | $ (15,308) | [2] | $ (48,352) | $ (76,664) | $ (47,130) | $ (52,240) | (97,334) | (221,777) | 2,286 | |||||
Interest on convertible debt | 4,428 | 9,365 | ||||||||||||||||||
Accretion of debt discount | 2,889 | 5,597 | ||||||||||||||||||
Gain from change in fair value of derivative instruments | (25,630) | (127,109) | ||||||||||||||||||
Net loss attributable to Amyris, Inc. common stockholders after assumed conversion | $ (48,756) | $ (19,704) | $ (29,245) | $ (30,273) | $ (68,316) | $ (76,664) | $ (54,527) | $ (52,240) | $ (115,647) | $ (221,777) | $ (109,861) | |||||||||
Basic (in shares) | 273,406,492 | 249,190,339 | 223,112,019 | 207,199,563 | 206,661,506 | 140,374,297 | 80,041,152 | 79,222,051 | 238,440,197 | 126,961,576 | 78,400,098 | |||||||||
Basic (in dollars per share) | $ (0.18) | [2] | $ (0.08) | [2] | $ (0.06) | [2] | $ (0.07) | [2] | $ (0.23) | [2] | $ (0.55) | [2] | $ (0.59) | [2] | $ (0.66) | [2] | $ (0.41) | $ (1.75) | $ 0.03 | |
Convertible promissory notes (in shares) | 26,204,252 | 43,459,343 | ||||||||||||||||||
Weighted common stock equivalents (in shares) | 26,204,252 | 43,459,343 | ||||||||||||||||||
Diluted weighted-average common shares (in shares) | 273,406,492 | 249,190,339 | 262,896,140 | 260,932,085 | 231,014,248 | 140,374,297 | 87,421,439 | 79,222,051 | 264,644,449 | 126,961,576 | 121,859,441 | |||||||||
Diluted (in dollars per share) | $ (0.18) | $ (0.08) | $ (0.11) | $ (0.12) | $ (0.30) | $ (0.55) | $ (0.62) | $ (0.66) | $ (0.44) | $ (1.75) | $ (0.90) | |||||||||
[1] | The amount represents a net gain related to a change in the fair value of a liability classified common stock warrant included in the Company's consolidated statement of operations for the year ended December 31, 2015. The warrant has a nominal exercise price and shares issuable upon exercise of the warrant are considered equivalent to the Company's common shares for the purpose of computation of basic earnings per share and consequently losses are adjusted to exclude the gain. The warrant was exercised in 2015. | |||||||||||||||||||
[2] | Basic loss per share for the fourth quarter of 2015 is calculated by excluding from net income (loss) attributable to common stockholders a gain of $6,424 (thousand) related to a change in the fair value of a liability classified common stock warrant included in the Company’s consolidated statement of operations. The warrant has a nominal exercise price and shares issuable upon exercise of the warrant are considered equivalent to the Company’s common shares for the purpose of computation of basic earnings per share and consequently losses are adjusted to exclude the gain. |
Note 2 - Summary of Significa45
Note 2 - Summary of Significant Accounting Policies - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares | 12 Months Ended | |||
Dec. 31, 2016 | Dec. 31, 2015 | Dec. 31, 2014 | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares) | 61,433,836 | 93,924,188 | 40,423,573 | |
Period-end Stock Options to Purchase Common Stock [Member] | ||||
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares) | 13,487,685 | 12,930,112 | 10,539,978 | |
Convertible Promissory Notes [Member] | ||||
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares) | [1] | 35,933,931 | 72,537,306 | 26,887,005 |
Period-end Common Stock Warrants [Member] | ||||
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares) | 5,021,087 | 2,901,926 | 1,021,087 | |
Period-end Restricted Stock Units [Member] | ||||
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares) | 6,991,133 | 5,554,844 | 1,975,503 | |
[1] | The potentially dilutive effect of convertible promissory notes was computed based on conversion ratios in effect as of December 31, 2016. A portion of the convertible promissory notes issued carries a provision for a reduction in conversion price under certain circumstances, which could potentially increase the dilutive shares outstanding. Another portion of the convertible promissory notes issued carries a provision for an increase in the conversion rate under certain circumstances, which could also potentially increase the dilutive shares outstanding. |
Note 3 - Fair Value of Financ46
Note 3 - Fair Value of Financial Instruments (Details Textual) $ in Thousands, BRL in Millions | Dec. 15, 2015USD ($)shares | Apr. 30, 2014shares | Jan. 31, 2013shares | Dec. 31, 2016USD ($) | Dec. 31, 2015USD ($) | Dec. 31, 2014USD ($) | Dec. 31, 2016BRL | May 31, 2016shares | Feb. 28, 2016shares | Jul. 31, 2015shares | Jul. 29, 2015USD ($) |
Proceeds from Warrant Exercises | $ | $ 5,000 | $ 285 | |||||||||
Stock Issued During Period, Shares, New Issues | shares | 943,396 | 5,033,557 | |||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 1,602,562 | ||||||||||
Temasek Funding Warrant [Member] | |||||||||||
Derivative Liability | $ | $ 18,900 | $ 19,400 | |||||||||
Proceeds from Warrant Exercises | $ | $ 100 | ||||||||||
Stock Issued During Period, Shares, New Issues | shares | 12,700,000 | ||||||||||
Banco Pine July 2012 Loan Agreement [Member] | Interest Rate Swap [Member] | |||||||||||
Derivative, Notional Amount | $ 6,800 | BRL 22 | |||||||||
Derivative, Fixed Interest Rate | 3.94% | 3.94% | |||||||||
Tranche I Notes [Member] | Temasek Funding Warrant [Member] | |||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 127,194 | ||||||||||
Tranche II Notes [Member] | Temasek Funding Warrant [Member] | |||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 2,335,342 | ||||||||||
Fair Value, Inputs, Level 3 [Member] | Derivative Liability, Compound Embedded Derivatives [Member] | |||||||||||
Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value | $ | $ 4,135 | 46,430 | $ 56,026 | ||||||||
Derivative Liabilities [Member] | Fair Value, Inputs, Level 3 [Member] | Derivative Liability, Compound Embedded Derivatives [Member] | |||||||||||
Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value | $ | $ 4,100 | $ 46,400 |
Note 3 - Fair Value of Financ47
Note 3 - Fair Value of Financial Instruments - Fair Value, Assets, and Liabilities Measured on Recurring Basis (Details) - Fair Value, Measurements, Recurring [Member] - USD ($) $ in Thousands | Dec. 31, 2016 | Dec. 31, 2015 | ||
Money market funds | $ 1,549 | $ 2,078 | ||
Certificates of deposit | 1,373 | 1,520 | ||
Total financial assets | 2,922 | 3,598 | ||
Loans payable | 53,579 | [1] | 9,541 | [2] |
Credit facilities | 51,261 | [1] | 34,893 | [2] |
Convertible notes | 117,767 | [1] | 96,291 | [2] |
Compound embedded derivative liabilities | 4,135 | 46,430 | ||
Currency interest rate swap derivative liability | 3,343 | 5,009 | ||
Total financial liabilities | 230,085 | 192,164 | ||
Fair Value, Inputs, Level 1 [Member] | ||||
Money market funds | 1,549 | 2,078 | ||
Certificates of deposit | 1,373 | 1,520 | ||
Total financial assets | 2,922 | 3,598 | ||
Loans payable | [1] | [2] | ||
Credit facilities | [1] | [2] | ||
Convertible notes | [1] | [2] | ||
Compound embedded derivative liabilities | ||||
Currency interest rate swap derivative liability | ||||
Total financial liabilities | ||||
Fair Value, Inputs, Level 2 [Member] | ||||
Money market funds | ||||
Certificates of deposit | ||||
Total financial assets | ||||
Loans payable | 53,579 | [1] | 9,541 | [2] |
Credit facilities | 51,261 | [1] | 34,893 | [2] |
Convertible notes | [1] | [2] | ||
Compound embedded derivative liabilities | ||||
Currency interest rate swap derivative liability | 3,343 | 5,009 | ||
Total financial liabilities | 108,183 | 49,443 | ||
Fair Value, Inputs, Level 3 [Member] | ||||
Money market funds | ||||
Certificates of deposit | ||||
Total financial assets | ||||
Loans payable | [1] | [2] | ||
Credit facilities | [1] | [2] | ||
Convertible notes | 117,767 | [1] | 96,291 | [2] |
Compound embedded derivative liabilities | 4,135 | 46,430 | ||
Currency interest rate swap derivative liability | ||||
Total financial liabilities | $ 121,902 | $ 142,721 | ||
[1] | These liabilities are carried on the consolidated balance sheet on a historical cost basis. | |||
[2] | These liabilities are carried on the consolidated balance sheet on a historical cost basis (noting that the Remaining Notes subject to the Maturity Treatment Agreement were revalued to fair value on July 29, 2015, see Note 5 "Debt" for details). |
Note 3 - Fair Value of Financ48
Note 3 - Fair Value of Financial Instruments - Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation (Details) - Fair Value, Inputs, Level 3 [Member] - Convertible Debt [Member] - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2016 | Dec. 31, 2015 | |
Balance, convertible notes | $ 96,291 | $ 222,031 |
Additions to convertible notes | 25,000 | 31,984 |
Conversion/extinguishment of convertible notes | (28,310) | (127,583) |
Change in fair value of convertible notes | 24,786 | (30,141) |
Balance at December 31 | $ 117,767 | $ 96,291 |
Note 3 - Fair Value of Financ49
Note 3 - Fair Value of Financial Instruments - Reconciliation for Compound Embedded Derivative Liability (Details) - USD ($) $ in Thousands | 12 Months Ended | |||
Dec. 31, 2016 | Dec. 31, 2015 | Dec. 31, 2014 | ||
Gain from change in fair value of derivative liabilities | [1] | $ (3,825) | ||
Fair Value, Inputs, Level 3 [Member] | Derivative Liability, Compound Embedded Derivatives [Member] | ||||
Balance, convertible notes | 46,430 | 56,026 | ||
Additions to Level 3 | 2,050 | 40,359 | ||
Derecognition on conversion/extinguishment | (2,886) | (30,806) | ||
Gain from change in fair value of derivative liabilities | (41,459) | (19,149) | ||
Balance at December 31 | $ 4,135 | $ 46,430 | $ 56,026 | |
[1] | The amount represents a net gain related to a change in the fair value of a liability classified common stock warrant included in the Company's consolidated statement of operations for the year ended December 31, 2015. The warrant has a nominal exercise price and shares issuable upon exercise of the warrant are considered equivalent to the Company's common shares for the purpose of computation of basic earnings per share and consequently losses are adjusted to exclude the gain. The warrant was exercised in 2015. |
Note 3 - Fair Value of Financ50
Note 3 - Fair Value of Financial Instruments - Market-based Assumption and Estimates for Compound Embedded Derivative Liabilities Valuation (Details) - $ / shares | Jul. 29, 2015 | Dec. 31, 2016 | Dec. 31, 2015 |
Fair Value Assumptions, Risk Free Interest Rate | 2.00% | ||
Fair Value Assumptions, Expected Dividend Rate | |||
Fair Value Assumptions, Expected Volatility Rate | 74.00% | 45.00% | 45.00% |
Probability of change in control | 5.00% | 5.00% | |
Stock price (in dollars per share) | $ 0.73 | $ 1.62 | |
Expected term (in years) (Year) | 10 years | ||
Minimum [Member] | |||
Fair Value Assumptions, Risk Free Interest Rate | 0.55% | 1.26% | |
Fair Value Assumptions, Expected Dividend Rate | 12.80% | 35.80% | |
Credit spread | 11.59% | 34.48% | |
Estimated conversion dates | 2,017 | 2,016 | |
Maximum [Member] | |||
Fair Value Assumptions, Risk Free Interest Rate | 1.31% | 1.40% | |
Fair Value Assumptions, Expected Dividend Rate | 22.93% | 45.93% | |
Credit spread | 21.64% | 44.55% | |
Estimated conversion dates | 2,019 | 2,019 |
Note 3 - Fair Value of Financ51
Note 3 - Fair Value of Financial Instruments - Derivative Instruments Classification (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2016 | Dec. 31, 2015 | Dec. 31, 2014 | |
Currency Interest Rate Swap [Member] | Not Designated as Hedging Instrument [Member] | Gain (Loss) From Change in Fair Value of Derivative Instruments [Member] | |||
Currency interest rate swap | $ 1,946 | $ (3,367) | $ (480) |
Note 3 - Fair Value of Financ52
Note 3 - Fair Value of Financial Instruments - Derivative Liabilities (Details) - USD ($) $ in Thousands | Dec. 31, 2016 | Dec. 31, 2015 |
Non-current fair market value of swap obligation | $ 3,343 | $ 5,009 |
Fair value of compound embedded derivative liabilities | 4,135 | 46,430 |
Total derivative liabilities (of which $584 is a current liability) | $ 7,478 | $ 51,439 |
Note 3 - Fair Value of Financ53
Note 3 - Fair Value of Financial Instruments - Derivative Liabilities (Details) (Parentheticals) - USD ($) $ in Thousands | Dec. 31, 2016 | Dec. 31, 2015 |
Derivative liabilities, current | $ 584 | $ 584 |
Note 4 - Balance Sheet Compon54
Note 4 - Balance Sheet Components (Details Textual) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2016 | Dec. 31, 2015 | Dec. 31, 2014 | |
Property, Plant and Equipment, Net | $ 53,735 | $ 59,797 | |
Property, Plant and Equipment, Gross | 140,930 | 132,619 | |
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment | 87,195 | 72,822 | |
Depreciation, Depletion and Amortization | 11,374 | 12,920 | $ 14,969 |
Capital Lease Obligations [Member] | |||
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment | 600 | 500 | |
Property, Plant and Equipment, Including Capital Leases [Member] | |||
Depreciation, Depletion and Amortization | 11,400 | 12,900 | $ 15,000 |
Property, Plant and Equipment, Including Capital Leases [Member] | Capital Lease Obligations [Member] | |||
Property, Plant and Equipment, Gross | 3,100 | $ 2,700 | |
SMSA Site [Member] | |||
Property, Plant and Equipment, Net | 1,900 | ||
Loss on Purchase Commitments and Impairment of Property, Plant, and Equipment [Member] | |||
Impaired Assets to be Disposed of by Method Other than Sale, Amount of Impairment Loss | 7,300 | ||
Loss on Purchase Commitments and Impairment of Property, Plant, and Equipment [Member] | SMSA Site [Member] | |||
Impaired Assets to be Disposed of by Method Other than Sale, Amount of Impairment Loss | 4,200 | ||
Loss on Purchase Commitments and Impairment of Property, Plant, and Equipment [Member] | Biomin Assets [Member] | |||
Impaired Assets to be Disposed of by Method Other than Sale, Amount of Impairment Loss | $ 3,100 |
Note 4 - Balance Sheet Compon55
Note 4 - Balance Sheet Components - Inventory, Current (Details) - USD ($) $ in Thousands | Dec. 31, 2016 | Dec. 31, 2015 |
Raw materials | $ 3,159 | $ 2,204 |
Work-in-process | 1,848 | 3,583 |
Finished goods | 1,206 | 5,099 |
Inventories, net | $ 6,213 | $ 10,886 |
Note 4 - Balance Sheet Compon56
Note 4 - Balance Sheet Components - Property, Plant and Equipment (Details) - USD ($) $ in Thousands | Dec. 31, 2016 | Dec. 31, 2015 |
Property, plant and equipment | $ 140,930 | $ 132,619 |
Less: accumulated depreciation and amortization | (87,195) | (72,822) |
Property, plant and equipment, net | 53,735 | 59,797 |
Leasehold Improvements [Member] | ||
Property, plant and equipment | 38,785 | 38,519 |
Machinery and Equipment [Member] | ||
Property, plant and equipment | 82,688 | 72,876 |
Computer Equipment and Software [Member] | ||
Property, plant and equipment | 9,585 | 9,117 |
Furniture and Fixtures [Member] | ||
Property, plant and equipment | 2,333 | 2,234 |
Building [Member] | ||
Property, plant and equipment | 4,699 | 3,922 |
Vehicles [Member] | ||
Property, plant and equipment | 164 | 215 |
Land [Member] | ||
Property, plant and equipment | 460 | |
Construction in Progress [Member] | ||
Property, plant and equipment | $ 2,216 | $ 5,736 |
Note 4 - Balance Sheet Compon57
Note 4 - Balance Sheet Components - Other Assets, Noncurrent (Details) - USD ($) $ in Thousands | Dec. 31, 2016 | Dec. 31, 2015 |
Deposits on property and equipment, including taxes | $ 291 | $ 243 |
Recoverable taxes from Brazilian government entities, net | 13,723 | 8,887 |
Other | 1,450 | 1,227 |
Total other assets | $ 15,464 | $ 10,357 |
Note 4 - Balance Sheet Compon58
Note 4 - Balance Sheet Components - Accrued and Other Current Liabilities (Details) - USD ($) $ in Thousands | Dec. 31, 2016 | Dec. 31, 2015 |
Professional services | $ 6,876 | $ 4,017 |
Accrued vacation | 2,034 | 2,023 |
Payroll and related expenses | 4,310 | 3,122 |
Tax-related liabilities | 2,610 | 2,505 |
Withholding tax related to conversion of related party notes | 1,370 | 4,723 |
Deferred rent, current portion | 1,111 | 1,111 |
Accrued interest | 4,847 | 1,984 |
SMA relocation accrual | 3,641 | 3,641 |
Other | 2,389 | 1,142 |
Total accrued and other current liabilities | $ 29,188 | $ 24,268 |
Note 5 - Debt and Mezzanine E59
Note 5 - Debt and Mezzanine Equity (Details Textual) $ / shares in Units, BRL in Millions | Dec. 28, 2016USD ($) | Dec. 02, 2016USD ($) | Oct. 27, 2016USD ($) | Oct. 26, 2016USD ($) | Oct. 21, 2016USD ($) | Jun. 24, 2016USD ($) | May 10, 2016USD ($) | Feb. 15, 2016USD ($)$ / sharesshares | Feb. 12, 2016USD ($)$ / sharesshares | Feb. 12, 2016EUR (€) | Dec. 02, 2015USD ($) | Nov. 30, 2015USD ($) | Oct. 20, 2015USD ($) | Oct. 14, 2015USD ($)$ / sharesshares | Jul. 29, 2015USD ($)$ / sharesshares | Apr. 02, 2015 | Aug. 01, 2013 | Jan. 31, 2017USD ($) | Dec. 31, 2016USD ($)$ / sharesshares | May 31, 2016USD ($) | Mar. 31, 2016USD ($) | Mar. 31, 2016EUR (€) | Feb. 29, 2016USD ($)$ / sharesshares | Nov. 30, 2015USD ($) | Jul. 31, 2015USD ($)$ / sharesshares | Jun. 30, 2014USD ($) | May 31, 2014USD ($)$ / shares | Apr. 30, 2014USD ($)$ / shares | Mar. 31, 2014USD ($) | Jan. 31, 2014USD ($)$ / shares | Dec. 31, 2013USD ($) | Oct. 31, 2013USD ($)$ / shares | Aug. 31, 2013USD ($)$ / sharesshares | Jan. 31, 2013USD ($) | Dec. 31, 2012USD ($) | Jul. 31, 2012USD ($) | Dec. 31, 2011BRL | Nov. 30, 2010 | Mar. 31, 2017USD ($) | Dec. 31, 2016USD ($)$ / sharesshares | Dec. 31, 2016USD ($)$ / sharesshares | Dec. 31, 2016USD ($)$ / sharesshares | Dec. 31, 2016BRL | Dec. 31, 2015USD ($)shares | Dec. 31, 2014USD ($) | Mar. 01, 2017shares | Jan. 10, 2017USD ($) | Dec. 31, 2016BRLshares | Dec. 19, 2016USD ($) | Dec. 01, 2016USD ($)$ / shares | Sep. 30, 2016USD ($) | Sep. 30, 2016BRL | Sep. 02, 2016USD ($) | May 30, 2016USD ($)$ / shares | Mar. 21, 2016USD ($) | Feb. 24, 2016 | Feb. 16, 2016$ / shares | Dec. 31, 2015BRLshares | Oct. 31, 2015USD ($) | Jun. 30, 2015 | Apr. 30, 2015USD ($) | Mar. 31, 2015USD ($) | Jan. 31, 2015USD ($)$ / shares | Jul. 31, 2014USD ($)$ / shares | Oct. 04, 2013 | Sep. 30, 2013USD ($)shares | Jul. 31, 2013USD ($)$ / shares | Jun. 30, 2013USD ($)$ / shares | Mar. 31, 2013$ / shares | Sep. 14, 2012USD ($)$ / shares | Jul. 31, 2012BRL | Jul. 30, 2012USD ($) | Jun. 30, 2012USD ($) | Feb. 28, 2012USD ($)$ / shares |
Proceeds from Issuance of Long-term Debt | $ 63,911,000 | $ 66,931,000 | $ 83,171,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Repayments of Long-term Debt | 9,759,000 | 40,819,000 | 5,733,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from Issuance of Private Placement | $ 5,000,000 | $ 25,000,000 | $ 4,000,000 | $ 15,000,000 | $ 37,200,000 | 24,625,000 | 4,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Extinguishment of Debt, Amount | $ 5,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Gain (Loss) on Extinguishment of Debt | $ 4,200,000 | (4,146,000) | (1,141,000) | $ (10,512,000) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Long-term Debt | $ 227,043,000 | $ 227,043,000 | $ 227,043,000 | 227,043,000 | $ 151,974,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 1,602,562 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares | $ 0.01 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Unamortized Discount | $ 42,500,000 | $ 42,500,000 | $ 42,500,000 | $ 42,500,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Outstanding | shares | 14,663,411 | 14,663,411 | 14,663,411 | 14,663,411 | 4,343,733 | 14,663,411 | 4,343,733 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Letters of Credit Outstanding, Amount | $ 1,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Restricted Cash and Cash Equivalents, Noncurrent | $ 957,000 | $ 957,000 | $ 957,000 | $ 957,000 | $ 957,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt, Future Minimum Payments Due, Next Twelve Months | 79,913,000 | 79,913,000 | 79,913,000 | 79,913,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Future Minimum Payments Due in Two Years | 71,148,000 | 71,148,000 | 71,148,000 | 71,148,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Future Minimum Payments Due in Three Years | $ 128,439,000 | $ 128,439,000 | $ 128,439,000 | 128,439,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reduction in Noncurrent Debt [Member] | December 31, 2015 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Prior Period Reclassification Adjustment | 2,800,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reduction in Current Debt [Member] | December 31, 2015 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Prior Period Reclassification Adjustment | 1,400,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reduction in Noncurrent Assets [Member] | December 31, 2015 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Prior Period Reclassification Adjustment | 2,800,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reduction in Prepaid Expenses and Other Current Assets [Member] | December 31, 2015 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Prior Period Reclassification Adjustment | $ 1,400,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Exchange Warrants [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares | $ 0.01 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
JVCO Joint Venture [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Equity Method Investment, Ownership Percentage | 25.00% | 25.00% | 25.00% | 25.00% | 25.00% | 25.00% | 25.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Original Debt, Amount | $ 70,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Debt | $ 5,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Converted Instrument, Shares Issued | shares | 30,400,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total [Member] | JVCO Joint Venture [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Equity Method Investment, Percentage Investment Sold | 50.00% | 50.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Equity Method Investment, Ownership Percentage by Counterparty | 75.00% | 75.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion of All Outstanding Fidelity Notes for Aggregate Principal Amount of 2015 144A Notes [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Loans Payable | $ 19,100,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Original Debt, Amount | $ 19,100,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Converted Instrument, Exchange Ratio of Converted Debt to Original Debt | 1.25 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion of All Outstanding Fidelity Notes for Aggregate Principal Amount of 2015 144A Notes [Member] | Subsequent Event [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Gain (Loss) on Extinguishment of Debt | $ 100,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Related Party Convertible Notes [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Debt | $ 42,800,000 | $ 42,800,000 | $ 42,800,000 | $ 42,800,000 | 42,800,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Gain (Loss) on Extinguishment of Debt | $ (9,400,000) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Long-term Debt | 42,754,000 | 42,754,000 | 42,754,000 | 42,754,000 | 42,749,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Debt Discount, Related Party | 5,400,000 | 5,400,000 | 5,400,000 | 5,400,000 | 4,900,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt, Future Minimum Payments Due, Next Twelve Months | 4,837,000 | 4,837,000 | 4,837,000 | 4,837,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Future Minimum Payments Due in Two Years | 16,550,000 | 16,550,000 | 16,550,000 | 16,550,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Future Minimum Payments Due in Three Years | 34,260,000 | 34,260,000 | 34,260,000 | 34,260,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Related Party Convertible Notes [Member] | The Second Tranche [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Term | 1 year | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price | $ / shares | $ 2.87 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Promissory Notes, Period After Which Notes Will Be Due | 5 years | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note Discount, Number of Days for Trailing Weighted-average Closing Price | 60 days | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price, Interest Accrued, Rate Applicable to the First 180 Days | 13.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price, Interest Accrued Thereafter | 16.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price, Interest Accrued for Defaults | 12.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes, Recurring Term of Option to Prepay After Initial Payment Period | 180 days | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Exchanged and Cancelled | $ 6,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price, Interest Accrued | 10.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price, Interest Period | 3 years | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Rule 144A Related Party Convertible Notes [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Debt | 17,300,000 | 17,300,000 | 17,300,000 | 17,300,000 | 14,600,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Debt Discount, Related Party | 7,400,000 | 7,400,000 | 7,400,000 | 7,400,000 | 10,100,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Loans Payable [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Long-term Debt | 26,527,000 | 26,527,000 | 26,527,000 | 26,527,000 | 13,606,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt, Future Minimum Payments Due, Next Twelve Months | 16,628,000 | 16,628,000 | 16,628,000 | 16,628,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Future Minimum Payments Due in Two Years | 2,808,000 | 2,808,000 | 2,808,000 | 2,808,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Future Minimum Payments Due in Three Years | 2,699,000 | 2,699,000 | 2,699,000 | 2,699,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Senior Secured Loan Facility [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Long-term Line of Credit | 27,700,000 | 27,700,000 | 27,700,000 | 27,700,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net | 900,000 | 900,000 | 900,000 | 900,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
BNDES Credit Facility [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Long-term Line of Credit | 1,200,000 | 1,200,000 | 1,200,000 | 1,200,000 | 1,900,000 | BRL 3.8 | BRL 7.6 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Line of Credit Facility, Maximum Borrowing Capacity | 6,900,000 | BRL 22.4 | 6,900,000 | 6,900,000 | 6,900,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 7.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Number of Monthly Installments | 60 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage | 0.10% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Collateral Provided by Company Certain Equipment and Other Tangible Assets, Amount | BRL 24.9 | 7,700,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Line of Credit Facility Bank Guarantee Percentage | 10.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Guarantor Obligations, Liquidation Proceeds, Percentage | 130.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
BNDES Credit Facility [Member] | First Tranche [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Line of Credit Facility, Maximum Borrowing Capacity | BRL | BRL 19.1 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
BNDES Credit Facility [Member] | The Second Tranche [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Line of Credit Facility, Maximum Borrowing Capacity | BRL | BRL 3.3 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Line of Credit Facility Bank Guarantee Percentage | 90.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Line of Credit Facility, Borrowings Above Which is New Tranche | BRL | BRL 19.1 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
FINEP Credit Facility [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Long-term Line of Credit | 700,000 | 700,000 | 700,000 | 700,000 | 900,000 | BRL 2.3 | 3.4 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Line of Credit Facility, Maximum Borrowing Capacity | $ 2,000,000 | BRL 6.4 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 5.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Number of Monthly Installments | 81 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
DebtDefualtPenaltyAndFineOnObligationInDefaultPercentage | 10.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument Interest On Late Balance Percentage Per Month | 1.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
FINEP Credit Facility [Member] | Threshold Met [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 11.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Extinguishment of Debt, Amount | € | € 50,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Letter of Credit [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Restricted Cash and Cash Equivalents, Noncurrent | 1,000,000 | $ 1,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Private Placement February 2016 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Line of Credit Facility, Maximum Borrowing Capacity | $ 1,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 13.50% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | 20,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from Issuance of Private Placement | $ 2,000,000 | $ 18,000,000 | $ 20,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Private Placement February 2016 [Member] | Unsecured Promissory Notes, 2016 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 2,000,000 | $ 18,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 285,714 | 2,571,428 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares | $ 0.01 | $ 0.01 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Private Placement February 2016 [Member] | Stegodon [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Fee Amount, Current | 425,000 | 425,000 | 425,000 | 425,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Fee Amount, Noncurrent | 450,000 | 450,000 | 450,000 | 450,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Private Placement February 2016 [Member] | Stegodon [Member] | Ginkgo Collaboration Agreement [Member] | Senior Secured Loan Facility [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Additional Monies Agreed to Apply Toward Repayment of Outstanding Loans, Maximum | 3,000,000 | 3,000,000 | 3,000,000 | 3,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Private Placement February 2016 [Member] | Foris Ventures, LLC [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from Issuance of Private Placement | $ 16,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 2,285,714 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Unsecured Senior Convertible Promissory Notes [Member] | Total [Member] | Related Party Convertible Notes [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 20,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Guanfu Credit Agreement [Member] | Guanfu Holding Co., Ltd [Member] | Unsecured Debt [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Long-term Line of Credit | $ 25,000,000 | $ 25,000,000 | $ 25,000,000 | $ 25,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Line of Credit Facility, Maximum Borrowing Capacity | $ 25,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 10.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Term | 5 years | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Redemption Price, Percentage | 100.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common Stock, Volume Weighted Average Closing Sale Price, Percentage | 90.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common Stock, Volume Weighted Average Closing Sale Price, Number of Trading Days | 90 days | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trading Days, Number of Days Proceeding Default | 2 days | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fidelity Convertible Notes [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 57,600,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price | $ / shares | $ 7.0682 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Repurchase Amount | 8,800,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Repurchased Face Amount | $ 9,700,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Number of Equity Instruments | 2,165,898 | 2,165,898 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Promissory Note, Acquisition Right Amount Redeemable, Percentage | 101.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Promissory Note, Maximum Allowable Debt | $ 200,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Promissory Notes, Debt Percentage of Total Assets | 50.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Promissory Note, Maximum Amount of Secured Debt | $ 125,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Promissory Note, Secured Debt as a Percentage of Consolidated Total Assets | 30.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Promissory Note, Bridge Loan Amount, Convertible Promissory Note Covenants Waived | $ 35,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Additional Consideration for Covenant Waiving, Convertible Promissory Notes | 7,600,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fidelity Convertible Notes [Member] | Convertible Subordinated Debt [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable | $ 25,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Effective Percentage | 3.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Rule 144A Convertible Note Offering [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price | $ / shares | $ 3.74 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note Offering | $ 75,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Additional Convertible Note Offering | 15,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from Convertible Debt | 72,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from Convertible Debt Used to Repay Previously Issued Convertible Debt | $ 9,700,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Threshold Trading Days | 20 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Threshold Consecutive Trading Days | 30 days | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Threshold Days for Conversion Notification | 5 days | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note Substantial Change, Discount Rate Used in Calculate Value of Remaining Interest Payments | 0.75% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note Substantial Change, Percentage of Principal Repurchase Price | 100.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Rule 144A Convertible Note Offering [Member] | Affiliated Entity [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 6.50% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 57,600,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Repurchase Amount | 18,300,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Repurchased Face Amount | 22,900,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Amount of Convertible Debt Purchased by Affiliated Entities | $ 24,700,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Rule 144A Convertible Note Offering [Member] | Convertible Debt Securities [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Effective Percentage | 6.50% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Rule 144A Convertible Note Offering [Member] | Numerator [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Ratio | 267.037 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Rule 144A Convertible Note Offering [Member] | Denominator [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Rate, Principle Amount | $ / shares | $ 1,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Senior Notes, 9.5% [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 9.50% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 57,600,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price | $ / shares | $ 2.25 | $ 2.24 | $ 2.24 | $ 2.24 | $ 2.24 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Repurchase Amount | $ 3,700,000 | $ 3,700,000 | $ 3,700,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Number of Equity Instruments | 38,415,626 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Promissory Note, Maximum Allowable Debt | $ 200,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Promissory Note, Maximum Amount of Secured Debt | $ 65,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Promissory Note, Secured Debt as a Percentage of Consolidated Total Assets | 30.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from Convertible Debt | $ 54,400,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Rate, Principle Amount | $ / shares | $ 1,000 | $ 1,000 | $ 1,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note Substantial Change, Discount Rate Used in Calculate Value of Remaining Interest Payments | 0.75% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note Substantial Change, Percentage of Principal Repurchase Price | 100.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Rate, Shares | shares | 443.6557 | 446.6719 | 446.8707 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible Percentage of Average Price Per Share the Stock will be Valued upon Early Conversion | 92.50% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of Trading Days Notes Become Convertible | 10 days | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Restrictions, Maximum Outstanding Debt | $ 25,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Long-term Debt | $ 18,700,000 | $ 18,700,000 | $ 18,700,000 | $ 18,700,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Term | 5 years | 5 years | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Senior Notes, 9.5% [Member] | Subsequent Event [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Promissory Note, Additional Principal Amount Issued During Period | $ 19,100,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Decrease, Forgiveness | $ 15,300,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Senior Notes, 6.5% [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Repurchase Amount | 18,300,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Repurchased Face Amount | 22,900,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Senior Notes, 3% [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Repurchase Amount | 8,800,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Repurchased Face Amount | $ 9,700,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
The May 2016 Convertible Notes [Member] | Convertible Subordinated Debt [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 15,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Redemption Price, Percentage | 118.00% | 118.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price | $ / shares | $ 1.90 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from Convertible Debt | $ 9,900,000 | 5,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Debt | $ 10,000,000 | $ 2 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount, Contingent Second Closing | $ 5,000,000 | $ 5,000,000 | $ 5,000,000 | $ 5,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Additional Common Stock Payment, Maximum Percent of Aggregate Amount | 50.00% | 50.00% | 50.00% | 50.00% | 50.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Threshold Amount of Dollar-weighted Volume of Common Stock | $ 200,000 | $ 200,000 | $ 200,000 | $ 200,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Debt, Length of Time from Date of Issuance, Threshold | 120 days | 120 days | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Debt, Beneficial Common Stock Ownership, Maximum Percentage Except Under Specified Conditions | 4.99% | 4.99% | 4.99% | 4.99% | 4.99% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Debt, Beneficial Common Stock Ownership, Maximum Percentage Under Specified Conditions | 9.99% | 9.99% | 9.99% | 9.99% | 9.99% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Debt, Beneficial Common Stock Ownership, Maximum Percentage, Conditions, Number of Days After Written Notice | 61 days | 61 days | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Debt, Aggregate Number of Shares Issued With Respect to the Initial Closing, Maximum Percentage | 19.99% | 19.99% | 19.99% | 19.99% | 19.99% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Debt, Holder Limitations, Maximum Sale Price Per Share of Common Stock | $ / shares | $ 1.05 | $ 1.05 | $ 1.05 | $ 1.05 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Debt, Holders May Not Sell Shares, Price Floor, Threshold | $ / shares | $ 1 | $ 1 | $ 1 | $ 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
The May 2016 Convertible Notes [Member] | Convertible Subordinated Debt [Member] | Threshold 2 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Redemption Price, Percentage upon Triggering Event | 112.00% | 112.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
The December 2016 Convertible Note [Member] | Convertible Subordinated Debt [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 10,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price | $ / shares | $ 1.90 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from Convertible Debt | $ 9,900,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Additional Common Stock Payment, Maximum Percent of Aggregate Amount | 50.00% | 50.00% | 50.00% | 50.00% | 50.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Threshold Amount of Dollar-weighted Volume of Common Stock | $ 200,000 | $ 200,000 | $ 200,000 | $ 200,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Debt, Beneficial Common Stock Ownership, Maximum Percentage Except Under Specified Conditions | 4.99% | 4.99% | 4.99% | 4.99% | 4.99% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Debt, Beneficial Common Stock Ownership, Maximum Percentage Under Specified Conditions | 9.99% | 9.99% | 9.99% | 9.99% | 9.99% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Debt, Beneficial Common Stock Ownership, Maximum Percentage, Conditions, Number of Days After Written Notice | 61 days | 61 days | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Debt, Aggregate Number of Shares Issued With Respect to the Initial Closing, Maximum Percentage | 19.99% | 19.99% | 19.99% | 19.99% | 19.99% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Debt, Holder Limitations, Maximum Sale Price Per Share of Common Stock | $ / shares | $ 1.05 | $ 1.05 | $ 1.05 | $ 1.05 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Debt, Holders May Not Sell Shares, Price Floor, Threshold | $ / shares | $ 1 | $ 1 | $ 1 | $ 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Monthly Installments, Percent of Installment Amount | 118.00% | 118.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Events of Default, Percentage of Amount can be Redeemed by Holders | 118.00% | 118.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Events of Fundamental Transaction, Percentage of Amount can be Redeemed by Holders | 118.00% | 118.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total Purchase Agreement [Member] | Total [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 105,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Unsecured Senior Convertible Promissory Notes [Member] | Total [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 69,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Unsecured Senior Convertible Promissory Notes [Member] | Total [Member] | Related Party Convertible Notes [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 30,000,000 | $ 10,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Unsecured Senior Convertible Promissory Notes [Member] | Initial Closing [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price | $ / shares | $ 7.0682 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Unsecured Senior Convertible Promissory Notes [Member] | Initial Closing [Member] | Total [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 1.50% | 1.50% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 15,000,000 | $ 38,300,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of Installments | 2 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Unsecured Senior Convertible Promissory Notes [Member] | Initial Closing [Member] | Total [Member] | New Funding [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | 15,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Unsecured Senior Convertible Promissory Notes [Member] | Initial Closing [Member] | Total [Member] | Diesel Research and Development Funding [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 23,300,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Unsecured Senior Convertible Promissory Notes [Member] | Second Closing [Member] | Related Party Convertible Notes [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price | $ / shares | $ 3.08 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Unsecured Senior Convertible Promissory Notes [Member] | Second Closing [Member] | Total [Member] | Related Party Convertible Notes [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 20,000,000 | $ 10,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of Installments | 2 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Unsecured Senior Convertible Promissory Notes [Member] | Two Installments in Second Closing [Member] | Total [Member] | Related Party Convertible Notes [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 30,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Unsecured Senior Convertible Promissory Notes [Member] | Third Closing [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price | $ / shares | $ 4.11 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Unsecured Senior Convertible Promissory Notes [Member] | Third Closing [Member] | Total [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 10,850,000 | $ 10,850,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of Installments | 2 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Unsecured Senior Convertible Promissory Notes [Member] | Two Installments In Third Closing [Member] | Total [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 21,700,000 | $ 21,700,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price | $ / shares | $ 4.11 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
March 2013 Letter Agreement [Member] | Total [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price | $ / shares | $ 3.08 | $ 7.0682 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument Closing Price Plus Incremental Rate | $ / shares | 0.01 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Senior Secured Convertible Note [Member] | Total [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 1.50% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
July 2012 Agreements [Member] | Total [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 10,850,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price | $ / shares | $ 7.0682 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
March 2014 Letter Agreement [Member] | Total [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price | $ / shares | $ 4.11 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Debt | $ 75,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
March 2014 Letter Agreement [Member] | Two Installments In Third Closing [Member] | Total [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price | $ / shares | $ 4.11 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Unsecured Promissory Notes, 2016 [Member] | Total [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Extinguishment of Debt, Amount | 1,300,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
March 2016 R&D Note [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Extinguishment of Debt, Amount | 5,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Replacement Notes [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Effective Percentage | 1.50% | 1.50% | 1.50% | 1.50% | 1.50% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price | $ / shares | $ 3.08 | $ 3.08 | $ 3.08 | $ 3.08 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Promissory Note, Maximum Allowable Debt | $ 200,000,000 | $ 200,000,000 | $ 200,000,000 | $ 200,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Promissory Notes, Debt Percentage of Total Assets | 50.00% | 50.00% | 50.00% | 50.00% | 50.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Promissory Note, Maximum Amount of Secured Debt | $ 125,000,000 | $ 125,000,000 | $ 125,000,000 | $ 125,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Promissory Note, Secured Debt as a Percentage of Consolidated Total Assets | 30.00% | 30.00% | 30.00% | 30.00% | 30.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Long-term Debt | $ 3,700,000 | $ 3,700,000 | $ 3,700,000 | $ 3,700,000 | $ 3,700,000 | 5,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument Default Rate | 2.50% | 2.50% | 2.50% | 2.50% | 2.50% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Percentage of Principal Amount of Notes, Required to Be Repaid in Change of Control | 101.00% | 101.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
August 2013 Convertible Notes [Member] | Total [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cancellation of Convertible Debt | $ 13,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
August 2013 Convertible Notes [Member] | Total [Member] | Common Stock [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 1,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares | $ 0.01 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
August 2013 Convertible Notes [Member] | Total [Member] | First Tranche [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cancellation of Convertible Debt | $ 7,600,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
August 2013 Convertible Notes [Member] | Total [Member] | Second Tranche [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cancellation of Convertible Debt | 5,400,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
August 2013 Convertible Notes [Member] | Total and Temasek [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 73,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Private Placement Convertible Notes, Period | 2 years | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Number of Tranches | 2 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
August 2013 Convertible Notes [Member] | Total and Temasek [Member] | First Tranche [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 42,600,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
August 2013 Convertible Notes [Member] | Total and Temasek [Member] | Second Tranche [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | 30,400,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
August 2013 Convertible Notes [Member] | Temasek [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Extinguishment of Debt, Amount | 35,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bridge Loan | $ 35,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
August 2013 Convertible Notes [Member] | Temasek [Member] | Second Tranche [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from Convertible Debt | $ 25,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
August 2013 Convertible Notes [Member] | Private Placement [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 110,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 1,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Temasek Bridge Loan [Member] | Temasek [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 5.50% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
First Tranche [Member] | Related Party Convertible Notes [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price | $ / shares | $ 2.44 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from Convertible Debt | $ 7,600,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Gain (Loss) on Extinguishment of Debt | (19,900,000) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cancellation of Convertible Debt | $ 44,200,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Promissory Notes, Period After Which Notes Will Be Due | 5 years | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes, Discount Percentage to Determine Conversion Price | 15.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note Discount, Number of Days for Trailing Weighted-average Closing Price | 60 days | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes, Period After Which Convertible at the Option of Holder | 1 year 180 days | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Plant Manufacturing Production, Product Sales, Percentage | 5.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price, Interest Accrued, Rate Applicable to the First 180 Days | 6.50% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price, Interest Accrued Thereafter | 8.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price, Interest Accrued for Defaults | 6.50% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes, Period Over Which Interest is Payable in Kind | 2 years 180 days | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes, Recurring Term of Option to Prepay After Initial Payment Period | 180 days | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes, Initial Prepayment Term | 2 years 180 days | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
First Tranche [Member] | Related Party Convertible Notes [Member] | Total [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 51,800,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Extinguishment of Debt, Amount | 9,200,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
First Tranche [Member] | Related Party Convertible Notes [Member] | Temasek [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Extinguishment of Debt, Amount | 35,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Second Tranche [Member] | Related Party Convertible Notes [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Future Cancellation of Debt, Amount | $ 9,200,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Second Tranche [Member] | Related Party Convertible Notes [Member] | Wolverine [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 3,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cancellation of Convertible Debt | $ 25,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
The Second Tranche [Member] | Related Party Convertible Notes [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 34,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
The Second Tranche [Member] | Related Party Convertible Notes [Member] | Temasek [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Purchased | 25,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
The Second Tranche [Member] | Related Party Convertible Notes [Member] | Wolverine [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Purchased | 3,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
The Second Tranche [Member] | Related Party Convertible Notes [Member] | Total [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Purchased | $ 6,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Tranche I and Tranche II Notes [Member] | Related Party Convertible Notes [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price | $ / shares | $ 1.42 | $ 1.14 | $ 1.40 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Original Debt, Amount | $ 71,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Debt | $ 21,800,000 | $ 21,800,000 | $ 21,800,000 | $ 21,800,000 | 23,300,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Converted Instrument, Shares Issued | shares | 30,860,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Percentage of Principal Amount of Notes, Required to Be Repaid in Change of Control | 101.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Unamortized Discount | $ 0 | $ 0 | $ 0 | $ 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
June 2016 Private Placement [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 13.50% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 5,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from Issuance of Private Placement | $ 5,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
October 2016 Private Placement [Member] | Foris Ventures, LLC [Member] | Convertible Subordinated Debt [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from Issuance of Long-term Debt | $ 6,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 13.50% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 6,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
October 2016 Private Placement [Member] | Ginkgo Bioworks, Inc. [Member] | Convertible Subordinated Debt [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from Issuance of Long-term Debt | $ 8,500,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 13.50% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 8,500,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Salisbury Note [Member] | Salisbury Partners, LLC [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 5.00% | 5.00% | 5.00% | 5.00% | 5.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 3,500,000 | $ 3,500,000 | $ 3,500,000 | $ 3,500,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Term | 13 years | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Delinquency Penalty | 5.00% | 5.00% | 5.00% | 5.00% | 5.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Delinquency Penalty, Threshold | 5 days | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Nikko Note [Member] | Nikko [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 5.00% | 5.00% | 5.00% | 5.00% | 5.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 3,900,000 | $ 3,900,000 | $ 3,900,000 | $ 3,900,000 | $ 3,900,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Term | 13 years | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Delinquency Penalty | 5.00% | 5.00% | 5.00% | 5.00% | 5.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Delinquency Penalty, Threshold | 5 days | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Percentage of Joint Venture Interests Owned By the Company Securing the Debt Instrument | 10.00% | 10.00% | 10.00% | 10.00% | 10.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Additional Payments Required in Four Monthly Installments | $ 400,000 | $ 400,000 | $ 400,000 | $ 400,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Additional Equal Monthly Installments, Amount | 100,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Nomis Bay Convertible Note [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt, Future Minimum Payments Due, Next Twelve Months | 11,800,000 | 11,800,000 | 11,800,000 | 11,800,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Maturity Treatment Agreement [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Future Minimum Payments Due in Two Years | 46,800,000 | 46,800,000 | 46,800,000 | 46,800,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Future Minimum Payments Due in Three Years | 46,800,000 | 46,800,000 | 46,800,000 | 46,800,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Related Party and Non-Related Party Convertible Debt [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Unamortized Discount | $ 42,500,000 | $ 42,500,000 | $ 42,500,000 | $ 42,500,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
TJLP Adjustment Factor [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
DebtInstruementInterestRateOfTheCentralBankOfBrazilUsedAsAThreshold | 6.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
TJLP Adjustment Factor [Member] | FINEP Credit Facility [Member] | Threshold Met [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Basis Spread on Variable Rate | 5.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Minimum [Member] | The May 2016 Convertible Notes [Member] | Convertible Subordinated Debt [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible Stock Price Trigger for Deferred Installments | $ / shares | $ 0.50 | $ 0.50 | $ 0.50 | $ 0.50 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible Threshold Consecutive Trading Days, Deferred Installments | 5 days | 5 days | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Minimum [Member] | March 2013 Letter Agreement [Member] | Total [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price | $ / shares | $ 3.08 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Maximum [Member] | The May 2016 Convertible Notes [Member] | Convertible Subordinated Debt [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible Stock Price Trigger for Deferred Installments | $ / shares | $ 1 | $ 1 | $ 1 | $ 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible Threshold Consecutive Trading Days, Deferred Installments | 30 days | 30 days | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Hercules Technology Growth Capital, Inc. (Hercules) [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Loans Payable | $ 25,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Prepayment Penalty, Percentage | 1.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Facility Charge, Percentage | 1.00% | 5.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, End of Term Fee, Percentage | 10.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Long-term Line of Credit | $ 25,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Forbearance Fee, Forgiven | $ 10,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Required Equity Financing, Amount | $ 50,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Unencumbered, Unrestricted, Cash Required, Percentage | 50.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Line of Credit Facility, Maximum Borrowing Capacity | $ 15,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Line of Credit Facility, Amount to be Raised Through Equity Triggering Withdrawal of the Credit Facility | $ 20,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Line of Credit Facility, Commitment Fee Percentage | 3.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Hercules Technology Growth Capital, Inc. (Hercules) [Member] | Subsequent Event [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Line of Credit Facility, Maximum Borrowing Capacity | $ 3,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Hercules Technology Growth Capital, Inc. (Hercules) [Member] | Hercules Credit Additional Amount [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Additional Amount Required | $ 5,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Hercules Technology Growth Capital, Inc. (Hercules) [Member] | Third Hercules Amendment [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Loans Payable | $ 31,700,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from Issuance of Long-term Debt | $ 10,960,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Repayments of Long-term Debt | $ 9,100,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 9.50% | 9.50% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid | $ 767,200 | $ 767,200 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Payments of Debt Issuance Costs | 1,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Hercules Technology Growth Capital, Inc. (Hercules) [Member] | Third Hercules Amendment [Member] | Portion of Debt Costs Owed in Connection with Expired Facility [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Payments of Debt Issuance Costs | 750,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Hercules Technology Growth Capital, Inc. (Hercules) [Member] | Third Hercules Amendment [Member] | Portion of Debt Costs Related to the Third Hercules Amendment [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Payments of Debt Issuance Costs | $ 250,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Hercules Technology Growth Capital, Inc. (Hercules) [Member] | Prime Rate [Member] | Third Hercules Amendment [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Basis Spread on Variable Rate | 6.25% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Hercules Technology Growth Capital, Inc. (Hercules) [Member] | Minimum [Member] | Prime Rate [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Basis Spread on Variable Rate | 6.25% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Hercules Technology Growth Capital, Inc. (Hercules) [Member] | Minimum [Member] | Prime Rate [Member] | Hercules Credit Additional Amount [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Basis Spread on Variable Rate | 5.25% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Hercules Technology Growth Capital, Inc. (Hercules) [Member] | Maximum [Member] | Prime Rate [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Basis Spread on Variable Rate | 9.50% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Hercules Technology Growth Capital, Inc. (Hercules) [Member] | Maximum [Member] | Prime Rate [Member] | Hercules Credit Additional Amount [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Basis Spread on Variable Rate | 8.50% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Nossa Caixa and Banco Pine Agreements [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 5.50% | 5.50% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 16,000,000 | $ 16,000,000 | $ 16,000,000 | $ 16,000,000 | BRL 52 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Collateral Provided by Company Certain Equipment and Other Tangible Assets, Amount | 20,900,000 | BRL 68 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Certain Farnesene Production Assets Pledged as Collateral for Loans | BRL | BRL 52 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Period of Interest Only QuarterlyPayments | 2 years | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Nossa Caixa and Banco Pine Agreements [Member] | Loans Payable [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Long-term Debt | 11,100,000 | 11,100,000 | 11,100,000 | 11,100,000 | 11,000,000 | BRL 36.3 | BRL 43 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Banco Pine [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | BRL | 22 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Nossa Caixa [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | BRL | BRL 30 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Banco ABC Brasil S.A. (ABC) [Member] | ABC Brasil Agreement [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Additional Export Financing Agreement | $ 0 | $ 2,200,000 | $ 0 | $ 0 | $ 0 | 1,600,000 | $ 1,600,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Temasek [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Original Debt, Amount | $ 71,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Converted Instrument, Shares Issued | shares | 30,860,633 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Temasek [Member] | Temasek Warrant 1 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 14,677,861 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Temasek [Member] | Temasek Warrant 2 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Numerator One | 30.60% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Denominator One | 69.40% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Numerator Two | 13.30% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Denominator Two | 86.70% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Temasek [Member] | Temasek Warrant Three [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Term | 10 years | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Common Stock Shares Used In Calculation | shares | 880,339 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Threshold Number of Securities | shares | 2,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Temasek [Member] | The 2013 Warrant [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 1,000,000 | 12,700,244 | 12,700,244 | 12,700,244 | 12,700,244 | 12,700,244 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares | $ 0.01 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Outstanding | shares | 2,462,536 | 2,462,536 | 2,462,536 | 2,462,536 | 2,462,536 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Temasek [Member] | If Total R&D Warrant is Exercised in Full [Member] | Temasek Warrant Three [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 880,339 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Temasek [Member] | If Total R&D Warrant is Exercised in Full [Member] | Subsequent Event [Member] | Temasek Warrant Three [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 880,339 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Threshold Number of Securities | shares | 2,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Temasek [Member] | Rule 144A Convertible Notes [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable | $ 10,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable | 27,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Original Debt, Amount | $ 70,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Converted Instrument, Shares Issued | shares | 30,434,782 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Extinguishment of Debt, Amount | € | € 50,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total [Member] | Total Funding Warrant [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 18,924,191 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Term | 5 years | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total [Member] | Total R&D Warrant [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 2,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total [Member] | Temasek Warrant 2 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 2,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total [Member] | Unsecured Senior Convertible Promissory Notes [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Extinguishment of Debt, Amount | $ 1,300,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total [Member] | Tranche I and Tranche II Notes [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable | $ 15,300,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total [Member] | Rule 144A Convertible Notes [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable | $ 9,700,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total and Temasek [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price | $ / shares | $ 2.30 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest Expense, Debt | $ 39,200,000 |
Note 5 - Debt and Mezzanine E60
Note 5 - Debt and Mezzanine Equity - Debt Components (Details) - USD ($) $ in Thousands | Dec. 31, 2016 | Dec. 31, 2015 | |
Debt | $ 227,043 | $ 151,974 | |
Less: current portion | (59,155) | (36,281) | |
Noncurrent portion of debt | 167,888 | 115,693 | |
Mezzanine equity(1) | [1] | 5,000 | |
FINEP Credit Facility [Member] | |||
Debt | 696 | 840 | |
BNDES Credit Facility [Member] | |||
Debt | 1,172 | 1,956 | |
Guanfu Credit Facility [Member] | |||
Debt | 19,564 | ||
Senior Secured Loan Facility [Member] | |||
Debt | 27,658 | 31,590 | |
Credit Facility [Member] | |||
Debt | 49,090 | 34,386 | |
Noncurrent portion of debt | 47,641 | ||
Convertible Debt [Member] | |||
Debt | 78,981 | 61,233 | |
Noncurrent portion of debt | 70,024 | ||
Related Party Convertible Notes [Member] | |||
Debt | 42,754 | 42,749 | |
Noncurrent portion of debt | 39,144 | ||
Related Party Loan Payable [Member] | |||
Debt | 29,691 | ||
Noncurrent portion of debt | |||
Loans Payable [Member] | |||
Debt | 26,527 | $ 13,606 | |
Noncurrent portion of debt | $ 11,079 | ||
[1] | See Note 8, "Significant Agreements" for details regarding the Bill & Melinda Gates Foundation Investment, classified as mezzanine equity. |
Note 5 - Debt and Mezzanine E61
Note 5 - Debt and Mezzanine Equity - Long-term Debt Instruments (Details) - USD ($) $ in Thousands | Dec. 31, 2016 | Dec. 31, 2015 | |
2,017 | $ 79,913 | ||
2,018 | 71,148 | ||
2,019 | 128,439 | ||
2,020 | 5,092 | ||
2,021 | 29,878 | ||
Thereafter | 4,075 | ||
Total future minimum payments(1) | [1] | 318,545 | |
Less: amount representing interest(2) | [2] | (91,502) | |
Present value of minimum debt payments | 227,043 | ||
Less: current portion | (59,155) | ||
Noncurrent portion of debt | 167,888 | $ 115,693 | |
Related Party Convertible Notes [Member] | |||
2,017 | 4,837 | ||
2,018 | 16,550 | ||
2,019 | 34,260 | ||
2,020 | |||
2,021 | |||
Thereafter | |||
Total future minimum payments(1) | [1] | 55,647 | |
Less: amount representing interest(2) | [2] | (12,893) | |
Present value of minimum debt payments | 42,754 | ||
Less: current portion | (3,610) | ||
Noncurrent portion of debt | 39,144 | ||
Convertible Debt [Member] | |||
2,017 | 18,883 | ||
2,018 | 18,142 | ||
2,019 | 88,902 | ||
2,020 | |||
2,021 | |||
Thereafter | |||
Total future minimum payments(1) | [1] | 125,927 | |
Less: amount representing interest(2) | [2] | (46,946) | |
Present value of minimum debt payments | 78,981 | ||
Less: current portion | (8,957) | ||
Noncurrent portion of debt | 70,024 | ||
Loans Payable [Member] | |||
2,017 | 16,628 | ||
2,018 | 2,808 | ||
2,019 | 2,699 | ||
2,020 | 2,592 | ||
2,021 | 2,483 | ||
Thereafter | 4,075 | ||
Total future minimum payments(1) | [1] | 31,285 | |
Less: amount representing interest(2) | [2] | (4,758) | |
Present value of minimum debt payments | 26,527 | ||
Less: current portion | (15,448) | ||
Noncurrent portion of debt | 11,079 | ||
Related Party Loan Payable [Member] | |||
2,017 | 32,551 | ||
2,018 | |||
2,019 | |||
2,020 | |||
2,021 | |||
Thereafter | |||
Total future minimum payments(1) | [1] | 32,551 | |
Less: amount representing interest(2) | [2] | (2,860) | |
Present value of minimum debt payments | 29,691 | ||
Less: current portion | (29,691) | ||
Noncurrent portion of debt | |||
Credit Facility [Member] | |||
2,017 | 7,014 | ||
2,018 | 33,648 | ||
2,019 | 2,578 | ||
2,020 | 2,500 | ||
2,021 | 27,395 | ||
Thereafter | |||
Total future minimum payments(1) | [1] | 73,135 | |
Less: amount representing interest(2) | [2] | (24,045) | |
Present value of minimum debt payments | 49,090 | ||
Less: current portion | (1,449) | ||
Noncurrent portion of debt | $ 47,641 | ||
[1] | Including $11.8 million in 2017 related to Nomis Bay convertible note which, at the Company's election, may be settled in shares or cash, be settled in shares and $46.8 million in 2018 and 2019 subject to Maturity Treatment Agreement, which will be converted to common stock at maturity, subject to there being no default under the terms of the debt. | ||
[2] | Including debt discount and issuance cost of $42.5 million associated with the related party and non-related party debt which will be accreted to interest expense under the effective interest method over the term of the debt. |
Note 6 - Commitments and Cont62
Note 6 - Commitments and Contingencies (Details Textual) BRL in Millions | 1 Months Ended | 12 Months Ended | ||||||||
Dec. 31, 2011BRL | Dec. 31, 2016USD ($) | Dec. 31, 2016BRL | Dec. 31, 2015USD ($) | Dec. 31, 2014USD ($) | Mar. 31, 2016USD ($) | Apr. 08, 2015USD ($) | Mar. 31, 2015USD ($) | Dec. 31, 2013USD ($) | Nov. 30, 2010 | |
Operating Leases, Rent Expense | $ 5,300,000 | $ 5,500,000 | $ 5,400,000 | |||||||
Restricted Cash and Cash Equivalents | 5,300,000 | 1,200,000 | ||||||||
Long-term Debt | 227,043,000 | 151,974,000 | ||||||||
Purchase Obligation | 800,000 | |||||||||
Contractual Obligation | 600,000 | |||||||||
Liabilities for Guarantees on Long-Duration Contracts, Guaranteed Benefit Liability, Net | 0 | 0 | ||||||||
Nossa Caixa and Banco Pine Agreements [Member] | ||||||||||
Collateral Provided by Company Certain Equipment and Other Tangible Assets, Amount | 20,900,000 | BRL 68 | ||||||||
Related Party Convertible Notes [Member] | Unsecured Debt [Member] | ||||||||||
Debt Instrument, Face Amount | $ 69,000,000 | |||||||||
Debt Instrument, Interest Rate, Stated Percentage | 1.50% | |||||||||
Related Party Convertible Notes [Member] | Secured Debt [Member] | ||||||||||
Debt Instrument, Face Amount | $ 10,850,000 | |||||||||
Purchase Obligation, Due in Second Year | $ 10,850,000 | |||||||||
Replacement Notes [Member] | ||||||||||
Long-term Debt | 3,700,000 | 5,000,000 | $ 3,700,000 | |||||||
Banco ABC Brasil S.A. (ABC) [Member] | ABC Brasil Agreement [Member] | ||||||||||
Export Financing Agreement | $ 1,600,000 | $ 2,200,000 | ||||||||
Payment Guarantee [Member] | Performance Guarantee [Member] | ||||||||||
Restricted Cash and Cash Equivalents | 0 | $ 0 | ||||||||
FINEP Credit Facility [Member] | ||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 5.00% | |||||||||
FINEP Credit Facility [Member] | Chattel Mortgage [Member] | ||||||||||
Research and Development Asset Acquired Other than Through Business Combination, Fair Value Acquired | 1,800,000 | 6 | ||||||||
BNDES Credit Facility [Member] | ||||||||||
Collateral Provided by Company Certain Equipment and Other Tangible Assets, Amount | BRL 24.9 | 7,700,000 | ||||||||
Debt Instrument, Interest Rate, Stated Percentage | 7.00% | |||||||||
BNDES Credit Facility [Member] | BNDES [Member] | ||||||||||
Collateral Provided by Company Certain Equipment and Other Tangible Assets, Amount | $ 7,700,000 | BRL 24.9 |
Note 6 - Commitments and Cont63
Note 6 - Commitments and Contingencies - Future Minimum Payments for Lease Obligations (Details) - USD ($) $ in Thousands | Dec. 31, 2016 | Dec. 31, 2015 |
Capital leases 2017 | $ 1,233 | |
Operating leases 2017 | 6,854 | |
Total lease obligations 2017 | 8,087 | |
Capital leases 2018 | 47 | |
Operating leases 2018 | 6,883 | |
Total lease obligations 2018 | 6,930 | |
Capital leases 2019 | 6 | |
Operating leases 2019 | 6,774 | |
Total lease obligations 2019 | 6,780 | |
Capital leases 2020 | ||
Operating leases 2020 | 7,004 | |
Total lease obligations 2020 | 7,004 | |
Capital leases 2021 | ||
Operating leases 2021 | 7,240 | |
Total lease obligations 2021 | 7,240 | |
Capital leases thereafter | ||
Operating leases thereafter | 10,948 | |
Total lease obligations thereafter | 10,948 | |
Total future minimum capital lease payments | 1,286 | |
Total future minimum operating lease payments | 45,703 | |
Total future minimum lease payments | 46,989 | |
Less: amount representing interest | (30) | |
Present value of minimum lease payments | 1,256 | |
Less: current portion | (922) | $ (523) |
Long-term portion | $ 334 | $ 176 |
Note 7 - Joint Ventures and N64
Note 7 - Joint Ventures and Noncontrolling Interest (Details Textual) | Dec. 19, 2016USD ($) | Dec. 05, 2016USD ($) | Feb. 12, 2016USD ($) | Feb. 12, 2016EUR (€) | Dec. 31, 2016USD ($) | Dec. 31, 2016BRL | Nov. 30, 2016USD ($)shares | Feb. 29, 2016USD ($) | Nov. 30, 2014USD ($) | Oct. 31, 2014USD ($) | Sep. 30, 2014USD ($) | Apr. 30, 2014USD ($) | Feb. 28, 2014 | Dec. 31, 2012USD ($) | Mar. 31, 2013USD ($) | Dec. 31, 2016USD ($) | Dec. 31, 2015USD ($) | Dec. 31, 2014USD ($) | Dec. 31, 2016EUR (€) | Dec. 31, 2016BRL | Jul. 31, 2016USD ($) | Jul. 19, 2016USD ($) | Mar. 31, 2016USD ($) | Mar. 21, 2016USD ($) | Oct. 14, 2015USD ($) | May 31, 2015USD ($) | Dec. 31, 2013USD ($) |
Extinguishment of Debt, Amount | $ 5,000,000 | ||||||||||||||||||||||||||
Operating Leases, Rent Expense | $ 5,300,000 | $ 5,500,000 | $ 5,400,000 | ||||||||||||||||||||||||
Total [Member] | |||||||||||||||||||||||||||
Extinguishment of Debt, Amount | € | € 50,000 | ||||||||||||||||||||||||||
Unsecured Senior Convertible Promissory Notes [Member] | Total [Member] | |||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 69,000,000 | ||||||||||||||||||||||||||
Unsecured Senior Convertible Promissory Notes [Member] | Total [Member] | |||||||||||||||||||||||||||
Extinguishment of Debt, Amount | $ 1,300,000 | ||||||||||||||||||||||||||
Convertible Senior Notes, 9.5% [Member] | |||||||||||||||||||||||||||
Debt Instrument, Repurchase Amount | $ 3,700,000 | $ 3,700,000 | $ 3,700,000 | ||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 57,600,000 | ||||||||||||||||||||||||||
Nikko Note [Member] | Nikko [Member] | |||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 3,900,000 | $ 3,900,000 | 3,900,000 | ||||||||||||||||||||||||
Novvi LLC [Member] | |||||||||||||||||||||||||||
Equity Method Investment, Ownership Percentage | 50.00% | 50.00% | |||||||||||||||||||||||||
Initial Term of Joint Venture | 20 years | ||||||||||||||||||||||||||
IP License, Value | $ 10,000,000 | ||||||||||||||||||||||||||
Equity Method Investments | $ 0 | $ 0 | $ 0 | 0 | |||||||||||||||||||||||
Joint Venture, Additional Membership Units Purchased, Aggregate Purchase Price | $ 600,000 | ||||||||||||||||||||||||||
Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures | $ 2,100,000 | ||||||||||||||||||||||||||
Loan Granted to Joint Venture | $ 1,900,000 | $ 3,700,000 | $ 1,600,000 | $ 1,100,000 | |||||||||||||||||||||||
Loan Granted to Joint Venture, Stated Annual Interest Rate | 0.36% | ||||||||||||||||||||||||||
Loan to Joint Venture, Percentage Provided by Each the Company and the Partner | 50.00% | 50.00% | |||||||||||||||||||||||||
Loan Granted to Joint Venture, Amount Disbursed by Company | $ 1,000,000 | $ 1,800,000 | |||||||||||||||||||||||||
Loan Granted to Joint Venture, Amount of First Installment Paid by Company | $ 1,200,000 | ||||||||||||||||||||||||||
Loan Granted to Joint Venture, Amount of Second Installment Paid by Company | $ 600,000 | ||||||||||||||||||||||||||
Novvi S.A. [Member] | |||||||||||||||||||||||||||
Joint Venture, Additional Membership Units Purchased, Aggregate Purchase Price | $ 200,000 | ||||||||||||||||||||||||||
JVCO Joint Venture [Member] | |||||||||||||||||||||||||||
Equity Method Investment, Ownership Percentage | 25.00% | 25.00% | 25.00% | 25.00% | 25.00% | 25.00% | |||||||||||||||||||||
Capitalization, Long-term Debt and Equity | $ 100,000 | $ 100,000 | € 100,000 | ||||||||||||||||||||||||
JVCO Joint Venture [Member] | Total [Member] | |||||||||||||||||||||||||||
Equity Method Investment, Ownership Percentage Exchanged for Cancellation of Debt | 25.00% | ||||||||||||||||||||||||||
Equity Method Investment, Ownership Percentage by Counterparty | 75.00% | 75.00% | |||||||||||||||||||||||||
SMA Industria Quimica S.A. [Member] | |||||||||||||||||||||||||||
Equity Method Investment, Ownership Percentage | 100.00% | 50.00% | 100.00% | 100.00% | 100.00% | ||||||||||||||||||||||
Initial Term of Joint Venture | 20 years | ||||||||||||||||||||||||||
Operation Commencement Timeline Requirement, Extension | 1 year 180 days | ||||||||||||||||||||||||||
Share Purchase and Sale Agreement Purchase Price of Shares | $ 15,342 | BRL 50,000 | |||||||||||||||||||||||||
Operating Leases, Rent Expense | BRL 9,853 | $ 3,023 | |||||||||||||||||||||||||
SMA Industria Quimica S.A. [Member] | SMSA [Member] | |||||||||||||||||||||||||||
Due from Joint Ventures | $ 19,000,000 | $ 19,000,000 | BRL 61,800,000 | ||||||||||||||||||||||||
Glycotech and Salisbury [Member] | |||||||||||||||||||||||||||
Joint Venture, Additional Membership Units Purchased, Aggregate Purchase Price | $ 4,350,000 | ||||||||||||||||||||||||||
Joint Venture, Aggregate Purchase Price, Promissory Note Consideration | $ 3,500,000 | ||||||||||||||||||||||||||
Neossance JV [Member] | |||||||||||||||||||||||||||
Loan Granted to Joint Venture | $ 500,000 | ||||||||||||||||||||||||||
Cosan [Member] | Novvi LLC [Member] | |||||||||||||||||||||||||||
Equity Method Investment, Ownership Percentage | 50.00% | ||||||||||||||||||||||||||
Obligation to Fund Agreement, Cash Portion | $ 10,000,000 | ||||||||||||||||||||||||||
Joint Venture, Additional Membership Units Purchased, Aggregate Purchase Price | $ 600,000 | ||||||||||||||||||||||||||
Loan to Joint Venture, Percentage Provided by Each the Company and the Partner | 50.00% | 50.00% | 50.00% | 50.00% | 50.00% | ||||||||||||||||||||||
American Refining Group [Member] | Novvi LLC [Member] | |||||||||||||||||||||||||||
Obligation to Fund Agreement, Cash Portion | $ 9,000,000 | $ 9,000,000 | $ 10,000,000 | $ 10,000,000 | |||||||||||||||||||||||
Chevron U.S.A. [Member] | Novvi LLC [Member] | |||||||||||||||||||||||||||
Obligation to Fund Agreement, Cash Portion | $ 1,000,000 | $ 1,000,000 | $ 1,000,000 | ||||||||||||||||||||||||
Joint Venture, Membership Units | shares | 20,000 | ||||||||||||||||||||||||||
Joint Venture, Ownership Stake | 3.00% | ||||||||||||||||||||||||||
Joint Venture, Additional Ownership Stake | 25.00% | ||||||||||||||||||||||||||
Nikko [Member] | Neossance JV [Member] | |||||||||||||||||||||||||||
Equity Method Investment, Ownership Percentage | 50.00% | ||||||||||||||||||||||||||
Loan Granted to Joint Venture | $ 1,500,000 | ||||||||||||||||||||||||||
Cash Investment Joint Venture | 10,000,000 | ||||||||||||||||||||||||||
Joint Venture, Maximum Distributions | $ 10,000,000 |
Note 7 - Joint Ventures and N65
Note 7 - Joint Ventures and Noncontrolling Interest - Variable Interest Entities (Details) - Variable Interest Entity, Primary Beneficiary [Member] - USD ($) $ in Thousands | Dec. 31, 2016 | Dec. 31, 2015 |
Assets | $ 2,277 | $ 6,993 |
Liabilities | $ 135 | $ 1,221 |
Note 7 - Joint Ventures and N66
Note 7 - Joint Ventures and Noncontrolling Interest - Noncontrolling Interest (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2016 | Dec. 31, 2015 | Dec. 31, 2014 | |
Balance, noncontrolling interest | $ (391) | ||
Foreign currency translation adjustment | (6,294) | $ 16,901 | $ 9,798 |
Income attributable to noncontrolling interest | 100 | 119 | |
Balance, noncontrolling interest | 937 | (391) | |
Noncontrolling Interest [Member] | |||
Balance, noncontrolling interest | 391 | 611 | |
Foreign currency translation adjustment | (320) | (92) | |
Income attributable to noncontrolling interest | (1,328) | 100 | |
Balance, noncontrolling interest | $ (937) | $ 391 | $ 611 |
Note 8 - Significant Agreemen67
Note 8 - Significant Agreements (Details Textual) $ / shares in Units, $ in Thousands | Sep. 30, 2016USD ($) | Jul. 25, 2016USD ($) | Apr. 08, 2016USD ($)$ / sharesshares | Mar. 08, 2016USD ($) | Dec. 31, 2016USD ($) | Jun. 30, 2016USD ($)$ / sharesshares | Sep. 30, 2015USD ($) | Mar. 31, 2015USD ($) | Apr. 30, 2014shares | Mar. 31, 2014USD ($) | Mar. 31, 2013USD ($) | Jan. 31, 2013shares | Mar. 31, 2017USD ($) | Mar. 31, 2016USD ($) | Mar. 31, 2017USD ($) | Mar. 31, 2017 | Dec. 31, 2016USD ($) | Dec. 31, 2015USD ($) | Dec. 31, 2014USD ($) | Aug. 31, 2016$ / sharesshares | Aug. 06, 2016$ / sharesshares | Jul. 31, 2015$ / sharesshares | |
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 1,602,562 | ||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares | $ 0.01 | ||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues | shares | 943,396 | 5,033,557 | |||||||||||||||||||||
Proceeds from Issuance of Common Stock | $ 180 | $ 614 | $ 2,488 | ||||||||||||||||||||
Temporary Equity, Carrying Amount, Attributable to Parent | [1] | $ 5,000 | 5,000 | ||||||||||||||||||||
At the Market Offering [Member] | |||||||||||||||||||||||
Common Stock, Value, Subscriptions | $ 50,000 | $ 50,000 | |||||||||||||||||||||
Commission Rate | 3.00% | ||||||||||||||||||||||
Gates Foundation Purchase Agreement [Member] | |||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues | shares | 4,385,964 | ||||||||||||||||||||||
Shares Issued, Price Per Share | $ / shares | $ 1.14 | ||||||||||||||||||||||
Debt Instrument, Convertible, Threshold Consecutive Trading Days | 20 days | ||||||||||||||||||||||
Proceeds from Issuance of Common Stock | $ 5,000 | ||||||||||||||||||||||
Redemption Base Price | $ / shares | $ 1.14 | ||||||||||||||||||||||
Compound Annual Return | 10.00% | ||||||||||||||||||||||
Temporary Equity, Carrying Amount, Attributable to Parent | 5,000 | 5,000 | |||||||||||||||||||||
Technology Investment Agreement with DARPA [Member] | |||||||||||||||||||||||
Collaboration Agreement Period | 4 years | ||||||||||||||||||||||
Revenue from Related Parties | 9,700 | 0 | |||||||||||||||||||||
Maximum DARPA Funding to be Received if all Milestones are Achieved | $ 35,000 | ||||||||||||||||||||||
Collective Obligation Due | $ 15,500 | ||||||||||||||||||||||
Intellectual Property License and Strain Access Agreement [Member] | |||||||||||||||||||||||
Proceeds from License Fees Received | $ 10,000 | ||||||||||||||||||||||
Firmenich [Member] | |||||||||||||||||||||||
Additional Grants and Collaboration Funding | $ 5,000 | ||||||||||||||||||||||
Firmenich [Member] | Collaborative Arrangement [Member] | |||||||||||||||||||||||
Revenue from Related Parties | 7,500 | 11,000 | |||||||||||||||||||||
Firmenich [Member] | Flavors and Fragrances Compounds [Member] | |||||||||||||||||||||||
Collaboration Agreement Period | 10 years | ||||||||||||||||||||||
Collaboration Agreement, Automatic Renewal Period | 3 years | ||||||||||||||||||||||
Collaborative Agreement, Notice Requirement before Terminating Current Term, Minimum | 12 years | ||||||||||||||||||||||
Collaboration Agreement Annual Funding Year One | $ 10,000 | ||||||||||||||||||||||
Collaboration Agreement Annual Funding Year Three | $ 10,000 | ||||||||||||||||||||||
Collaboration Agreement Annual Funding Year Two | $ 10,000 | ||||||||||||||||||||||
Firmenich [Member] | Flavors and Fragrances Compounds [Member] | Master Collaboration Agreement [Member] | |||||||||||||||||||||||
Revenue from Related Parties | 9,700 | $ 1,400 | |||||||||||||||||||||
Sales Margin Company Percentage Split | 30.00% | ||||||||||||||||||||||
Return Required for Collaboration Partner Before Adjusting Split on Sales Margin | $ 15,000 | ||||||||||||||||||||||
Sales Margin Company Percentage Split Following Return Requirements | 50.00% | ||||||||||||||||||||||
Success Bonus | $ 2,500 | ||||||||||||||||||||||
Sales Margin Collaborator Percentage Split | 70.00% | ||||||||||||||||||||||
Sales Margin Collaborator Percentage Split Following Return Requirements | 30.00% | ||||||||||||||||||||||
Firmenich [Member] | Flavors and Fragrances Compounds [Member] | Amended Collaboration Agreement [Member] | |||||||||||||||||||||||
Royalty Rate, Percent of Net Revenue | 10.00% | ||||||||||||||||||||||
Ginkgo Bioworks [Member] | |||||||||||||||||||||||
Collaboration Agreement Period | 3 years | ||||||||||||||||||||||
Collaboration Agreement, Automatic Renewal Period | 1 year | ||||||||||||||||||||||
Collaborative Agreement, Notice Requirement before Terminating Current Term, Minimum | 90 days | ||||||||||||||||||||||
Proceeds from Collaborators | $ 15,000 | $ 20,000 | |||||||||||||||||||||
Royalty Percentage | 10.00% | ||||||||||||||||||||||
Collaboration Agreement, Common Stock Options Agreed to Issue | shares | 5,000,000 | ||||||||||||||||||||||
Collaboration Agreement, Common Stock Options Agreed to Issue, Exercise Price Per Share | $ / shares | $ 0.50 | ||||||||||||||||||||||
Collaboration Agreement, Common Stock Options Agreed to Issue, Term Exercisable from Date of Issuance | 1 year | ||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 5,000,000 | 5 | |||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares | $ 0.50 | $ 0.50 | |||||||||||||||||||||
Collaborative Agreement, Notice Requirement before Terminating Current Term Due to Lack of Commitment | 30 days | ||||||||||||||||||||||
Collaboration Agreement, Performance of the Collaboration, Evaluation Period | 1 year 180 days | ||||||||||||||||||||||
Ginkgo Bioworks [Member] | Scenario, Forecast [Member] | |||||||||||||||||||||||
Proceeds from Collaborators | $ 5,000 | $ 5,000 | |||||||||||||||||||||
Collaborative Agreement Number Of Installments | 2 | ||||||||||||||||||||||
Ginkgo Bioworks [Member] | Initial Ginkgo Agreement [Member] | |||||||||||||||||||||||
Revenue from Related Parties | 15,000 | ||||||||||||||||||||||
Ginkgo Bioworks [Member] | Ginkgo Collaboration Agreement [Member] | |||||||||||||||||||||||
Revenue from Related Parties | $ 0 | ||||||||||||||||||||||
[1] | See Note 8, "Significant Agreements" for details regarding the Bill & Melinda Gates Foundation Investment, classified as mezzanine equity. |
Note 9 - Goodwill and Intangi68
Note 9 - Goodwill and Intangible Assets (Details Textual) $ in Millions | 1 Months Ended |
Oct. 31, 2011USD ($) | |
Draths Corporation [Member] | In Process Research and Development, Indefinite [Member] | |
Indefinite-lived Intangible Assets Acquired | $ 8.6 |
Note 9 - Goodwill and Intangi69
Note 9 - Goodwill and Intangible Assets - Intangible Assets and Goodwill (Details) - USD ($) $ in Thousands | 9 Months Ended | 12 Months Ended | ||
Sep. 30, 2016 | Dec. 31, 2016 | Dec. 31, 2015 | Dec. 31, 2014 | |
In-process research and development | $ (5,525) | $ (3,035) | ||
Intangible Assets, Net (Excluding Goodwill) | 0 | |||
Goodwill, carrying amount | 560 | 560 | ||
Goodwill, net carrying value | 560 | 560 | ||
9,892 | 9,892 | |||
(9,332) | (9,332) | |||
560 | 560 | |||
(9,332) | (9,332) | |||
Acquired Licenses and Permits [Member] | ||||
In-process research and development, carrying amount | 772 | 772 | ||
Acquired licenses and permits, useful life (Year) | 2 years | |||
Acquired licenses and permits | (772) | (772) | ||
In Process Research and Development, Indefinite [Member] | ||||
In-process research and development, carrying amount | 8,560 | 8,560 | ||
In-process research and development | (8,560) | (8,560) | ||
Intangible Assets, Net (Excluding Goodwill) |
Note 10 - Stockholders' Defic70
Note 10 - Stockholders' Deficit (Details Textual) - USD ($) $ / shares in Units, $ in Thousands | Jul. 29, 2015 | May 31, 2016 | Jul. 31, 2015 | Apr. 30, 2014 | Oct. 31, 2013 | Mar. 31, 2013 | Jan. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 | Dec. 31, 2016 | Dec. 31, 2015 | Dec. 31, 2014 | Nov. 30, 2016 | Aug. 31, 2016 | Aug. 06, 2016 | Feb. 29, 2016 | Jan. 31, 2016 | Sep. 28, 2010 |
Stock Issued During Period, Shares, New Issues | 943,396 | 5,033,557 | ||||||||||||||||
Stock Issued During Period, Price Per Share, New Issues | $ 1.14 | $ 1.56 | $ 4.24 | $ 2.98 | ||||||||||||||
Proceeds from Issuance of Private Placement | $ 5,000 | $ 25,000 | $ 4,000 | $ 15,000 | $ 37,200 | $ 24,625 | $ 4,000 | |||||||||||
Extinguishment of Debt, Amount | $ 5,000 | |||||||||||||||||
Extinguishment of Debt, Common Stock, Shares | 1,677,852 | |||||||||||||||||
Proceeds from Issuance of Private Placement, First Payment Received | $ 22,200 | |||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 1,602,562 | |||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 0.01 | |||||||||||||||||
Common Stock, Shares, Outstanding | 274,108,808 | 206,130,282 | ||||||||||||||||
Common Stock, Shares Authorized | 500,000,000 | 400,000,000 | ||||||||||||||||
Preferred Stock, Shares Authorized | 5,000,000 | 5,000,000 | ||||||||||||||||
Preferred Stock, Shares Outstanding | 0 | 0 | ||||||||||||||||
Fair Value Assumptions, Risk Free Interest Rate | 2.00% | |||||||||||||||||
Fair Value Assumptions, Expected Volatility Rate | 74.00% | 45.00% | 45.00% | |||||||||||||||
Fair Value Assumptions, Expected Dividend Rate | ||||||||||||||||||
Class of Warrant or Right, Outstanding | 14,663,411 | 4,343,733 | ||||||||||||||||
Ginkgo Bioworks [Member] | ||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 5,000,000 | 5 | ||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 0.50 | $ 0.50 | ||||||||||||||||
Nenter & Co., Inc. [Member] | ||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 10,000,000 | |||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 0.50 | |||||||||||||||||
Warrants in Connection With Capital Lease Arrangement [Member] | ||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 21,087 | |||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 10.67 | |||||||||||||||||
Warrants and Rights Outstanding | $ 200 | |||||||||||||||||
Class Of Warrant Or Right, Fair Value Assumptions, Expected Term | 10 years | |||||||||||||||||
Class Of Warrant Or Right, Fair Value Assumptions, Risk Free Interest Rate | 2.00% | |||||||||||||||||
Class Of Warrant Or Right, Fair Value Assumptions, Expected Volatility Rate | 86.00% | |||||||||||||||||
Class Of Warrant Or Right, Fair Value Assumptions, Expected Dividend Rate | 0.00% | |||||||||||||||||
Warrants in Connection with Issuance of Tranche I Convertible Promissory Notes [Member] | ||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 1,000,000 | |||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 0.01 | |||||||||||||||||
Warrants and Rights Outstanding | $ 1,300 | |||||||||||||||||
Class Of Warrant Or Right, Fair Value Assumptions, Expected Term | 3 years 146 days | |||||||||||||||||
Class Of Warrant Or Right, Fair Value Assumptions, Risk Free Interest Rate | 0.77% | |||||||||||||||||
Class Of Warrant Or Right, Fair Value Assumptions, Expected Volatility Rate | 45.00% | |||||||||||||||||
Class Of Warrant Or Right, Fair Value Assumptions, Expected Dividend Rate | 0.00% | |||||||||||||||||
Class Of Warrant Or Right, Cashless Exercise Provision, Number Exercised | 0 | 0 | ||||||||||||||||
Total and Temasek [Member] | ||||||||||||||||||
Fair Value Assumptions, Risk Free Interest Rate | 2.00% | |||||||||||||||||
Fair Value Assumptions, Expected Volatility Rate | 74.00% | |||||||||||||||||
Fair Value Assumptions, Expected Dividend Rate | 0.00% | |||||||||||||||||
Warrants in Connection with Issuance of Tranche III Convertible Promissory Notes [Member] | ||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 1,602,562 | |||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 0.01 | |||||||||||||||||
Class of Warrant or Right, Outstanding | 1,442,307 | |||||||||||||||||
Warrants in Connection with Issuance of Promissory Notes [Member] | ||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 2,857,142 | |||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 0.01 | |||||||||||||||||
Class of Warrant or Right, Outstanding | 2,857,142 | |||||||||||||||||
Equity Incentive Plan, 2010 [Member] | ||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized | 10,301,709 | 30,000,000 | ||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized, Percentage Increase of Common Stock Shares Outstanding | 5.00% | |||||||||||||||||
Employee Stock Purchase Plan, 2010 [Member] | ||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized | 1,030,170 | 10,000,000 | ||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized, Percentage Increase of Common Stock Shares Outstanding | 0.50% | |||||||||||||||||
Biolding Investment SA [Member] | ||||||||||||||||||
Stock Issued During Period, Shares, New Issues | 1,533,742 | |||||||||||||||||
Stock Issued During Period, Price Per Share, New Issues | $ 3.26 | |||||||||||||||||
Proceeds from Issuance of Private Placement | $ 5,000 | |||||||||||||||||
Commitment to Purchase Company Common Stock | $ 15,000 | 15,000 | ||||||||||||||||
Commitment Fulfilled [Member] | ||||||||||||||||||
Commitment to Purchase Company Common Stock | $ 10,000 | |||||||||||||||||
Common Stock [Member] | ||||||||||||||||||
Stock Issued During Period, Shares, New Issues | 4,385,964 | 16,025,642 | 14,177,849 | 16,025,642 | 943,396 | |||||||||||||
Common Stock, Shares, Outstanding | 206,034,184 |
Note 11 - Stock-based Compens71
Note 11 - Stock-based Compensation Plans (Details Textual) - USD ($) | 12 Months Ended | ||||
Dec. 31, 2016 | Dec. 31, 2015 | Dec. 31, 2014 | Jan. 31, 2016 | Sep. 28, 2010 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number | 13,427,685 | 12,930,112 | |||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | $ 3.63 | $ 4.77 | |||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period | 134 | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value | $ 0 | $ 0 | $ 600,000 | ||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 3,585,175 | 4,720,278 | 3,683,791 | ||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | $ 0.59 | $ 1.21 | $ 2.31 | ||
Allocated Share-based Compensation Expense | $ 7,325,000 | $ 9,134,000 | $ 14,105,000 | ||
Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Compensation Cost | $ 0 | $ 0 | $ 100,000 | ||
Share-based Compensation Arrangement by Share-based Payment Award, Accelerated Vesting, Number | 0 | 0 | 0 | ||
Employee Stock Option [Member] | |||||
Allocated Share-based Compensation Expense | $ 3,500,000 | $ 6,000,000 | $ 10,100,000 | ||
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized | $ 4,400,000 | $ 8,000,000 | 11,400,000 | ||
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition | 2 years 255 days | 3 years | |||
Restricted Stock Units (RSUs) [Member] | |||||
Allocated Share-based Compensation Expense | $ 3,600,000 | $ 2,800,000 | 3,300,000 | ||
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized | $ 5,400,000 | $ 7,700,000 | $ 3,600,000 | ||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period | 4,897,840 | 4,988,539 | 1,083,300 | ||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value | $ 0.61 | $ 1.82 | $ 3.51 | ||
Equity Incentive Plan, 2010 [Member] | |||||
Common Stock, Additional Capital Shares Reserved for Issuance | 2,193,704 | ||||
Shares Available for Issuance, Percentage of Total Outstanding Shares | 5.00% | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized | 10,301,709 | 30,000,000 | |||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Period Available to Grant | 10 years | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Minimum Percent of Execrise Price to Fair Market Value on Grant Date | 100.00% | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Minimum Percent of Shareholder Triggering Higher Exercise Price | 10.00% | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Minimum Percent of Execrise Price to Fair Market Value on Grant Date of Ten Percent or Greater Shareholder of Company | 110.00% | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number | 11,924,020 | 11,321,194 | |||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant | 8,285,891 | 1,833,004 | |||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | $ 3.01 | $ 4.27 | |||
Equity Incentive Plan, 2010 [Member] | Minimum [Member] | |||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period | 4 years | ||||
Equity Incentive Plan, 2010 [Member] | Maximum [Member] | |||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period | 5 years | ||||
Stock Options and Stock Issuance Plans, 2005 [Member] | |||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Period Available to Grant | 10 years | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Minimum Percent of Execrise Price to Fair Market Value on Grant Date | 100.00% | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Minimum Percent of Shareholder Triggering Higher Exercise Price | 10.00% | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Minimum Percent of Execrise Price to Fair Market Value on Grant Date of Ten Percent or Greater Shareholder of Company | 110.00% | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period | 5 years | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number | 1,503,665 | 1,548,918 | |||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant | 0 | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | $ 8.51 | $ 8.46 | |||
Employee Stock Purchase Plan, 2010 [Member] | |||||
Shares Available for Issuance, Percentage of Total Outstanding Shares | 1.00% | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized | 1,030,170 | 10,000,000 | |||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant | 885,821 | 1,221,896 | 168,627 | ||
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent | 85.00% | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period | 336,075 | 385,892 | |||
Allocated Share-based Compensation Expense | $ 100,000 | $ 300,000 | $ 500,000 |
Note 11 - Stock-based Compens72
Note 11 - Stock-based Compensation - Share-based Compensation, Stock Options and Stock Appreciation Rights Award Activity (Details) - USD ($) $ / shares in Units, $ in Thousands | 12 Months Ended | ||
Dec. 31, 2016 | Dec. 31, 2015 | Dec. 31, 2016 | |
Outstanding (in shares) | 12,930,112 | ||
Outstanding, weighted average exercise price (in dollars per share) | $ 4.77 | ||
Outstanding, weighted average remaining contractual life (Year) | 6 years 255 days | 7 years 142 days | |
Outstanding, aggregate intrinsic value | $ 22 | ||
Options granted (in shares) | 3,585,175 | ||
Options granted, weighted average exercise price (in dollars per share) | $ 0.59 | ||
Options exercised (in shares) | (134) | ||
Options exercised, weighted average exercise price (in dollars per share) | $ 0.28 | ||
Options cancelled (in shares) | (3,087,468) | ||
Options cancelled, weighted average exercise price (in dollars per share) | $ 4.92 | ||
Outstanding (in shares) | 13,427,685 | 12,930,112 | |
Outstanding, weighted average exercise price (in dollars per share) | $ 3.63 | $ 4.77 | |
Outstanding, aggregate intrinsic value | $ 22 | $ 22 | $ 443 |
Vested and expected to vest after December 31, 2016 (in shares) | 12,387,314 | ||
Vested and expected to vest after December 31, 2016, weighted average exercise price (in dollars per share) | $ 3.84 | ||
Vested and expected to vest after December 31, 2016, weighted average remaining contractual life (Year) | 6 years 197 days | ||
Vested and expected to vest after December 31, 2016, aggregate intrinsic value | $ 361 | ||
Exercisable at December 31, 2016 (in shares) | 7,357,308 | ||
Options Exercisable Weighted-Average Exercise Price (in dollars per share) | $ 5.48 | ||
Exercisable at December 31, 2016, weighted average remaining contractual life (Year) | 5 years 116 days | ||
Exercisable at December 31, 2016, aggregate intrinsic value | $ 1 |
Note 11 - Stock-based Compens73
Note 11 - Stock-based Compensation - Temporal Display of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity (Details) - Restricted Stock Units (RSUs) [Member] - $ / shares | 12 Months Ended | ||
Dec. 31, 2016 | Dec. 31, 2015 | Dec. 31, 2014 | |
Outstanding, RSUs (in shares) | 5,554,844 | ||
Outstanding, weighted average grant-date fair value (in dollars per share) | $ 2.03 | ||
Outstanding, weighted average remaining contractual life (Year) | 1 year 160 days | 1 year 222 days | |
Awarded (in shares) | 4,897,840 | 4,988,539 | 1,083,300 |
Awarded, weighted average grant-date fair value (in dollars per share) | $ 0.61 | $ 1.82 | $ 3.51 |
Vested (in shares) | (2,064,881) | ||
Vested, weighted average grant-date fair value (in dollars per share) | $ 1.98 | ||
Forfeited (in shares) | (1,390,719) | ||
Forfeited, weighted average grant-date fair value (in dollars per share) | $ 1.39 | ||
Outstanding, RSUs (in shares) | 6,997,084 | 5,554,844 | |
Outstanding, weighted average grant-date fair value (in dollars per share) | $ 1.18 | $ 2.03 | |
Expected to vest after December 31, 2016 (in shares) | 5,642,538 | ||
Expected to vest after December 31, 2016, weighted average grant-date fair value (in dollars per share) | $ 1.20 | ||
Expected to vest after December 31, 2016, weighted average remaining contractual life (Year) | 1 year 102 days |
Note 11 - Share-based Compensat
Note 11 - Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range (Details) | 12 Months Ended |
Dec. 31, 2016$ / sharesshares | |
Options Exercisable Weighted-Average Exercise Price (in dollars per share) | $ 5.48 |
Exercise Price Range 1 [Member] | |
Exercise Price, Lower (in dollars per share) | 0.28 |
Exercise Price, Upper (in dollars per share) | $ 0.57 |
Options Outstanding Number (in shares) | shares | 346,234 |
Options Outstanding Weighted- Average Remaining Contractual Life (Year) | 9 years 171 days |
Options Outstanding Weighted-Average Exercise Price (in dollars per share) | $ 0.43 |
Options Exercisable Number of Options (in shares) | shares | 2,734 |
Options Exercisable Weighted-Average Exercise Price (in dollars per share) | $ 0.28 |
Exercise Price Range 2 [Member] | |
Exercise Price, Lower (in dollars per share) | 0.59 |
Exercise Price, Upper (in dollars per share) | $ 0.59 |
Options Outstanding Number (in shares) | shares | 2,424,375 |
Options Outstanding Weighted- Average Remaining Contractual Life (Year) | 8 years 226 days |
Options Outstanding Weighted-Average Exercise Price (in dollars per share) | $ 0.59 |
Options Exercisable Number of Options (in shares) | shares | |
Options Exercisable Weighted-Average Exercise Price (in dollars per share) | |
Exercise Price Range 3 [Member] | |
Exercise Price, Lower (in dollars per share) | 0.78 |
Exercise Price, Upper (in dollars per share) | $ 1.67 |
Options Outstanding Number (in shares) | shares | 1,461,082 |
Options Outstanding Weighted- Average Remaining Contractual Life (Year) | 8 years 193 days |
Options Outstanding Weighted-Average Exercise Price (in dollars per share) | $ 1.46 |
Options Exercisable Number of Options (in shares) | shares | 396,916 |
Options Exercisable Weighted-Average Exercise Price (in dollars per share) | $ 1.61 |
Exercise Price Range 4 [Member] | |
Exercise Price, Lower (in dollars per share) | 1.69 |
Exercise Price, Upper (in dollars per share) | $ 1.96 |
Options Outstanding Number (in shares) | shares | 2,218,041 |
Options Outstanding Weighted- Average Remaining Contractual Life (Year) | 7 years 109 days |
Options Outstanding Weighted-Average Exercise Price (in dollars per share) | $ 1.84 |
Options Exercisable Number of Options (in shares) | shares | 863,045 |
Options Exercisable Weighted-Average Exercise Price (in dollars per share) | $ 1.85 |
Exercise Price Range 5 [Member] | |
Exercise Price, Lower (in dollars per share) | 1.98 |
Exercise Price, Upper (in dollars per share) | $ 2.85 |
Options Outstanding Number (in shares) | shares | 1,371,168 |
Options Outstanding Weighted- Average Remaining Contractual Life (Year) | 5 years 299 days |
Options Outstanding Weighted-Average Exercise Price (in dollars per share) | $ 2.61 |
Options Exercisable Number of Options (in shares) | shares | 1,129,021 |
Options Exercisable Weighted-Average Exercise Price (in dollars per share) | $ 2.67 |
Exercise Price Range 6 [Member] | |
Exercise Price, Lower (in dollars per share) | 2.87 |
Exercise Price, Upper (in dollars per share) | $ 3.44 |
Options Outstanding Number (in shares) | shares | 1,255,796 |
Options Outstanding Weighted- Average Remaining Contractual Life (Year) | 6 years 189 days |
Options Outstanding Weighted-Average Exercise Price (in dollars per share) | $ 3.02 |
Options Exercisable Number of Options (in shares) | shares | 1,095,271 |
Options Exercisable Weighted-Average Exercise Price (in dollars per share) | $ 3.01 |
Exercise Price Range 7 [Member] | |
Exercise Price, Lower (in dollars per share) | 3.51 |
Exercise Price, Upper (in dollars per share) | $ 3.51 |
Options Outstanding Number (in shares) | shares | 1,503,891 |
Options Outstanding Weighted- Average Remaining Contractual Life (Year) | 7 years 21 days |
Options Outstanding Weighted-Average Exercise Price (in dollars per share) | $ 3.51 |
Options Exercisable Number of Options (in shares) | shares | 1,020,549 |
Options Exercisable Weighted-Average Exercise Price (in dollars per share) | $ 3.51 |
Exercise Price Range 8 [Member] | |
Exercise Price, Lower (in dollars per share) | 3.55 |
Exercise Price, Upper (in dollars per share) | $ 4.08 |
Options Outstanding Number (in shares) | shares | 1,354,152 |
Options Outstanding Weighted- Average Remaining Contractual Life (Year) | 3 years 328 days |
Options Outstanding Weighted-Average Exercise Price (in dollars per share) | $ 3.88 |
Options Exercisable Number of Options (in shares) | shares | 1,296,826 |
Options Exercisable Weighted-Average Exercise Price (in dollars per share) | $ 3.88 |
Exercise Price Range 9 [Member] | |
Exercise Price, Lower (in dollars per share) | 4.31 |
Exercise Price, Upper (in dollars per share) | $ 24.20 |
Options Outstanding Number (in shares) | shares | 1,350,946 |
Options Outstanding Weighted- Average Remaining Contractual Life (Year) | 3 years 146 days |
Options Outstanding Weighted-Average Exercise Price (in dollars per share) | $ 13.05 |
Options Exercisable Number of Options (in shares) | shares | 1,350,946 |
Options Exercisable Weighted-Average Exercise Price (in dollars per share) | $ 12.05 |
Exercise Price Range 10 [Member] | |
Exercise Price, Lower (in dollars per share) | 24.50 |
Exercise Price, Upper (in dollars per share) | $ 30.17 |
Options Outstanding Number (in shares) | shares | 202,000 |
Options Outstanding Weighted- Average Remaining Contractual Life (Year) | 4 years 113 days |
Options Outstanding Weighted-Average Exercise Price (in dollars per share) | $ 27.52 |
Options Exercisable Number of Options (in shares) | shares | 202,000 |
Options Exercisable Weighted-Average Exercise Price (in dollars per share) | $ 27.52 |
Exercise Price Range 11 [Member] | |
Exercise Price, Lower (in dollars per share) | 0.28 |
Exercise Price, Upper (in dollars per share) | $ 30.17 |
Options Outstanding Number (in shares) | shares | 13,487,685 |
Options Outstanding Weighted- Average Remaining Contractual Life (Year) | 6 years 255 days |
Options Outstanding Weighted-Average Exercise Price (in dollars per share) | $ 3.63 |
Options Exercisable Number of Options (in shares) | shares | 7,357,308 |
Options Exercisable Weighted-Average Exercise Price (in dollars per share) | $ 5.48 |
Note 11 - Stock-based Compens75
Note 11 - Stock-based Compensation - Employee Service Share-based Compensation, Allocation of Recognized Period Costs (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2016 | Dec. 31, 2015 | Dec. 31, 2014 | |
Allocated share-based compensation expense | $ 7,325 | $ 9,134 | $ 14,105 |
Research and Development Expense [Member] | |||
Allocated share-based compensation expense | 1,948 | 2,306 | 3,508 |
Selling, General and Administrative Expenses [Member] | |||
Allocated share-based compensation expense | $ 5,377 | $ 6,828 | $ 10,597 |
Note 11 - Stock-based Compens76
Note 11 - Stock-based Compensation - Share-based Payment Award, Stock Options, Valuation Assumptions (Details) - Employee Stock Option [Member] | 12 Months Ended | ||
Dec. 31, 2016 | Dec. 31, 2015 | Dec. 31, 2014 | |
Risk-free interest rate | 1.40% | 1.80% | 1.90% |
Expected term (in years) (Year) | 6 years 58 days | 6 years 29 days | 6 years 36 days |
Expected volatility | 73.00% | 74.00% | 75.00% |
Note 12 - Employee Benefit Pl77
Note 12 - Employee Benefit Plan (Details Textual) - USD ($) $ in Millions | 12 Months Ended | |
Dec. 31, 2016 | Dec. 31, 2015 | |
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent | 90.00% | |
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay | 90.00% | |
Defined Contribution Plan, Minimum Service, Vesting Period | 1 year | |
Defined Contribution Plan, Employer Discretionary Contribution Amount | $ 0.5 | $ 0.5 |
Note 13 - Related Party Trans78
Note 13 - Related Party Transactions (Details Textual) - USD ($) | 1 Months Ended | 12 Months Ended | |||
Jul. 31, 2015 | May 31, 2014 | Dec. 31, 2016 | Dec. 31, 2015 | Dec. 31, 2014 | |
Debt Instrument, Unamortized Discount | $ 42,500,000 | ||||
Accounts Receivable, Related Parties | 872,000 | $ 1,176,000 | |||
Research and Development Expense | 51,412,000 | 44,636,000 | $ 49,661,000 | ||
Operating Leases, Rent Expense, Sublease Rentals | 400,000 | 700,000 | |||
Operating Leases, Rent Expense, Net | 400,000 | ||||
Related Party Convertible Notes [Member] | |||||
Convertible Debt | 72,400,000 | 42,700,000 | |||
Debt Instrument, Unamortized Discount | 6,700,000 | 4,900,000 | |||
Derivative Liability | 800,000 | 7,900,000 | |||
Derivative, Gain (Loss) on Derivative, Net | 7.60 | 10,500,000 | 141,200,000 | ||
Total [Member] | |||||
Convertible Debt | $ 5,000,000 | ||||
Revenue from Related Parties | 200,000 | 900,000 | 600,000 | ||
Accounts Receivable, Related Parties | 800,000 | 1,200,000 | |||
Total [Member] | Pilot Plant Agreements [Member] | |||||
Related Party Agreement Term | 5 years | ||||
Related Party Transaction, Amounts of Transaction | 100,000 | ||||
Related Party Transaction, Fees Waived | $ 2,000,000 | ||||
Research and Development Expense | 800,000 | 900,000 | |||
Accounts Payable, Related Parties | 2,200,000 | 1,400,000 | |||
Total [Member] | Pilot Plant Agreements [Member] | Sublease Agreement [Member] | |||||
Proceeds from Fees Received | 1,700,000 | ||||
Total [Member] | Pilot Plant Agreements [Member] | Sublease Payments and Service Fees [Member] | |||||
Related Party Transaction, Amounts of Transaction | 400,000 | 900,000 | |||
Total [Member] | Pilot Plant Agreements [Member] | Scale-up Services and Training [Member] | |||||
Related Party Transaction, Amounts of Transaction | $ 900,000 | ||||
Novvi LLC [Member] | |||||
Revenue from Related Parties | 1,400,000 | 0 | $ 100,000 | ||
Accounts Receivable, Related Parties | 0 | 0 | |||
Novvi LLC [Member] | Sublease Agreement [Member] | |||||
Sublease Receivable, Related Parties | $ 200,000 | $ 0 |
Note 14 - Income Taxes (Details
Note 14 - Income Taxes (Details Textual) - USD ($) $ in Thousands | 12 Months Ended | |||
Dec. 31, 2016 | Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | |
Income Tax Expense (Benefit) | $ 553 | $ 468 | $ 495 | |
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount | 26,700 | 47,900 | 28,300 | |
Unrecognized Tax Benefits | 9,101 | 8,634 | 17,081 | $ 6,080 |
Deferred Tax Assets, Operating Loss Carryforwards | 236,741 | 207,241 | 195,536 | |
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued | 0 | $ 0 | $ 0 | |
Increase in Unrecognized Tax Benefits is Reasonably Possible | 0 | |||
Decrease in Unrecognized Tax Benefits is Reasonably Possible | 0 | |||
Portion Resulting from Excess Stock-based Compensation [Member] | ||||
Deferred Tax Assets, Operating Loss Carryforwards | 0 | |||
Additional Provision [Member] | ||||
Income Tax Expense (Benefit) | 0 | |||
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | ||||
Operating Loss Carryforwards | 645,300 | |||
Income Tax Examination, Liability (Refund) Adjustment from Settlement with Taxing Authority | $ 0 | |||
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Earliest Tax Year [Member] | ||||
Open Tax Year | 2,004 | |||
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Research Tax Credit Carryforward [Member] | ||||
Tax Credit Carryforward, Amount | $ 9,800 | |||
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Portion Resulting from Excess Stock-based Compensation [Member] | ||||
Operating Loss Carryforwards | 27,200 | |||
State and Local Jurisdiction [Member] | ||||
Operating Loss Carryforwards | $ 208,700 | |||
State and Local Jurisdiction [Member] | Earliest Tax Year [Member] | ||||
Open Tax Year | 2,004 | |||
State and Local Jurisdiction [Member] | Portion Resulting from Excess Stock-based Compensation [Member] | ||||
Operating Loss Carryforwards | $ 12,900 | |||
State and Local Jurisdiction [Member] | California Franchise Tax Board [Member] | Research Tax Credit Carryforward [Member] | ||||
Tax Credit Carryforward, Amount | $ 11,400 | |||
Foreign Tax Authority [Member] | Secretariat of the Federal Revenue Bureau of Brazil [Member] | Earliest Tax Year [Member] | ||||
Open Tax Year | 2,009 |
Note 14 - Income Taxes - Compon
Note 14 - Income Taxes - Components of Income Loss (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2016 | Dec. 31, 2015 | Dec. 31, 2014 | |
United States | $ (101,210) | $ (188,943) | $ 10,847 |
Foreign | 4,429 | (24,457) | (5,275) |
Income (loss) before income taxes and loss from investments in affiliates | $ (96,781) | $ (213,400) | $ 5,572 |
Note 14 - Income Taxes - Comp81
Note 14 - Income Taxes - Components of Benefit (Provision) (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2016 | Dec. 31, 2015 | Dec. 31, 2014 | |
Current: | |||
Federal | |||
State | |||
Foreign | 553 | 468 | 495 |
Total current provision | 553 | 468 | 495 |
Deferred: | |||
Federal | |||
State | |||
Foreign | |||
Total deferred provision | |||
Total provision for income taxes | $ 553 | $ 468 | $ 495 |
Note 14 - Income Taxes - Effect
Note 14 - Income Taxes - Effective Tax Rate Reconciliation (Details) | 12 Months Ended | ||
Dec. 31, 2016 | Dec. 31, 2015 | Dec. 31, 2014 | |
Statutory tax rate | (34.00%) | (34.00%) | (34.00%) |
State tax rate, net of federal benefit | 0.00% | (0.30%) | 23.30% |
Stock-based compensation | 0.10% | (2.80%) | |
Federal R&D credit | (0.80%) | (0.60%) | 31.00% |
Derivative liabilities | 1.40% | 3.60% | 541.50% |
Non-Deductible Interest | 5.00% | 5.50% | 0.00% |
Other | (3.20%) | 0.10% | (7.80%) |
Foreign losses | 0.50% | (1.20%) | 32.30% |
Change in valuation allowance | 31.70% | 27.10% | (592.40%) |
Effective income tax rate | 0.60% | 0.30% | (8.90%) |
Note 14 - Income Taxes - Deferr
Note 14 - Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands | Dec. 31, 2016 | Dec. 31, 2015 | Dec. 31, 2014 |
Net operating loss carryforwards | $ 236,741 | $ 207,241 | $ 195,536 |
Fixed assets | 12,917 | 10,519 | 1,299 |
Research and development credits | 17,348 | 16,612 | 14,701 |
Foreign Tax Credit | 2,452 | 1,899 | 1,431 |
Accruals and reserves | 30,303 | 26,366 | 16,425 |
Stock-based compensation | 17,184 | 19,048 | 18,773 |
Capitalized start-up costs | 9,182 | 9,568 | 13,095 |
Capitalized research and development costs | 65,962 | 63,339 | 56,880 |
Other | 6,714 | 9,999 | 6,700 |
Total deferred tax assets | 398,803 | 364,591 | 324,840 |
Fixed assets | |||
Debt discount and derivative | (11,936) | (4,402) | (12,517) |
Total deferred tax liabilities | (11,936) | (4,402) | (12,517) |
Net deferred tax asset prior to valuation allowance | 386,867 | 360,189 | 312,323 |
Less: Valuation allowance | (386,867) | (360,189) | (312,323) |
Net deferred tax assets (liabilities) | $ 0 | $ 0 | $ 0 |
Note 14 - Income Taxes - Uncert
Note 14 - Income Taxes - Uncertain Tax Benefits (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2016 | Dec. 31, 2015 | Dec. 31, 2014 | |
Balance | $ 8,634 | $ 17,081 | $ 6,080 |
Increases in tax positions for prior period | 4,736 | ||
Increases in tax positions during current period | 781 | 957 | 6,265 |
Balance | 9,101 | 8,634 | $ 17,081 |
Decreases in tax positions for prior period | $ (314) | $ (9,404) |
Note 15 - Reporting Segments (D
Note 15 - Reporting Segments (Details Textual) | Dec. 31, 2016 |
Segment Reporting, Number Of Business Activities | 1 |
Note 15 - Reporting Segments -
Note 15 - Reporting Segments - Revenues by Geography (Details) - USD ($) $ in Thousands | 3 Months Ended | 12 Months Ended | |||||||||
Dec. 31, 2016 | Sep. 30, 2016 | Jun. 30, 2016 | Mar. 31, 2016 | Dec. 31, 2015 | Sep. 30, 2015 | Jun. 30, 2015 | Mar. 31, 2015 | Dec. 31, 2016 | Dec. 31, 2015 | Dec. 31, 2014 | |
Revenues | $ 22,238 | $ 26,544 | $ 9,599 | $ 8,811 | $ 9,847 | $ 8,591 | $ 7,843 | $ 7,872 | $ 67,192 | $ 34,153 | $ 43,274 |
UNITED STATES | |||||||||||
Revenues | 30,944 | 20,897 | 21,331 | ||||||||
BRAZIL | |||||||||||
Revenues | 489 | 5,070 | 5,961 | ||||||||
Europe [Member] | |||||||||||
Revenues | 23,612 | 3,557 | 9,738 | ||||||||
Asia [Member] | |||||||||||
Revenues | 12,068 | 4,629 | 6,244 | ||||||||
Other Area [Member] | |||||||||||
Revenues | $ 79 |
Note 15 - Reporting Segments 87
Note 15 - Reporting Segments - Long-Lived Assets by Geography (Details) - USD ($) $ in Thousands | Dec. 31, 2016 | Dec. 31, 2015 |
Long-Lived Assets | $ 53,735 | $ 59,797 |
UNITED STATES | ||
Long-Lived Assets | 9,342 | 18,401 |
BRAZIL | ||
Long-Lived Assets | 44,153 | 41,093 |
Europe [Member] | ||
Long-Lived Assets | $ 240 | $ 303 |
Note 16 - Subsequent Events (De
Note 16 - Subsequent Events (Details Textual) | Dec. 28, 2016USD ($) | Jul. 29, 2015USD ($)shares | Mar. 31, 2016USD ($) | Mar. 31, 2017USD ($) | Dec. 31, 2016USD ($) | Dec. 31, 2015USD ($) | Dec. 31, 2014USD ($) | Apr. 13, 2017USD ($) | Mar. 01, 2017shares | Jan. 10, 2017USD ($) | Nov. 30, 2016USD ($) | Jul. 31, 2016USD ($) | Jul. 19, 2016USD ($) | May 30, 2016USD ($) | Mar. 21, 2016USD ($) | Feb. 12, 2016USD ($) | Oct. 14, 2015USD ($) | Jul. 31, 2015shares | Mar. 31, 2015USD ($) | Mar. 31, 2014USD ($) |
Gain (Loss) on Extinguishment of Debt | $ 4,200,000 | $ (4,146,000) | $ (1,141,000) | $ (10,512,000) | ||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 1,602,562 | |||||||||||||||||||
Novvi LLC [Member] | American Refining Group [Member] | ||||||||||||||||||||
Obligation to Fund Agreement, Cash Portion | 9,000,000 | $ 10,000,000 | $ 10,000,000 | |||||||||||||||||
Novvi LLC [Member] | Chevron U.S.A. [Member] | ||||||||||||||||||||
Obligation to Fund Agreement, Cash Portion | $ 1,000,000 | $ 1,000,000 | ||||||||||||||||||
The May 2016 Convertible Notes [Member] | Convertible Subordinated Debt [Member] | ||||||||||||||||||||
Convertible Debt, Aggregate Number of Shares Issued With Respect to the Initial Closing, Maximum Percentage | 19.99% | |||||||||||||||||||
Debt Instrument, Face Amount | $ 15,000,000 | |||||||||||||||||||
Convertible Senior Notes, 9.5% [Member] | ||||||||||||||||||||
Debt Instrument, Repurchase Amount | $ 3,700,000 | $ 3,700,000 | $ 3,700,000 | |||||||||||||||||
Debt Instrument, Face Amount | $ 57,600,000 | |||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 9.50% | |||||||||||||||||||
Conversion of All Outstanding Fidelity Notes for Aggregate Principal Amount of 2015 144A Notes [Member] | ||||||||||||||||||||
Debt Conversion, Original Debt, Amount | $ 19,100,000 | |||||||||||||||||||
Debt Conversion, Converted Instrument, Exchange Ratio of Converted Debt to Original Debt | 1.25 | |||||||||||||||||||
Loans Payable | $ 19,100,000 | |||||||||||||||||||
Subsequent Event [Member] | Ginkgo Collaboration Note [Member] | ||||||||||||||||||||
Debt Instrument, Face Amount | $ 3,000,000 | |||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 13.50% | |||||||||||||||||||
Subsequent Event [Member] | Conversion of All Outstanding Fidelity Notes for Aggregate Principal Amount of 2015 144A Notes [Member] | ||||||||||||||||||||
Gain (Loss) on Extinguishment of Debt | $ 100,000 | |||||||||||||||||||
Hercules Technology Growth Capital, Inc. (Hercules) [Member] | ||||||||||||||||||||
Line of Credit Facility, Maximum Borrowing Capacity | $ 15,000,000 | |||||||||||||||||||
Loans Payable | $ 25,000,000 | |||||||||||||||||||
Hercules Technology Growth Capital, Inc. (Hercules) [Member] | Subsequent Event [Member] | ||||||||||||||||||||
Line of Credit Facility, Maximum Borrowing Capacity | $ 3,000,000 | |||||||||||||||||||
Total [Member] | ||||||||||||||||||||
Debt Conversion, Original Debt, Amount | $ 70,000,000 | |||||||||||||||||||
Total [Member] | Total R&D Warrant [Member] | ||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 2,000,000 | |||||||||||||||||||
Temasek [Member] | ||||||||||||||||||||
Debt Conversion, Original Debt, Amount | $ 71,000,000 | |||||||||||||||||||
Temasek [Member] | Temasek Warrant Three [Member] | ||||||||||||||||||||
Class of Warrant or Right, Common Stock Shares Used In Calculation | shares | 880,339 | |||||||||||||||||||
Class of Warrant or Right, Threshold Number of Securities | shares | 2,000,000 | |||||||||||||||||||
Temasek [Member] | Temasek Warrant Three [Member] | If Total R&D Warrant is Exercised in Full [Member] | ||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 880,339 | |||||||||||||||||||
Temasek [Member] | Subsequent Event [Member] | Temasek Warrant Three [Member] | If Total R&D Warrant is Exercised in Full [Member] | ||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 880,339 | |||||||||||||||||||
Class of Warrant or Right, Threshold Number of Securities | shares | 2,000,000 |
Supplementary Financial Data 89
Supplementary Financial Data - Selected Quarterly Financial Data (Details Textual) $ in Thousands | 3 Months Ended |
Dec. 31, 2015USD ($) | |
Fair Value Adjustment of Warrants | $ 6,424 |
Supplemental Financial Data - S
Supplemental Financial Data - Selected Quarterly Financial Data - Selected Quarterly Financial Data (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | 12 Months Ended | |||||||||||||||||
Dec. 31, 2016 | Sep. 30, 2016 | Jun. 30, 2016 | Mar. 31, 2016 | Dec. 31, 2015 | Sep. 30, 2015 | Jun. 30, 2015 | Mar. 31, 2015 | Dec. 31, 2016 | Dec. 31, 2015 | Dec. 31, 2014 | |||||||||
Total revenues | $ 22,238 | $ 26,544 | $ 9,599 | $ 8,811 | $ 9,847 | $ 8,591 | $ 7,843 | $ 7,872 | $ 67,192 | $ 34,153 | $ 43,274 | ||||||||
Product sales | 11,467 | 6,820 | 4,922 | 3,140 | 5,233 | 4,228 | 3,340 | 2,095 | 26,349 | 14,896 | 23,439 | ||||||||
Gross loss from product sales | (11,290) | (8,056) | (2,969) | (8,038) | (6,084) | (4,227) | (7,619) | (4,548) | |||||||||||
Net loss attributable to common stockholders (for basic loss per share) | (48,756) | [1] | (19,704) | [1] | (13,566) | [1] | (15,308) | [1] | (48,352) | (76,664) | (47,130) | (52,240) | (97,334) | (221,777) | 2,286 | ||||
Net loss attributable to common stockholders (for diluted loss per share) | $ (48,756) | $ (19,704) | $ (29,245) | $ (30,273) | $ (68,316) | $ (76,664) | $ (54,527) | $ (52,240) | $ (115,647) | $ (221,777) | $ (109,861) | ||||||||
Basic (in dollars per share) | $ (0.18) | [1] | $ (0.08) | [1] | $ (0.06) | [1] | $ (0.07) | [1] | $ (0.23) | [1] | $ (0.55) | [1] | $ (0.59) | [1] | $ (0.66) | [1] | $ (0.41) | $ (1.75) | $ 0.03 |
Diluted (in dollars per share) | $ (0.18) | $ (0.08) | $ (0.11) | $ (0.12) | $ (0.30) | $ (0.55) | $ (0.62) | $ (0.66) | $ (0.44) | $ (1.75) | $ (0.90) | ||||||||
Basic (in shares) | 273,406,492 | 249,190,339 | 223,112,019 | 207,199,563 | 206,661,506 | 140,374,297 | 80,041,152 | 79,222,051 | 238,440,197 | 126,961,576 | 78,400,098 | ||||||||
Diluted (in shares) | 273,406,492 | 249,190,339 | 262,896,140 | 260,932,085 | 231,014,248 | 140,374,297 | 87,421,439 | 79,222,051 | 264,644,449 | 126,961,576 | 121,859,441 | ||||||||
[1] | Basic loss per share for the fourth quarter of 2015 is calculated by excluding from net income (loss) attributable to common stockholders a gain of $6,424 (thousand) related to a change in the fair value of a liability classified common stock warrant included in the Company’s consolidated statement of operations. The warrant has a nominal exercise price and shares issuable upon exercise of the warrant are considered equivalent to the Company’s common shares for the purpose of computation of basic earnings per share and consequently losses are adjusted to exclude the gain. |
Schedule II - Valuation and Q91
Schedule II - Valuation and Qualifying Accounts - Schedule II Valuation and Qualifying Accounts (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2016 | Dec. 31, 2015 | Dec. 31, 2014 | |
Allowance for Doubtful Accounts [Member] | |||
Balance at Beginning of Period | $ 969 | $ 479 | $ 479 |
Additions | 490 | ||
Write-off Adjustments | (468) | ||
Balance at End of Period | 501 | 969 | 479 |
Valuation Allowance of Deferred Tax Assets [Member] | |||
Balance at Beginning of Period | 360,189 | 312,323 | 284,021 |
Additions | 26,678 | 47,866 | 28,302 |
Write-off Adjustments | |||
Balance at End of Period | $ 386,867 | $ 360,189 | $ 312,323 |